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1. General introduction into leprosy 
i. Leprosy 
Leprosy is an infectious disease that affects the skin, nerves and eyes and is caused by the 
Mycobacterium leprae. Even though the disease has been well curable since the introduction of 
multidrug treatment (MDT) in the early 1980’s, leprosy remains a public health problem in 
different parts of the world. Skeletal remains from 2000 B.C. discovered in India provide 
evidence that leprosy already exists for millennia. From India, the disease spread to other parts 
of the world [1], including to Europe where it reached its peak during the 13th and 14th century 
[2]. Leprosy disappeared from Europe in the eighteenth century, even before there was any 
treatment for leprosy available. Leprosy is now only known as a disease of the poor, and is 
mostly prevalent in low resource countries. The causative agent of leprosy, M. leprae, was 
discovered in 1873 by Armauer Hansen. It was the first time a bacillus was identified as a cause 
of disease in humans [3].  
Even though leprosy is one of the oldest diseases known to man, there is still an incomplete 
understanding on the mode(s) of transmission, the mechanisms behind the immune response, 
nerve damage and reactions and unfortunately so far no effective vaccine has been developed 
to prevent clinical leprosy. Studying M. leprae is complex, since the organism has never been 
successfully cultured in vitro.  
ii. Symptoms and diagnosis 
Hypopigmented skin lesions are often the first symptoms of leprosy [4], however, due to low 
awareness or fear of stigma patients often wait to seek medical help until they experience more 
advanced symptoms caused by nerve function impairment, such as numbness or muscle 
weakness, [5,6]. The diagnosis for leprosy can be made when at least one of the three following 
cardinal signs is present: enlarged peripheral nerves, diminished touch perception in skin lesions 
or bacilli in skin smears. From skin smears or biopsies the bacterial index (BI) is derived which 
expresses the density of M. leprae on a logarithmic scale from 1 to 6 [7]. This can be used for 
diagnosis and to determine the effectiveness of therapy.  
iii. Transmission 
The incubation time of leprosy is usually long with reported maxima of 20 years, but is in most 
cases between 2 and 5 years [8]. The long incubation time makes it difficult to determine when 
and under what circumstances the disease was contracted, and therefore transmission of 
leprosy is not well-understood. The main transmission route is presumed to be from person-to-
person through nasal droplets via the upper respiratory tract [9], although abraded skin is 
considered a possible port-of-entry as well [8]. Furthermore, M. leprae has been found to 
survive in soil for 46 days [10], which could also be a factor in transmission.  
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Only patients with the lepromatous type are considered infectious (see §3.i), and they remain 
infectious until the start of treatment with multi-drug therapy (MDT). Being a contact of a leprosy 
patient increases the risk of contracting the disease, depending on the intensity and duration of 
the contact [8,11]. Household members of lepromatous patients have the highest relative risk: 
8-10 times the risk of the general population. In non-endemic areas, transmission within 
households plays an important role [12].  
iv. Treatment  
In the 1940’s, dapsone was discovered as treatment against M. leprae. However, the bacteria 
developed resistance against the monotherapy and therefore a multi-drug therapy was 
introduced in 1982. The MDT is provided for free by the World Health Organization (WHO) since 
1995. The WHO advises a therapy of 6 months for paucibacillary (PB) leprosy, with a daily dose 
of dapsone and a monthly dose of rifampicin. Multibacillary (MB) leprosy patients should follow a 
treatment of 12 months with daily doses of clofazimine and dapsone, together with rifampicin 
plus a high clofazimine dose once a month [13]. In line with older WHO guidelines, in some 
countries 24 months of MDT is given to MB patients. 
v. Prevention 
Even though there is no effective vaccine against leprosy, the BCG vaccine against tuberculosis 
also protects against leprosy [14,15]. The efficacy differs between populations, as case-controls 
studies have shown that vaccine protection lays between 20 and 90% [14].  
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2. Epidemiology  
i. Prevalence  
Between the introduction of MDT in 1982 and the early 2000’s, the leprosy prevalence dropped 
by 90% [16]. However, in the last decade the decrease in prevalence has stabilized. The 
prevalence is defined as the number of leprosy cases on treatment, and thus depends on which 
treatment guidelines are followed [17]. A more stable indicator is the new case detection rate 
(NCDR), which shows the number of new detected cases in one year per 100 000 population. 
Elimination of leprosy, defined as less than 1 leprosy case per 10 000 population, was reached 
in 2000 at global level, but this target has not been reached in many regions of leprosy endemic 
countries.  
In 2014, the total number of reported new leprosy cases was 213 899 [18]. Eighty-nine percent 
of these new cases were concentrated in eight countries: Bangladesh, Brazil, Democratic 
Republic of Congo, Ethiopia, India, Indonesia, Nepal and Nigeria. India alone accounted for 
59% of new detected leprosy cases in 2014. In total, 13 countries had a new case detection of 
>1000.  
Details of the eight countries with the highest number of new cases are shown in Table 1. The 
PB/MB ratio differs between countries. Leprosy is more frequently seen in males, the male-
female ratio is about 1.5 to 2:1 [19]. Also, leprosy is seen most often in the age group 20-30 
years [20], but the disease has been diagnosed in children as young as three weeks old [21]. 
Table 1 also contains the proportion of new patients with Grade 2 Disabilities – i.e. visible 
impairments and/or deformities. This is a useful indicator of delayed detection of leprosy.  
 
Table 1- New case detection, prevalence and patient details for the eight countries with the      
               highest new case detection rates in 2014 [18] 
Country New case 
detection 
Prevalence % 
MB 
% 
female 
% 
children 
% grade 2 
disabilities 
       India 125785 88833 53 37 9 5 
Brazil 31064 25738 66 45 8 7 
Indonesia 17025 19949 83 37 11 9 
Ethiopia  3758 3758 74 NR 13 10 
Bangladesh 3622 3310 46 38 5 11 
Congo 3272 3231 64 46 12 14 
Nepal 3046 2382 52 37 6 4 
Nigeria 2983 3147 93 43 9 14 
 
 
13 
ii. Countries  
The TENLEP study described in this thesis took place in four of the countries listed in Table 1: 
India, Bangladesh, Nepal and Indonesia. The new case detection rate (NCDR) of these 
countries is shown in Figure 1, together with the location of the centres where the studies were 
carried out.  
In India (Figure 1.A), we worked together with two centres. The first is the Foundation for 
Medical Research (FMR), a research institute located in Mumbai, which was cooperating with a 
referral centre in Mumbai to include patients in our studies. The second is JALMA institute, a 
specialised governmental leprosy hospital located in Agra. Several studies within this thesis 
were done in Bangladesh (Figure 1.B), all in Nilphamari Leprosy Mission Hospital, a specialized 
hospital with multiple outpatient clinics in the Rangpur district. In Nepal (Figure 1.C), also two 
centres were involved. The first is Anandaban Leprosy Hospital, located near the capital 
Kathmandu, also run by The Leprosy Mission. They are holding weekly clinic days in 
Kathmandu. The second is Lalgadh Leprosy Services Centre, a more rural hospital, which is 
one of the busiest leprosy centres in the world. In Figure 1.D the centre in Indonesia is shown. 
We worked together with the dermatology department of Dr. Soetomo hospital in Surabaya. 
Most patients came from the island of Madura, and were visited monthly by the staff.  
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Figure 1- Country maps indicating the new case detection rate in 2014 per district per 10 000 inhabitants              
and the location of the hospitals for (A) India, (B) Bangladesh, (C) Indonesia, and (D) Nepal 
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3. Immunology and leprosy reactions 
i. Immune response and classification 
Leprosy is classified in two ways, the Ridley-Joplin and the WHO classification. The five-group 
Ridley-Jopling system is based on the characteristics of skin lesions and bacterial load and is 
used for research and clinical purposes [22]. The patient’s immune response to the bacilli 
determines which type develops. At one end of the spectrum, patients with a mild form of the 
disease, the tuberculoid (TT) form, can be found. These patients show a strong cell-mediated 
immune response and have few well-defined skin lesions and no or low bacteria counts. At the 
other, more severe end, the lepromatous (LL) patient’s immune system has a weak or absent 
response to M. leprae, resulting in multiple macules and/or nodules with many bacilli present 
[23]. In between these two extremes, the majority of the patients are classified in one of the 
three unstable borderline forms: borderline tuberculoid (BT), borderline borderline (BB) and 
borderline lepromatous (BL). The cellular immunity becomes weaker the more one gets to the 
lepromatous side. The intensity of this response can change and therefore patients can switch 
between the three borderline types, although most patients will move towards the lepromatous 
side (downgrading). 
 It is not always possible to carry out and examine a skin smear test under field circumstances, 
therefore the WHO advises to use a simpler two-group classification system in these cases. 
When a person has up to five skin lesions the disease is classified as paucibacillary (PB) and 
patients with more than five lesions fall under the multibacillary (MB) group [13]. The PB group 
contains TT and BT types and the MB group includes BT, BB, BL and LL types [24,25]. If a skin 
smear is positive the patient should always be treated as an MB case.  
Next to determining which leprosy type develops, immunology is also very important regarding 
the susceptibility for leprosy. Analyses of M. leprae DNA in nasal swabs show that up to 31% of 
the general population in endemic areas carry the bacilli in their nose [9,26-28]. However, it is 
assumed that less than 1% of people exposed to M. leprae will develop clinical leprosy [20,29]. 
This means that a vast majority of the population has a strong immune response, leading to 
containment and spontaneous clearing of the disease. The factors leading to the differences in 
immune response between persons are not completely understood, but genetics, nutritional 
status and socioeconomic status are thought to influence the host reaction to the leprosy bacilli 
[30-33].  
ii. Reactions 
In part of the leprosy patients, the antigens of the (dying) leprosy bacilli generate an increased 
activity of the immune system leading to acute inflammation of skin and nerves. These reactions 
can occur before MDT, but commence mostly during or after treatment. When not treated in 
time, the nerves can be severely damaged during these reactions – i.e. neuropathy, which can 
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lead to disabilities. Leprosy is curable, but even when taking MDT the risk on neuropathy due to 
reactions is still present, until years after treatment has ended [34-36].  
There are two types of reactions. Type 1 reactions, also called reversal reactions, arise in 
around 25-30% of the patients with borderline leprosy [37]. The number of skin lesions may 
increase and they become inflamed, red, swollen and tender. The peripheral nerves become 
swollen and the resulting intra-neural pressure may affect their function, leading to anaesthesia 
or paralysis of hands, feet and eyes [38].  
Type 2 reactions, or erythema nodosum leprosum (ENL), only occur in lepromatous and 
borderline lepromatous types, respectively in approximately 10 and 50% of the patients [19,39]. 
ENL is seen as a chronic disease, since reactions can relapse over several years. Painful red 
papules or nodules appear on the skin. Next to involvement of nerves and skin, also other 
organs as testes, eyes, kidneys, joints and lymph nodes can be affected [40]. The reactions 
cause fever and general malaise and severe ENL can be life-threatening.  
Both type 1 and 2 reactions are treated with corticosteroids. The WHO advises a 12-week 
course of prednisolone, however, studies show that longer treatments may be more effective 
[13,41]. When patients with severe type 2 reactions do not respond well to prednisolone, 
thalidomide or clofazimine are given.  
iii. Nutrition and immunology 
As mentioned, nutritional status may influence the effectiveness of the immune response 
towards the leprosy bacilli or its antigens. The relation between nutrition, immunology and 
infections has been acknowledged for decades [42]. The essential defence against 
Mycobacterium leprae, an intracellular micro-organism, is dependent on the cell-mediated 
immune response [24]. Protein-energy malnutrition (PEM) as well as inadequate intake of 
vitamins and minerals are related to a reduced cell-mediated immunity [43-46].  
For centuries (mal)nutrition has been linked to susceptibility to leprosy, for example by the Dutch 
physician Fortestu in the 17th century [47]. Various foods as fish, salt, pork meat and alcoholic 
drinks have been ‘blamed’ for causing leprosy [48]. However, until this day only little research 
has been carried out on the exact role of nutrition on the susceptibility and development of 
leprosy and thus this relation remains unclear. With the long incubation time of M. leprae it is 
very hard to study the nutritional status at the moment of infection. In addition, the relation 
between nutrition and infection runs both ways: infections may have major impact on nutritional 
status as well. This makes it almost impossible to distinguish between cause and consequence.  
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4. Leprosy neuropathy 
i. Neuropathy and nerve function impairment 
Leprosy is regarded as a disease of skin and nerves, but it is the neurological aspect that 
makes leprosy a disease with a high impact. Neuropathy can arise gradually or can be a 
consequence of reactions. New patients often present with some level of nerve function 
impairment (NFI), the percentage varies between 2% and 55%, with lower figures for PB cases 
[34,49-51]. On top of that, 2.4-29% of the patients develops neuropathy during or after 
treatment [35,50,52], also depending on classification and pre-existing nerve function 
impairments.  
M. leprae bacilli settle and reproduce in the Schwann cells [53,54]. The severity and 
extensiveness of neuropathy depends on the type of leprosy. Patients on the tuberculoid end of 
the spectrum often have only one or few nerves affected. Granulomatous inflammation causes 
enlargement of the nerves, oedema and loss of nerve tissue and structure. The damage occurs 
fast and severe. 
At the lepromatous end, often multiple nerves are bilaterally and symmetrically involved [55]. The 
lack of cell mediated immunity results in extensive infiltration of bacilli. The continued 
multiplication and high bacterial load cause damage to the nerves. This process is very slow, 
the nerve structure and function are often maintained for a long period of time. In borderline 
leprosy, the worst of the two above mentioned classes is combined: the wide involvement of 
nerves as in LL with the formation of granulomas and accompanying destruction of nerves as in 
TT. Patients in the borderline groups have therefore a high chance on severe neuropathy [53]. 
Generally in leprosy, sensory nerves are affected before motor nerves. Older histopathological 
studies showed that neuropathy occurs first in the small nerve fibres (unmyelinated C-fibres 
followed by myelinated Aδ-fibres), which conduct pain, warm and cold sensation and are 
responsible for the autonomic function (i.e. sweating) [56-58]. Subsequently, the large fibres 
(Aβ-fibres) are affected, responsible for vibration, touch and pressure perception. The INFIR 
study found, however, that the order of first affected modality and nerve fibre differs from patient 
to patient [59]. When autonomic nerves are affected, sweat gland function is lost, which leads 
to dryness of the skin and an increased risk of ulceration. 
The specific nerves affected by leprosy are the facial nerve, the ulnar, median and the radial 
cutaneous in the arm and hand, and the posterior tibial and the sural in the leg and foot. The 
most commonly affected nerves are the posterior tibial, sural and ulnar nerve [35,60,61].  
To estimate which patients are at risk of developing NFI, Croft and colleagues developed the 
Clinical Prediction Rule. They established that MB patients who already have some nerve 
function impairment have the highest risk for new NFI and should have regular follow-ups in the 
first 2 years after diagnosis [62].    
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ii. Disabilities  
When nerve function impairment is not treated within 6 months of onset, the damage can 
become irreversible and this will have severe consequences. Insensible feet and hands are extra 
vulnerable for burns and ulcers, with amputation as a result in the most extreme cases. This 
neurological aspect of leprosy, and the possibility of developing chronic disabilities, is what 
make leprosy such a serious disease. The disabilities make patients vulnerable for stigma and 
exclusion. Early detection of leprosy and neuropathy is therefore very important. 
iii. Diagnosis and nerve function assessment 
Diminished sweat function or blood flow (autonomic), pain, touch, pressure, warmth, cold and 
vibration sensation (sensory), and muscle strength (motor) can be assessed to detect leprosy 
neuropathy. Common methods used in the field to detect sensory nerve function impairments 
are monofilament testing (MFT) and ball point testing (BPT); both assess touch sensation on the 
hands and feet. A standard set of Semmes-Weinstein monofilaments consists of 6 filaments, 
with increasing thickness and pressure (from 70 mg to 300 mg). This is a reliable and 
standardized method to test for sensory impairments, in contrast to a BPT for which pressure is 
not standardized and which can only provide a yes/no outcome, although the low costs and 
high availability give BPT a huge advantage.  
For the detection of motor nerve function impairments, voluntary muscle testing (VMT) is 
performed by examining the ability of the patient to move a body part to a given position and to 
hold that position against resistance applied by the tester [63]. The modified 0–5 MRC scale is 
used, ranging from full range of motion and full resistance to complete paralysis.  
Both VMT and MFT require training and practice, but then both can be executed reliably [64-
66]. When the nerve function is impaired according to one or both of these tests, it is seen as 
clinically impaired. 
The INFIR study showed that neuropathy was more widespread than could be detected with 
the MFT and VMT [67]. Before the nerve function impairment is clinically detectable, the majority 
of nerves already showed some subclinical neuropathy as can be detected with more sensitive 
methods. The warm detection threshold (WDT) and nerve conduction studies (NCS) were able 
to detect subclinical neuropathy up to 12 weeks before the clinical neuropathy was noticeable 
with MFT or VMT.  
Nerve conduction studies basically assess how fast an electrical pulse is conducted through a 
nerve. This can both be done for sensory and motor nerves, and the latency, amplitude and 
velocity of the pulse are recorded. The disadvantage of these two methods is that they are very 
expensive and require electricity and acclimatized conditions. When WDT and/or NCS are 
impaired, it is seen as subclinical impairment. 
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iv. Treatment of nerve function impairments  
Nerve function impairment of recent onset (≤ 6 months) can be treated with corticosteroids [35, 
38]. The standard treatment recommended by the WHO starts at 40-60 mg per day and is 
decreased over 12 weeks [68]. Ideally, each patient would receive an individual, tailored 
therapy, but this is only possible in referral centres. In the non-specialized clinics in the field, 
standard treatment is used. 
Several studies have been conducted to examine treatment of clinical NFI using prednisolone. In 
one cohort, the WHO recommended 12-week prednisolone regimen was found not to be 
successful in the prevention and reversal of NFI in MB patients [69]. Also a 16-week 
prednisolone regimen, usual practice nowadays, was found not to be very effective in two 
randomized controlled trials (RCT) [70,71]. There is reason to assume that longer steroid 
treatment might be more beneficial, since one RCT showed that a 5-month corticosteroid 
regimen was significantly more effective than a 3-month regimen. Since steroids can have 
severe side effects as diabetes, peptic ulcer, osteoporosis, glaucoma, cataract, psychosis, 
and hypertension, it is important that there is clear evidence for longer use of steroids. A 
Cochrane review concluded, however, that the evidence of the RCTs is not enough to draw 
robust conclusions about the long-term effect of corticosteroids on reactions and NFI in leprosy 
[53]. More research needs to be done to determine the optimal dose and duration of 
prednisolone for treating clinical NFI in leprosy.   
Interestingly, several studies have reported spontaneous recovery of nerve function 
impairments, even for old impairments. The Tripod studies showed that after 12 months 75% 
and 50% of the nerves spontaneously healed in mild and long-standing impairment, 
respectively. This was also seen in the AMFES trial in Ethiopia, where acute neuropathy 
recovered spontaneously in 42% and old neuropathy recovered in 23% of the cases [35,72].  
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5. The TENLEP study 
Nerve function impairment is a vicious but frequent consequence of leprosy. Unfortunately, 
optimal treatments to restore and prevent NFI have not unequivocally been established yet. For 
this reason, the TENLEP study (Treatment of Early Neuropathy in LEProsy) was set up in four 
Asian countries: Bangladesh, India, Indonesia and Nepal. The study consists of two randomized 
controlled trials, one focusing on restoring and one on preventing NFI. The aim of the first trial 
was to assess whether prednisolone treatment of 32 weeks duration is more effective than 
treatment of 20 weeks duration in restoring nerve function in patients with clinical sensory 
and/or motor NFI of recent onset (<6 months). The second trial was designed to determine 
whether prednisolone treatment of early subclinical neuropathy, as detected with WDT and 
NCS, would prevent clinical sensory and/or motor function loss in leprosy patients. In both trials, 
patients were followed for 18 months. The first patient was taken in in June 2012 and the data 
collection was completed in October 2015.  
In addition to the primary aims of the study, the information gathered from this study may be 
useful to refine the clinical prediction rule as designed by Croft et al [73]. Guidelines for 
prophylactic prednisolone could be developed for certain high risk groups to make steps 
forward in the prevention of disabilities and deformities in newly diagnosed leprosy patients. 
However, this is outside the scope of this thesis. 
The study took place in six leprosy centres: Anandaban Leprosy Hospital and Lalgadh Leprosy 
Services Centre in Nepal, the Foundation for Medical Research and the JALMA institute in India, 
Dr. Soetomo hospital in Surabaya, Indonesia, and Nilphamari-Leprosy Mission Hospital in 
Bangladesh (see maps in §2.ii). 
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6. Research questions 
The first objective of this thesis is to study methods that help early detection and treatment of 
neuropathy in order to prevent irreversible nerve function impairment and the resulting 
disabilities in leprosy patients. Regarding risk factors for leprosy we studied differences in diet 
and food security between leprosy patients and a control group without leprosy. The research 
questions of this thesis are: 
1. How can the detection of nerve function impairment in leprosy at field level be 
improved?  
2. How can irreversible nerve function impairment best be prevented in leprosy? 
3. Which nutritional factors possibly underlie the development of clinical leprosy? 
 
This thesis is divided in three sections. In the first part, the focus lays on methodological studies. 
The TENLEP study protocol is presented in Chapter 2, describing the details of the 
assessments and treatment for both the Clinical and Subclinical trial in depth. Chapters 3, 4 and 
5 cover the first research question. In Chapter 3, a study in India and Nepal defining the normal 
values for monofilament tests for two additional nerves is described. The results of reliability 
testing for monofilament and voluntary muscle testing in the six TENLEP centres are given in 
Chapter 4. Chapter 5 presents a study in which several new portable, battery operated tests 
are compared to determine if they are useful in early detection of leprosy neuropathy in the field. 
The second section of this thesis concentrates on study results. Chapter 6 answers the 
second research question by presenting the results of the clinical TENLEP trial, aimed to 
examine whether prednisolone can restore clinical nerve function impairment in leprosy patients. 
The serious adverse events in the TENLEP trials are addressed in Chapter 7. Finally, Chapter 
8 discusses the results of a case-control study in Bangladesh, comparing the diet and food 
security between newly diagnosed leprosy patients and a control population. In the third and 
final part, Chapter 9, the results are discussed and the research questions are answered.  
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Abstract 
Introduction   
Nerve damage in leprosy often causes disabilities and deformities. Prednisolone is used to treat 
nerve function impairment (NFI). However, optimal dose and duration of prednisolone treatment 
has not been established yet. Besides treating existing NFI it would be desirable to prevent NFI. 
Studies show that before NFI is clinically detectable, nerves often show subclinical damage. 
Within the ‘Treatment of Early Neuropathy in LEProsy’ (TENLEP) study two double blind 
randomized controlled trials (RCT) will be carried out: a trial to establish whether prednisolone 
treatment of 32 weeks duration is more effective than 20 weeks in restoring nerve function in 
leprosy patients with clinical NFI (Clinical trial) and a trial to determine whether prednisolone 
treatment of early subclinical NFI can prevent clinical NFI (Subclinical trial). 
Methods  
Two RCTs with a follow up of 18 months will be conducted in six centres in Asia. In the Clinical 
trial leprosy patients with recent (<6 months) clinical NFI, as determined by Monofilament Test 
and Voluntary Muscle Test, are included. The primary outcomes are the proportion of patients 
with restored or improved nerve function. In the Subclinical trial leprosy patients with subclinical 
neuropathy, as determined by Nerve Conduction Studies (NCS) and/or Warm Detection 
Threshold (WDT), and without any clinical signs of NFI are randomly allocated to a placebo 
group or treatment group receiving 20 weeks prednisolone. The primary outcome is the 
proportion of patients developing clinical NFI. Reliability and normative studies are carried out 
before the start of the trial. 
Discussion  
This study is the first RCT testing a prednisolone regimen with a duration longer than 24 weeks. 
Also it is the first RCT assessing the effect of prednisolone in the prevention of clinical NFI in 
patients with established subclinical neuropathy. The TENLEP study will add to the current 
understanding of neuropathy due to leprosy and provide insight in the effectiveness of 
prednisolone on the prevention and recovery of NFI in leprosy patients. In this paper we present 
the research protocols for both Clinical and Subclinical trials and discuss the possible findings 
and implications. 
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Introduction 
Damage to peripheral nerves is the main consequence of leprosy and may cause deformities 
and disabilities in patients. Nerve damage can occur before, during and after multidrug therapy 
(MDT) and is a result of inflammation in the nerves due to immunological reactions [1]. For many 
years corticosteroids, mostly prednisolone, have been used to treat nerve function impairment 
(NFI) in leprosy patients [2]. However, an optimal dose and duration of steroid treatment has yet 
to be established [3]. In addition, research should focus also on possibilities of timely detection 
and treatment of early (subclinical) neuropathy in order to prevent NFI and its consequences [4]. 
The TENLEP study is designed to obtain additional information about prednisolone treatment for 
preventing and restoring nerve function in people affected by leprosy. Within the TENLEP study 
two randomized clinical trials will be conducted; one trial focusing on patients with subclinical 
neuropathy, and the second trial focusing on patients with clinical NFI. 
Between 6 and 27% of the 228 474 newly detected leprosy cases in 2010 [5] presented with 
visible impairment (grade 2 disability) [2,4]. This WHO leprosy disability grading system is the 
most widely used method to assess impairment in leprosy patients and is generally used for 
monitoring program quality [6,7]. More accurate assessments for NFI are Voluntary Muscle 
Testing (VMT) and Monofilament Testing (MFT) or ball point tests [8], which are widely used in 
clinical practice to assess motor and sensory NFI, respectively. Recently, more sensitive 
methods have been introduced to detect early, subclinical neuropathy. The INFIR study found 
that nerve conduction studies (NCS) and Warm Detection Threshold (WDT) are the most 
effective methods for finding subclinical nerve damage [1]. With these tests subclinical 
neuropathy can be detected at least 3 months before VMT and MFT can determine the first 
clinical impairments. Subclinical changes during and following MDT were also found to be 
predictive of new onset NFI [9]. 
To examine treatment of clinical NFI several studies have been conducted using prednisolone. 
In one cohort the WHO recommended prednisolone regimen (starting with 40 mg 
prednisolone/day, tapered down over 12 weeks [2]) was found not to be successful in the 
prevention and reversal of NFI in multibacillary (MB) patients treated for reactions or neuropathy 
[10]. Also a 16-week prednisolone regimen, usual practice nowadays, was found not to be very 
effective in two randomized controlled trials (RCT) [11,12]. One trial was in patients with Type 1 
Reactions and/or NFI, receiving either prednisolone or prednisolone with intravenous 
methylprednisolone. Close to 50% of the patients required additional prednisolone during or 
after the treatment period [11]. The second RCT in MB patients with mild sensory impairment 
did not show a difference in NFI as measured with MFT 12 months after start of prednisolone 
treatment [12]. Van Veen et al. [3], reviewing RCTs comparing placebo to prednisolone 
treatment, conclude that studies so far have not provided enough evidence to draw robust 
conclusions about the long-term effect of corticosteroids on reactions and NFI. However, there 
is reason to assume that longer steroid treatment might be more beneficial, since one study 
showed that a 5-month corticosteroid regimen was significantly more effective than a 3-month 
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regimen [13]. In TENLEP we aim to assess whether prednisolone treatment of 32 weeks 
duration is more effective than treatment of 20 weeks duration in restoring nerve function in 
patients with clinical sensory and/or motor NFI of recent onset (<6 months), as detected by 
VMT and/or MFT. 
The effect of prednisolone treatment on patients with subclinical neuropathy to prevent clinical 
NFI as determined with MFT and/or VMT has not been studied in a RCT before. The objective of 
the Subclinical trial is therefore to determine whether prednisolone treatment of early subclinical 
neuropathy, as detected with WDT and NCS, would prevent clinical sensory and/or motor 
function loss in leprosy patients. This paper presents the protocols for both the Clinical and the 
Subclinical trial. 
 
Methods 
Definitions 
General 
Neuropathy (peripheral) 
Functional impairment and/or structural damage to autonomic, sensory, and motor nerve fibres 
within the peripheral nervous system. 
 
Nerve function impairment 
Sensory, motor or autonomic neuropathy evidenced by clinically detectable reduction in 
function in sensory, motor and/or autonomic fibres. The ‘level’ of impairment that is clinically 
detectable depends on the sensitivity of the testing instruments used. (It does not include 
abnormality of nerve conduction that is detectable only by electrophysiological means and 
WDT). 
 
Nerve damage 
An imprecise but common term for ‘neuropathy’, which is also used in relation to trauma. Here 
it indicates clinical or subclinical damage to a nerve, whether reversible or irreversible. 
 
Neuritis 
A condition in which inflammatory cells are found in the nerve, detectable by swelling and/or 
functional impairment with spontaneous nerve pain and/or nerve tenderness on palpation. 
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Subclinical neuropathy 
Patients have normal values for Voluntary Muscle Testing and Monofilament Testing, but are 
impaired on Nerve Conduction Studies (NCS) and/or Warm Detection Threshold (WDT). 
 
Entry criteria Clinical trial 
At least one nerve with either a VMT score of 4 or less on the 0–5 (modified) MRC scale or with 
a monofilament threshold increased compared to normal subjects by three or more 
monofilament levels on any test-site, two levels on one test-site AND at least one level on 
another test-site, OR one level on three or more test-sites for one nerve. With VMT each nerve 
is tested with one specific test assessing the strength of a muscle (group) innervated by that 
nerve. For MFT each nerve is tested on three sites. 
 
Entry criteria Subclinical trial 
Any one parameter (Motor Nerve Conduction, Sensory Nerve Conduction, Warm Detection 
Threshold) abnormal in at least two nerves or any two parameters abnormal in at least one 
nerve. VMT and MFT values are normal. 
 
Outcome criteria Clinical trial 
Restored nerve function 
Monofilament Test and/or Voluntary Muscle Test of a nerve are recovered to normal levels (MFT 
= 0, VMT = 5). 
 
Improved nerve function 
At least one nerve shows better results on Monofilament Test and/or Voluntary Muscle Test. 
The MF thresholds should be reduced by three or more monofilament levels on any site, two 
levels on one site AND at least one level on another site, OR one level on three or more sites for 
one nerve. VMT score should be increased by at least 1 point. 
 
Improved Reaction Severity Scale score 
When the score on the Reaction Severity Scale [14] decreases by at least 3 points on the sum 
score or at least 2 points on any individual item in the scale. 
 
Count of nerve function impairments (CNFI) 
The sum of MFT and VMT scores (5 being normal) for all nerves tested in the study. 
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Improved SALSA scale score 
The SALSA scale [15] score decreases at least with 1 category in standardized categories of 
SALSA values as described in SALSA Scale User’s Manual (Salsa Scale User’s Manual, Version 
1.1, July 2010) 
 
Improved Participation scale score 
The Participation scale [16] score decreases at least 1 grade on the “Grades of participation 
restriction” scale (as described on P-scale form). 
 
Outcome criteria Subclinical trial 
Clinical motor impairment (MI) 
Motor neuropathy resulting in weakness of the muscles innervated by a given nerve. A patient is 
diagnosed as having clinical motor impairment if the VMT score for a muscle test is 4 or less on 
the 0–5 (modified) MRC scale. If a score of 4 is found, the test will be repeated by a second 
assessor. 
 
Clinical sensory impairment (SI) 
A patient is diagnosed as having sensory impairment of a nerve if the monofilament threshold is 
increased by three or more monofilament levels on any site, two levels on one site AND at least 
one level on another site, OR one level on three or more sites for one nerve. 
 
Subclinical nerve function score (SNFS) 
The Subclinical Nerve Function Score (SNFS) will be computed for NC parameters (amplitude 
and latency) and warm detection threshold, where non-impaired parameter adds 1 point to the 
overall score. 
 
Improved SNFS 
Subclinical Nerve Function Score increased with at least 1 point 
 
Deteriorated SNFS 
Subclinical Nerve Function Score decreased with at least 1 point 
Design of study 
The TENLEP study consists of two multi-centre randomized triple blind controlled trials, both 
with two treatment arms, to study the effectiveness of prednisolone treatment restoring (Clinical 
trial) and in preventing (Subclinical trial) clinical nerve function loss. 
 
 
35 
Six institutions in four different countries participate in this study: Nepal (Lalgadh Hospital and 
Anandaban Hospital); India (JALMA Institute for Leprosy -Agra and Foundation for Medical 
Research-Mumbai); Bangladesh (Nilphamari Hospital); and Indonesia (Dr. Soetomo Hospital- 
Surabaya). Anandaban Hospital and Dr Soetomo Hospital will only take part in the Clinical trial. 
All collaborative institutions are referral hospitals specialized in the detection and treatment of 
leprosy. At each institution a Principal Investigator (PI) is responsible for the research at that 
centre. The overall responsibility lies with the International Coordinator (dr. E. Post), guided by 
an International Steering Committee. 
Participants 
In the Clinical trial leprosy patients with clinical NFI will be randomly allocated to either treatment 
of standard duration (20 weeks) or an interventional treatment of longer duration (32 weeks). 
Both multibacillary (MB) and paucibacillary (PB) patients diagnosed with clinical sensory and/or 
motor nerve impairment of less than six months duration are enrolled. For the Subclinical trial 
leprosy patients with subclinical neuropathy will be randomly divided into an intervention group 
and a placebo group. Newly registered MB and PB patients without clinical NFI but having 
subclinical sensory and/or motor neuropathy at diagnosis, or developing this within their first 
three months of MDT treatment, will be eligible for inclusion in the trial. Patients from the 
Subclinical trial developing NFI in the first three months of the trial can enter the Clinical trial, but 
only data of patients that were allocated to the placebo group of the Subclinical trial will be 
analysed. 
Inclusion and exclusion criteria 
Patients included in the trials should be between 15 and 60 years of age, must give informed 
consent and should be free from conditions that may affect the peripheral nervous system, such 
as diabetes mellitus, and other active underlying diseases for example hypertension, 
osteoporosis and tuberculosis. Included patients receive deworming treatment with 
Mebendazol before steroid treatment starts. In both studies patients will be followed-up for 18 
months. Excluded will be women pregnant at diagnosis, patients who need steroids for reasons 
other than recent NFI and patients with a single skin lesion on the trunk as the only sign of 
leprosy. 
Randomization and blinding 
In both trials patients will be randomly allocated to one of the two study arms. Randomization 
tables are provided by the statistician and drugs are labelled accordingly by the manufacturer. 
The key is held by the International Coordinator, Study Manager and PI of each centre and will 
be broken after the data analysis is completed or earlier for patients with adverse events, and 
new or worsening NFI. 
 
 
36 
Sample size calculation 
For the Clinical trial a recovery of 60% is presumed for the standard regimen in the control 
group [17]. To detect a recovery of 70% in the treatment group, compensating for 20% of loss 
to follow-up, a total of 720 subjects need to be enrolled. 
The INFIR study shows that of the leprosy patients having subclinical neuropathy 16% will 
eventually develop clinical NFI [1]. For the Subclinical trial we assume a reduction in patients 
developing clinical NFI by half in the treated group (8%). Anticipating a loss to follow-up of 20% 
at 18 months, a sample size of 275 subjects per trial arm is required. For both sample size 
calculations, a one-tailed alternative hypothesis, 80% power and 5% significance is used 
Follow-up 
Patients will be followed-up for 18 months. Nerve function is monitored by monthly VMT and 
MFT in both trials and assessments with NCS and WDT takes place at 20 weeks, 12 and 18 
months from intake in the Subclinical trial. Participants can be withdrawn from the trials because 
of medical or clinical reasons or pregnancy. Subjects missing their appointment will be visited at 
home by research staff within two weeks when contact by cell phone is not possible or did not 
result in late attendance at the clinic. In cases when only one appointment is missed and 
medication is not taken for a maximum of one month, treatment will continue from the first 
package missed. The TENLEP trials started in April 2012, with a planned duration of intake of 
1.5 years. 
Medication 
In both trials the medication provided is prednisolone. Prednisolone will be allocated based on 
two bodyweight classes. The low weight class (patients below 50 kg), will receive prednisolone 
treatment based on a body weight of 45 kg. The high weight class (patients 50 kg and more) 
receives treatment based on a body weight of 60 kg. 
Treatment arms 
In the Clinical trial patients in the intervention arm receive prednisolone for 32 weeks, in tablets 
of 5 mg. The control arm will follow a regimen of 20 weeks and receive placebo tablets to keep 
the number of tablets equal to the treatment group for effective treatment time and duration. 
The dose in both treatment and control arm starts at 1 mg/kg/day (either 45 or 60 mg/day 
depending on weight class) and will be tapered down over 32 and 20 weeks, respectively. 
Figure 1.A shows the dose over time of both arms in the Clinical trial. In contrast to previous 
trials, the middle range of the prednisolone dose will be maintained at a high level (0.44 
mg/kg/day) for a longer period (12 weeks). In the Subclinical trial patients receive either 
prednisolone or placebo for 20 weeks in tablets of 5 mg. The prednisolone dose starts at 1 
mg/kg/day (either 45 or 60 mg/day depending on weight class) and will be tapered down over 
20 weeks. Figure 1.B shows the timeline and dosage. The total dosage of prednisolone over 20 
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weeks will be 2.8 grams for patients under 50 kg body weight, and 3.7 grams for patients over 
50 kg body weight. 
 
 
 
Figure 1 A- Timeline prednisolone dose for patients under 50 kg in the Clinical trial. Figure 1 B- Timeline 
prednisolone dose for patients under 50 kg in the Subclinical trial 
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Adverse events 
Prednisolone has known adverse events, ranging from mild adverse events, such as moon face, 
fungal infections and acne, to serious adverse events such as peptic ulcer, osteoporosis 
glaucoma, cataract, psychosis, diabetes and hypertension [18,19]. Serious adverse events have 
not been encountered frequently in previous trials studying prednisolone for treating NFI in 
leprosy patients [20], however strict monitoring of adverse events will take place in the TENLEP 
trials. In case of serious adverse events the PI will break the key and initiate an individualized 
treatment scheme. In the event of minor side effects additional medication will be prescribed 
according to normal protocol in the clinic, but the key will not be broken. 
 
Data collection 
General assessments 
Before intake, the general health of all possible eligible patients will be checked and history will 
be taken according to the protocol. Additionally, patients will be tested for specific medical 
conditions related to neuropathy and prednisolone intake such as diabetes mellitus (urine test) 
and osteoporosis (FRAX). Leprosy status will be categorized using both WHO classification 
(PB/MB), and Ridley-Jopling classification [21]. The latter will be done on clinical grounds, but a 
skin biopsy can be taken on voluntary basis for confirmation of the classification by a trained 
pathologist. For this procedure an additional consent procedure is in place. Of each patient a 
slit skin smear will be taken for determining the Bacteriological Index (BI). 
 
Clinical nerve function tests 
After intake, eligible subjects will be assessed for clinical sensory and motor nerve impairment. 
The clinical sensory function is tested with monofilaments using a standard set of 5 Semmes-
Weinstein monofilaments ranging from blue (200 mg) to pink (300 g) [22]. This test of touch 
sensibility is based on indenting the skin surface with a series of standard nylon filaments. For 
each thickness it is recorded whether or not the patient feels the touch, starting with the 
thinnest filament. For hands the normal threshold is the blue filament and for feet the purple (2 
mg) filament; when these filaments are felt by the patient it results in a score of 0. The score 
increases with 1 for each thicker filament not felt, with a maximum score of 5 in hands and 4 in 
feet (filament of 300 g not felt) for every site. Each nerve will be tested on 3 sites. The trigeminal 
nerve is tested by assessing the blink regularity. A patient is diagnosed as having sensory 
impairment if the monofilament threshold is increased by three or more monofilament levels in 
one single nerve (over 3 sites). 
Motor nerve impairment will be assessed with Voluntary Muscle Testing (VMT) using the 0–5 
MRC scale [23,24]. The test is performed by checking the ability of the patient to move a body 
part to a given position and to hold that position against resistance applied by the tester. A 
nerve scoring lower than 5 is considered impaired. When a single score of 4 is found this score 
should be independently confirmed by a second assessor. 
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Subclinical nerve function tests 
When new patients show no abnormal values by VMT and MFT they will be tested further for 
possible inclusion in the Subclinical trial. For detecting subclinical neuropathy sensory and 
motor Nerve Conduction Studies (NCS), carried out with the Neurocare 2000® EMG machine 
(BioTech Ltd, Mumbai), and Warm Detection Threshold (WDT) test, using the TSA II (MEDOC, 
Israel), will be performed. NCS and WDT will take place in an air-conditioned room at 
approximately 20-25 °C. 
All assessments will be carried out at both sides of the body. Table 1 shows which nerves will 
be tested and methods used. MFT and VMT will be assessed at start of the trial and 
subsequently every month in both studies and follow-up periods on all subjects. WDT, Sensory 
Nerve Conduction (SNC) and Motor Nerve Conduction (MNC) will be carried out at baseline, 
end of treatment period (20 weeks) and at 12 and 18 months. For the Clinical trial additional 
information will be obtained using the Reaction Severity Scale (RSS) [25], the Screening of 
Activity Limitation and Safety Awareness (SALSA) scale [26] and the Participation Scale [27]. All 
scales will be filled in at baseline, end of treatment period (32 weeks), 12 and 18 months. 
 
Table 1- Nerves assessed by the different methods 
Nerve VMT MFT MNC SNC WDT 
Trigeminal  blink    
Facial x     
Ulnar x x x x x 
Median x x x x x 
Radial x x  x x 
Common peroneal x  x   
Posterior tibial x x x  x 
Sural  x  x x 
 
Reliability and normative studies 
Prior to intake inter-tester reliability studies have taken place for all assessments (MFT, VMT, 
WDT, NCS) to test and improve comparability of the results and ensure high measurement 
quality. After reliability studies for NCS and WDT, normative studies were carried out to establish 
the local normal values for each separate collaborative centre. For each nerve a minimum of 
150 normal subjects from surrounding areas were tested, equally spread over both sexes and 3 
age categories (15–30, 31–45 and 46–60 years of age). Normal subjects will be screened to 
ascertain they do not have diabetes or nerve function impairment. 
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Standard operating procedures and training 
For all assessments standard operating procedures (SOP) have been developed. To achieve 
consistency of the assessments between all research centres, the PI and two main assessors of 
each centre received training in research protocol procedures and handling equipment. In 
addition, an online Good Clinical Practice (GCP) course was completed by all PI’s. 
Outcome measures 
The Clinical trial 
The primary study outcome is the proportion of patients with restored and improved nerve 
function (of all nerves) measured by VMT/MFT at 18 months. Secondary outcomes are based 
on results of the Reaction Severity Scale, SALSA and Participation Scale (Figure 2). 
Furthermore, a Count of Nerve Function Impairment (CNFI) will be computed to measure the 
results of treatment on nerve function, with special interest for most commonly affected nerves. 
The CNFI will consist of the count of nerve function impairments detected by monofilament and 
VMT testing and will be validated in this trial. 
 
The Subclinical trial 
The proportion of patients developing clinical NFI as measured by MFT and VMT is the primary 
outcome indicator (Figure 2). Secondary outcome measures focus on results of the specific 
assessments for detection of subclinical neuropathy (WDT, SNC and MNC). 
Data analysis 
After the data is entered for each centre, data will be checked and cleaned. Regular weekly 
back-ups will be made for local off-site storage in addition to a monthly upload of data via a 
web-based repository to the project statistician. 
 
Reliability studies 
Inter-rater reliability for categorical outcomes of VMT and MFT are assessed using weighted 
Kappa statistics. Comparing differences and averages of paired assessments for WDT, SNC 
and MNC tests are based on Bland-Altman plots. In addition, a mixed model analysis of 
variance will be used to compute the intraclass correlation coefficient. 
 
Normative studies 
To determine normative values for WDT and NCS for each centre, outliers are excluded before 
limits of normal function are calculated using an approach based on regression analysis taking 
into account age-related trends. The 97.5th percentile is used to define abnormal function. 
 
 
 
41 
Primary outcomes 
Analysis of primary outcomes will be done at 20 (Subclinical trial) or 32 weeks (Clinical trial), 12 
and 18 months. Possible effects of potential covariates (gender, age, leprosy classification) will 
be assessed with ANCOVA. All analyses will be carried out using Stata statistical software. 
 
Secondary outcomes 
Continuous outcome measures will be analysed with Analysis of (co)variance, assessing one or 
more covariates. Categorical outcomes may be analysed using chi-squared test or log linear 
models. For Survival outcomes the log rank test will be used. 
Ethics 
All national Research Ethics Committees have approved the study protocol, which are for India: 
Indian Council of Medical Research; Nepal: Nepal Health Research Council (NHRC); Indonesia: 
Komite Etik Penelitian Kesehatan RSUD Dr. Soetomo Surabaya; Bangladesh: Bangladesh 
Medical Research Council- National Research Ethics Committee. In addition, all local Research 
Ethics Committees have given their approval as well. Written consent will be obtained from 
individual subjects before inclusion and for minors additional consent from their guardians will 
be sought. 
 
Discussion 
This paper describes the protocols of two randomized controlled clinical trials within the 
TENLEP study. In the Clinical trial the effect of long term prednisolone treatment on the 
restoration of clinical NFI will be investigated. In the Subclinical trial the efficacy of prednisolone 
in preventing the development of clinical NFI, in patients with subclinical neuropathy, will be 
examined. 
The optimal dose and duration of prednisolone for treating clinical NFI in leprosy has not been 
established yet and there is not enough evidence available from randomized controlled clinical 
trials on the long term effect of prednisolone treatment [3]. The TENLEP study addresses this 
knowledge gap and will extend the current understanding of prednisolone regimens for the 
treatment of clinical NFI by comparing a prednisolone treatment of 32 weeks and 20 weeks 
under controlled circumstances. If a 32 weeks treatment proves to be effective in restoring or 
improving clinical NFI in leprosy patients, new guidelines can be developed which can 
significantly improve patient management in leprosy care and especially a positive effect on the 
prevention of disabilities (POD) can be expected. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- Overview of intake, assessments and outcomes in the Clinical and Subclinical trial    
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This study will be the first to evaluate prednisolone treatment for the prevention of clinical NFI in 
people affected by leprosy diagnosed with subclinical neuropathy. The results of the preceding 
TRIPOD trial provide some insight in possible effects of prednisolone in preventing new NFI [28]. 
To prevent new NFI and reactions, leprosy patients with and without pre-existing NFI at 
diagnosis (as determined with VMT and MFT) received a prophylactic low dose of prednisolone 
(20 mg/day) for four months, tapered down in the last month. Although a reduced incidence of 
new NFI and reactions was observed at the end of treatment at four months, this was not 
sustained at one year. More important however, the preventive effect of prednisolone at four 
months was more than three times higher in patients with no pre-existing NFI [28]. A second 
study that has some similarities with our Subclinical trial is of that of Capadia et al. (2010), who 
studied the effect of prednisolone on neuropathy as assessed with NCS. In their study, 
neuropathy was divided in mild, moderate and severe groups, as percentages deviating from 
normative values. Their findings suggest that a 12-week prednisolone course is not effective in 
preventing or reversing nerve damage. However, they found that mildly affected nerves showed 
higher improvement rates than moderately and severely affected nerves (53%, 21% and 14% of 
the nerves improved respectively). 
The better outcomes of prednisolone treatment and prophylaxis on non-affected and mildly 
affected nerves from both studies of TRIPOD and Capadia et al. [29] show the importance of 
early treatment of neuropathy in leprosy patients. With the Subclinical trial we hope to establish 
that prednisolone treatment can prevent the development of clinical NFI and in this way can 
prevent disabilities and deformities in newly diagnosed leprosy patients. 
If the prednisolone treatment turns out to be effective in the prevention of clinical NFI, the 
implementation of treatment for patients with evident subclinical neuropathy in clinical practice 
will be complicated. The methods to detect subclinical neuropathy used in this study (TSA II and 
Neurocare 2000) will not be available in the field, since the devices are expensive and conditions 
under which the assessments have to take place, a steady environmental temperature of 20–25 
°C, are difficult to realize in tropical climates. Therefore, it is important to search for a cheaper, 
portable method to detect subclinical neuropathy that can be easily used in field clinics. 
However, also without a test to determine subclinical neuropathy the results of this study can be 
useful to improve treatment guidelines. The current prediction rule allows to distinguish leprosy 
patients with a high risk for developing NFI [30]. However, at the moment, providing 
prophylactic prednisolone treatment to this group of patients is considered unethical, as a 
significant number of patients will take prednisolone unnecessarily. With the information of the 
TENLEP trials we hope the prediction rule can be refined so administering prophylactic 
prednisolone is acceptable in certain, well defined groups. 
In conclusion, the TENLEP study will add to the current understanding of neuropathy due to 
leprosy and will provide better insight into the effectiveness of prednisolone treatment in the 
prevention and recovery of nerve function loss in leprosy patients. If this study shows the 
effectiveness of prednisolone in the prevention and recovery of NFI it will improve treatment 
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options and contribute therefore to the prevention of permanent sensory and/or motor nerve 
function loss in people affected by leprosy and hence prevent disabilities and deformities which 
will improve the lives of many of these patients. 
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Abstract 
Introduction 
The monofilament test (MFT) is a reliable method to assess sensory nerve function in leprosy 
and other neuropathies. Assessment of the radial cutaneous and sural nerve in addition to 
usually tested nerves can help improve diagnosis and monitoring of nerve function impairment 
(NFI). To enable the detection of impairments in leprosy patients, it is essential to know the 
monofilament threshold in normal subjects of these two nerves.  
Methods  
The radial cutaneous, sural, ulnar, median and posterior tibial nerves of 245 volunteers were 
tested. All nerves were tested at three sites on both left and right body side. Normal 
monofilament thresholds were calculated per test-site and per nerve.  
Results  
We assessed 490 radial cutaneous and 482 sural nerves. The normal monofilament was 2-g 
(Filament Index Number (FIN) 4.31) for the radial cutaneous and 4-g (FIN 4.56) for the sural 
nerve, although heavy manual labourers demonstrated a threshold of 10-g (FIN 5.07) for the 
sural nerve. For median and ulnar nerves, the 200-mg (FIN 3.61) filament was confirmed as 
normal while the 4-g (FIN 4.56) filament was normal for the posterior tibial. Age and occupation 
have an effect on the mean touch sensitivity but do not affect the normal threshold for radial 
cutaneous and sural nerves.  
Conclusion  
The normal thresholds for the radial cutaneous and sural nerves are determined at the 2-g (FIN 
4.31) and the 4-g (FIN 4.56) filament respectively. The addition of the radial cutaneous and sural 
nerve to sensory nerve assessment may improve the diagnosis of patients with impaired 
sensory nerve functions. 
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Introduction 
In leprosy care, accurate diagnosis and monitoring of nerve function impairment (NFI) are 
crucial. With early diagnosis and treatment of NFI, severe peripheral nerve impairment, often 
resulting in disabilities, can be prevented. The main tests used for diagnosis and monitoring of 
NFI in clinical practice are voluntary muscle tests (VMTs), ball-point tests (BPTs) and 
monofilament tests (MFTs) on, primarily, hands and feet. In leprosy affected nerves, sensory 
function loss often precedes motor function loss [1,2]. MFTs are able to detect and monitor 
sensory nerve function loss accurately, using variation in pressure. They offer more sensitive 
results than BPTs which generally provide only a yes/no outcome [3]. Monofilament testing is 
quick, sensitive and reliable and, therefore, a useful method to diagnose and monitor nerve 
impairment over time [4-6].  
Most studies that assess NFI in leprosy patients examine the ulnar, median and posterior tibial 
nerves because these nerves are responsible for sensation on the hand palms and foot soles, 
comprising areas of the body most prone to ulceration and burns because of loss of protective 
sensation. In addition to these three nerves, assessment of the radial cutaneous (innervating a 
part of the dorsal side of the hand (Figure 1A) and the sural nerves (innervating the lateral side of 
the foot (Figure 1B) might also prove informative. Impairments of the sensory radial cutaneous 
and sural nerves are rarely tested in clinical and research settings because these impairments 
have little functional effect on patients. However, including assessment of the radial cutaneous 
and sural nerve can yield additional information to improve the diagnosis and monitoring of NFI. 
The inclusion of the dorsum of the hands and feet in sensory testing procedures has been 
recommended by Wexler et al. (2007) and Kuipers et al. (1994) because lesions and sensory 
impairment were located frequently on this part of the hands and feet [7,8]. Furthermore, the 
ILEP Nerve Function Impairment and Reaction (INFIR) study indicates that the sural and radial 
cutaneous nerve play an important role in the diagnosis of NFI. In that study, newly diagnosed 
patients without NFI were followed for two years, during which the sural became impaired in 
37.2% of patients tested with MFTs (2), and the radial cutaneous was found to be affected as 
often as the median nerve (8.8%). Khambati et al. (2009) also reported sensory impairment in 
28% and 23% of the sural and radial cutaneous nerves, respectively, in newly diagnosed 
multibacillary (MB) patients. However, these studies omitted to establish normal values for the 
MFT thresholds in relation to these two nerves.  
In patients who are at risk of NFI, diagnosis of impairment is necessary before reaction 
treatment can be started. However, impairment can only be determined when the monofilament 
threshold of normal subjects is known. For MFTs, the normal threshold represents the filament 
felt by a certain percentage (usually 95 or 97.5%) of normal subjects (not affected by the 
disease). Studies in different Asian countries determined that the 200-mg (FIN 3.61) filament 
represents the normal threshold for the palm of the hand (median and ulnar nerves) while the 2-
g (FIN 4.31) filament was normal for the plantar side of the forefeet (posterior tibial nerve) [9-11]. 
These studies provide for the diagnosis of NFI in median, ulnar and posterior tibial nerves in 
Asian patients. However, before the radial cutaneous and sural nerves can be reliably used in 
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the diagnosis and follow-up of NFI, the normal values must be known. In this study, we 
establish normal threshold values for the radial cutaneous and sural nerves in Indian and Nepali 
volunteers and provide recommendations for clinical practice. Additionally, we assess the 
median, ulnar and posterior tibial nerves in order to compare our results with previous normative 
studies.  
 
Methods 
Subjects 
Subjects were recruited from four leprosy hospitals, two in Nepal and two in India. In each 
country, one urban and one rural hospital was selected. Visitors accompanying patients, 
patients from other departments (e.g. dermatology), and hospital staff were asked to 
participate. Subjects were excluded when they suffered from conditions with neurological 
implications, such as diabetes mellitus. Nearly all persons invited were willing to participate. A 
total of 245 Indian and Nepali volunteers, not known to have a history of leprosy, were recruited 
for MFT assessment. This study to establish normal values, was part of the Treatment of Early 
Neuropathy in Leprosy (TENLEP) trials, for which ethical approval was obtained from the Indian 
Council of Medical Research and the Nepal Health Research Council. All subjects were 
informed about the goal and procedures of the study and verbally agreed to participate. 
Data collection 
Age, occupation and dominant hand were recorded for all subjects. Prior to analysis, 
occupation was grouped into three categories: office work (e.g. students, business people and 
drivers) manual labour (e.g. cleaners, housewives, nurses and tailors) and heavy manual labour 
(e.g. farmers, labourers and porters). Three age groups were constructed before analyses: 15-
30, 30-45 and 45-60. Some subjects were interviewed to determine their smoking behaviour 
(n=170); and habits of wearing footwear and types of footwear (closed shoes, sandals or a 
combination) (n=114), and whether and how often they sit cross-legged (n=116).  
Monofilaments 
The MFT is a touch sensibility test which indents the skin surface with a series of standard nylon 
filaments of same length but with varying degrees of thickness. A standard “pocket” set of six 
coloured Semmes-Weinstein monofilaments was used (Sorri-Bauru, São Paulo, Brazil), with 
bending forces ranging from 70-mg (green, FIN 2.81) to 300-g (pink, FIN 6.65) (Table 1) [12].  
Test procedure 
According to standard protocol [13], filaments were applied at a straight angle to the skin and 
with sufficient force to make the filament bend slightly (C shape). The filaments were applied 
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slowly, the pressure maintained briefly and then removed slowly, taking approximately one 
second for each step. The subjects were asked to keep their eyes closed during this procedure 
and to indicate the place where they had felt the touch. Deviation of roughly two centimetres 
from the exact touch location was considered acceptable when there was adequate response 
time. The filaments were applied in sequential order from lightest (70-mg) to heaviest (300-g), 
applying the 70-mg (FIN 2.83) and 200-mg (FIN 3.61) filaments with a maximum of three times 
per site when the monofilament slipped or was not detected by the subject. The same applied 
for the 2-g (FIN 4.31) filament used on the feet. In order to keep the subjects focused, efforts 
were made to keep the test room silent and fans were switched off to minimize noise and the 
effect of the circulating air on the skin. A pre-test was carried out on all subjects before 
outcomes were recorded to make sure they understood the test. All data was collected by one 
trained assessor.  
 
Table 1- Characteristics of the standard pocket set of Semmes-Weinstein monofilaments 
 
Filament Filament index number Bending force (grams) 
Green  2.83 0.07  
Blue 3.61 0.2 
Purple 4.31 2 
Red 4.56 4 
Orange 5.07 10 
Pink 6.65 300 
                   
Note: The filament index number is calculated from the bending force in milligram: FIN = log (force *10) 
Test sites 
In addition to the radial cutaneous and sural nerves, the ulnar, median and posterior tibial 
nerves were tested. For each nerve, three test-sites were assessed on both the left and right 
side of the body. For the ulnar, median and posterior tibial nerves, the same sites were 
examined as in the INFIR study [14]. However, we made one exception to the INFIR 
methodology by assessing the tip of the middle finger as the third point for the median rather 
than the index finger. The three test-sites for the radial cutaneous and sural nerves were 
selected as shown in Figure 1. The radial cutaneous nerve innervates a part of the dorsal 
surface of the hand: the proximal radial site of the index finger and thumb web space. This is 
shown in grey in Figure 1A [15]. The sural nerve innervates part of the plantar lateral surface of 
the foot and the lateral aspect of the ankle. The three test-sites can be found on the plantar 
lateral surface in one straight line about 1.5 cm above the sole of the foot (Figure 1B). 
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Figure 1 A- Dorsal innervation area of radial cutaneous nerve and the three test-sites. Figure 1 B- 
Innervation area of the sural nerve and the three test-sites  
 
Outcome 
For every test-site, the lightest filament detected was recorded, using a scoring method. The 
lightest filament (70-mg, FIN 2.83) was given a score of 0, and the score increased with one 
point for each thicker filament felt, with score 1 for 200-mg (FIN 3.61), 2 for 2-g (FIN 4.31), 3 for 
4-g (FIN 4.56) and 4 for the heaviest, 10-g, filament (FIN 5.07). A patient is diagnosed with NFI 
when the overall score of a nerve from the total of the three test-sites is 3 or higher [14,16-18]. 
Weights and FINs are used to describe the filaments in this study because weights are well 
understood in the field and FINs are often used in scientific studies [10,19-22]. 
The normal threshold value for a test-site is defined as the monofilament that was detected by 
95% of the volunteers, indicating that subjects only able to detect filaments heavier than the 
threshold are very likely to have NFI. Figure 2 shows an example in which 2-g, the first filament 
detected by at least 95% of the subjects, represents the normal threshold value. From the three 
individual test-sites, the overall normal value for the nerve is derived. The heaviest monofilament 
detected in any of the three sites determines the normal value for the entire nerve. 
 
 
1 
2 
3
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3
55 
 
  
Figure 2- Explanation of the determination of our 95% normal threshold value (an example) 
 
Data analysis 
Normal monofilament thresholds were calculated per test-site and per nerve. A McNemar test 
for correlated proportions was carried out to test whether the percentage of subjects detecting 
the 200-mg and 2-g filament differed between the right and left hand and foot respectively. 
When no difference was found, the 95% normal thresholds were calculated for all nerves. 
Mann-Whitney tests were used to explore the association of sex, country of origin and dominant 
hand on mean FIN, calculated by averaging the three test-sites per nerve. Kruskal-Wallis tests 
were carried out to analyse the effect of age and occupational group on the mean FIN. 
Furthermore, the effect of footwear types and cross-legged sitting on the average filament 
detected by both nerves in the feet (sural and posterior tibial) was examined in a subgroup of 
volunteers using Kruskal-Wallis tests. Based on the assumption of independent data, all 
univariate analyses are performed on the nerves of the right body side only. A p-value of less 
than 5% was considered statistically significant. All tests were done using SPSS statistical 
package 19.0.  
 
Results 
Radial cutaneous and sural nerves were assessed in 119 men and 126 women. Ulnar, median 
and posterior tibial nerves were tested in 198 of these persons. The mean age of the subjects 
was 35.5 years. Table 2 gives an overview of the characteristics of the 245 volunteers. 
The weight of the monofilament detected by left and right body side did not significantly differ 
for any test-site. As a result, normal threshold values were calculated using 490 hands and feet, 
independent of body side. Normal thresholds, based on the 95% cut-off, are shown in Table 3 
for the entire study group and separately for the three age groups because age is known to 
have a significant effect on touch sensitivity [10,22,23]. For the radial cutaneous and sural 
nerves, the normal threshold values differed between the three test-sites. In consequence, the 
heaviest filament was used to determine the normal threshold for the entire nerve. 
Normal threshold value is 2-g (FIN 4.31):  
the minimum of 95% is reached at this filament 
79%* 93% 98% 100% 
* percentage of subjects detecting filament 
100% 
0.07 g  0.2 g  2 g  4 g  10 g 
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Table 2- Subjects characteristics of 245 volunteers 
 
                                                          % 
 Sex (male) 48.6 
  
Age (years) 15-29 34.3 
30-44 40.4 
45-60 25.3 
   
Country 
(n = 245) 
India 38.8 
Nepal 61.2 
   
Smoking 
(n = 174) 
No 81.6 
Yes 18.4 
   
Occupation 
(n =229) 
Office 41.9 
Manual 41.5 
Heavy 16.6 
   
Dominant Hand 
(n = 218) 
Right 95.4 
Left 4.6 
   
Shoe wearing 
(n = 114) 
Sandals 64.0 
Shoes 19.3 
Both 16.7 
   
Cross leg sitting 
(n = 116) 
No 28.4 
Sometimes 28.4 
Often 43.1 
 
This resulted in a normal threshold of 2-g (FIN 4.31) for the radial cutaneous and 4-g (FIN 4.56) 
for the sural. For both ulnar and median nerves, the 200-mg (FIN 3.61) represents the normal 
threshold while for the posterior tibial it was the 4-g (FIN 4.56) filament.  
Univariate analyses identified age as the only variable that showed significant different mean FIN 
between the groups across all nerves. The higher the age group, the higher the mean filament 
weight detected by the subjects (Figure 3). However, comparison of the normal thresholds for 
the entire study group and the three age groups (Table 3) showed that thresholds are barely 
affected by age. The youngest group (15-30 years) shows lower thresholds for the radial, sural 
and posterior tibial; the oldest group (45-60 years) has a higher threshold for the median nerve. 
Occupation was significantly associated with the touch sensitivity of all nerves except the radial 
cutaneous nerve (Table 4). Volunteers undertaking heavy manual labour detected a higher mean 
size monofilament than those undertaking office work and manual labour, indicating a lower 
touch sensitivity. Moreover, the heavy manual labour group had a higher normal threshold than 
the entire study group for sural, ulnar, median and posterior tibial nerves. We also found that for 
the sural nerve, wearing shoes and never sitting cross-legged resulted in a lower normal 
threshold, hence a higher touch sensitivity. 
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Discussion 
This study showed that the normal threshold for monofilament testing for the radial cutaneous is 
the 2-g (FIN 4.31) filament. For the sural nerve, this threshold is the 4-g (FIN 4.56) filament. 
Furthermore, we established that the 200-mg (FIN 3.61) filament is the normal threshold for the 
ulnar and median nerve, while the 4-g (FIN 4.56) filament represents the normal threshold for 
the posterior tibial nerve.  
In this study, we confirmed the threshold for the palm of the hand as found in previous 
normative studies in Asians. The 200-mg (FIN 3.61) filament was identified as normal value for 
the median and ulnar nerve in two studies in Nepal, using a threshold cut-off of 95% (9) and 
97% [11]. A study in Thailand showed that 97% of the normal subjects detected a 3.84 filament 
(this filament is not used in our study and is placed between 200-mg (FIN 3.61) and 2-g (FIN 
4.31)) [10]. Furthermore, these three studies agreed the 2-g (FIN 4.31) filament was the normal 
threshold for the plantar side of the foot (posterior tibial nerve). This was not confirmed by our 
findings that the 4-g (FIN 4.56) filament represents the normal threshold for this nerve. It is 
possible that certain subgroups were overrepresented in previous studies, lowering the 
thresholds. For example, in the study by Kets et al. (1996), 64% of their subjects were under the 
age of 30. With this age distribution, a lower threshold is to be expected because we found that 
the youngest age group (15-29) has a lower threshold for the posterior tibial nerve than the 
entire group. This might also apply to groups which are left-handed, wearing closed shoes or sit 
cross-legged sometimes. The earlier studies, however, did not report on these parameters.  
The threshold we established for the radial cutaneous was consistent with our expectations, 
based on studies in Nepal, Thailand and India [19]. We assumed that the touch sensitivity of the 
dorsum of the hand would be similar to the palmar side of the hand and would lie between 200-
mg (FIN 3.61) and 2-g (FIN 4.31), resulting in a threshold of the 2-g (FIN 4.31) filament. The 
Indian study, testing 57 normal subjects, assessed one test-site for the radial cutaneous nerve, 
corresponding with our second test-site in the radial cutaneous [19]. 
However, the cut-off used to determine the normal threshold is not clearly defined in the Indian 
study. We calculated from their data that the 200-mg (FIN 3.61) filament was detected on the 
right and left hand by 94.7% and 98.2% respectively. With 95% cut-off used in our study, the 
normal threshold would then correspond with the 2-g (FIN 4.31) and 200-mg (FIN 3.61) filament 
respectively. 
The difference in threshold between the dorsal and palmar side of the hand may be related to 
the number of cutaneous nerve endings. The density of tactile receptors can be mapped in 
detail by a 2-point discrimination test. From this test, it is known that the fingertips and the palm 
of the hands have a higher density of nerve endings than the dorsum of the hands [24].  
 
  
Table 3- Monofilament thresholds per test-site and per nerve for all subjects and per age group 
                 Nerves Radial cutaneous Sural Ulnar Median Posterior tibial 
                   Sites* R1 R2 R3 S1 S2 S3 U1 U2 U3 M1 M2 M3 P1 P2 P3 
                All subjects  
 Result per test-site  4.31 4.31 3.61 4.56 4.56 4.31 3.61 3.61 3.61 3.61 3.61 3.61 4.56 4.56 4.56 
 Percentage feeling     
    MF threshold 100 99.8 98.4 97.9 99.0 98.5 99.0 98.2 98.0 98.7 96.7 98.2 98.2 99.5 99.0 
 Result per nerve 4.31 4.56 3.61 3.61 4.56 
Age groups  
15-29  (n=168)  
 Result per test-site  3.61 3.61 3.61 4.31 4.31 4.31 3.61 2.83 2.83 3.61 3.61 2.83 4.31 4.31 4.31 
 Percentage feeling  
    MF threshold 97.0 98.2 98.8 96.4 98.2 100 100 96.6 97.9 100 100 97.9 95.9 98.6 98.6 
 Result per nerve 3.61 4.31 3.61 3.61 4.31 
30-44  (n=198)  
 Result per test-site  4.31 4.31 3.61 4.56 4.31 4.31 3.61 3.61 3.61 3.61 3.61 3.61 4.56 4.31 4.31 
 Percentage feeling     
    MF threshold 100 99.5 97.0 99.5 95.8 99.0 98.0 98.6 98.0 98.6 97.3 98.0 100 95.9 96.6 
 Result per nerve 4.31 4.56 3.61 3.61 4.56 
45-60  (n=124)  
 Result per test-site  4.31 4.31 3.61 4.56 4.56 4.31 3.61 3.61 3.61 3.61 4.31 3.61 4.56 4.56 4.56 
 Percentage feeling     
    MF threshold 100 100 100 95.1 95.9 95.9 99.0 95.1 95.1 97.1 100 96.1 95.1 100 98.0 
 Result per nerve 4.31 4.56 3.61 4.31 4.56 
*calculated over left and right body side combined 
R1= Radial Cutaneous test-site 1, R2= Radial Cutaneous test-site 2, R3= Radial Cutaneous test-site 3, S1= Sural test-site 1, S2= Sural test-site 2, S3= Sural test-site 3, U1= Ulnar test-site 1, 
U2= Ulnar test-site 2, U3= Ulnar test-site 3, M1= Median test-site 1, M2= Median test-site 2, M3= Median test-site 3, P1= Posterior tibial test-site 1, P2= Posterior tibial test-site 2, P3= 
Posterior tibial test-site 3 
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Figure 3- Trend line mean Filament Index Number (FIN) for three test-sites for a radial cutaneous and                              
sural nerves for right body side  
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The sural threshold established (red, FIN 4.56) was higher than expected. Given that there is no 
literature on normal thresholds for the sural nerve, we assumed that the lateral border of the 
foot would have a similar threshold as the plantar side of the foot, determined in previous 
studies as 2-g (FIN 4.31). Although the threshold was not as expected, our assumption was 
correct because the threshold for the plantar and the lateral side of the foot were similar.  
 To determine whether we should implement different thresholds for different groups, we 
performed univariate analyses and compared the thresholds per group (e.g. males vs. females 
et cetera). The analyses revealed that age and occupation were important variables associated 
with touch sensitivity. The decreased sensitivity with increasing age was also reported in other 
normative studies [10,11,22]. Mitchell and Mitchell (2000) discuss that neural degeneration, 
reducing the number of touch receptors and slowing down conduction, is the probable cause. 
In the heavy manual occupational group, normal thresholds were one level higher for the sural, 
ulnar, median and posterior tibial nerve. A normative study in Thailand found the same pattern 
with heavy manual labour being associated with higher sensory thresholds [10]. Heavy manual 
workers, like farmers and labourers, might have thicker callus on hands and feet, leading to 
higher monofilament thresholds. This would also explain why the radial cutaneous threshold 
does not differ between the labour groups because the dorsum of the hand is not involved in 
manual work and is therefore not likely to develop callus. The monofilament threshold for the 
radial cutaneous and sural nerve, as established in this study, can be used for all persons, with 
exception of the heavy manual labourer group for whom a higher threshold for the sural nerve 
applies. 
Given the multi-centre, multi-country study design, our findings are generalizable and especially 
useful for Asian countries where leprosy is often still prevalent and where neuropathies will 
become more widespread with the rising diabetes prevalence [25]. However, there are some 
factors that should be taken into account when evaluating our results. First, we mainly assessed 
close contacts of leprosy patients, such as family and staff of the hospitals. Our volunteers 
could have been unknowingly infected with leprosy because we did not test for leprosy. Hence, 
the potential presence of NFI could have resulted in higher thresholds. Second, we had to take 
into account the habit of this population to take family and friends into the test rooms. As a 
result, and despite our efforts, it was not always possible to test the volunteer in silence. This 
could have led to diminished focus and higher thresholds. However, the habit of bringing family 
will also occur in clinical practice so that our results will be still acceptable to determine the NFI 
status in leprosy patients. Both factors may have led to an overestimation of the thresholds but 
overestimation is better than underestimation that might lead to unnecessary treatment. In 
addition, we intended to correct the outcomes for multiple important variables in a multivariate 
analysis. However, no reliable tests were available since the data is nested, not independent, 
not normally distributed and categorical. Finally, even though monofilament testing is an optimal 
method in clinical practice to quantify NFI, most leprosy programs do not have access to the 
relatively expensive monofilaments. However, we hope that the rising prevalence of diabetes will 
stimulate the search for low-cost sources of monofilaments. If this is the case, leprosy clinics 
will be able to benefit as well.  
 
  
          Table 4- Mean filament index number (FIN) ± SD per nerve for different variable groups for right body side 
 Radial cutaneous          Sural        Ulnar         Median Posterior tibial 
      Age (n)            
   15-29    (84) 3.04# ±0.22 3.69# ±0.34 2.88 ±0.12 2.90 ±0.14 3.75# ±0.42 
   30-44    (99) 3.19 ±0.32 3.92 ±0.31 2.98 ±0.25 3.00 ±0.27 3.90 ±0.40 
   45-60    (102) *3.28 ±0.31 *4.05 ±0.38 *3.02 ±0.30 *3.101 ±0.35 *4.06 ±0.45 
Sex  (n)           
  Male  (119) 3.19 ±0.33 3.91 ±0.36 2.97 ±0.26 2.99 ±0.29 3.92 ±0.44 
  Female  (126) 3.13 ±0.28 3.84 ±0.37 2.93 ±0.21 2.98 ±0.25 3.84 ±0.43 
Dominance  (n)           
  Right (208) 3.16 ±0.30 3.87 ±0.38 2.95 ±0.23 2.99 ±0.27 3.90 ±0.44 
  Left (10) 3.19# ±0.22 *4.012 ±0.30 2.98 ±0.24 2.961 ±0.27 *3.72# ±0.42 
Country  (n)           
  India   (95) 3.16 ±0.33 3.82# ±0.39 2.93 ±0.20 2.96 ±0.25 3.82 ±0.49 
  Nepal (150) 3.16 ±0.28 3.90 ±0.34 2.96 ±0.25 3.00 ±0.28 3.93 ±0.40 
Occupation  (n)           
  Office   (96) 3.18 ±0.30 3.79 ±0.36 2.90 ±0.17 2.93 ±0.22 3.80 ±0.40 
  Manual (95)  3.15 ±0.30 3.89 ±0.35 2.94 ±0.22 3.00 ±0.25 3.92 ±0.42 
  Heavy manual (38) 3.15 ±0.29 *4.052 ±0.41 *3.071 ±0.32 *3.091  ±0.35 *3.992  ±0.51 
Smoking  (n)           
  No    (142)  3.11# ±0.25 3.82 ±0.38 2.93 ±0.21 2.96 ±0.25 3.85 ±0.44 
  Yes  (32) 3.17 ±0.33 *3.97 ±0.42 2.98 ±0.26 3.02 ±0.29 *4.04 ±0.46 
ShoeŦ  (n)           
   Sandals (73)   3.90 ±0.33     3.98 ±0.40 
   Shoes   (22)   3.76# ±0.29     3.82# ±0.33 
   Both     (19)   *4.09 ±0.28     3.99 ±0.39 
Cross legŦ  (n)           
  No         (33)    3.88# ±0.30     3.86 ±0.39 
  Sometimes  (33)   3.74 ±0.34     3.89# ±0.43 
  Often  (50)   *4.00 ±0.34     4.04 ±0.35 
              * a significant (p<0.05) difference between groups, Ŧresults shown only for nerves in foot, #Normal threshold is one FIN lower than the threshold for total group  
             1Normal threshold is 2-g (FIN 4.31) where the total group threshold is 200-mg (FIN 3.61), 2Normal threshold is 10-g (FIN 5.07) where the total group threshold is 4-g (FIN 4.56)  
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Similar to large studies on leprosy neuropathy (INFIR, TENLEP), three test-sites per nerve were 
assessed so that it was possible to use the scoring system described by Anderson [14,16,18]. 
Despite this, we chose to present our final results per nerve. The monofilament test is a quick 
and simple field method, and it is desirable to work with a minimal number of threshold values 
to guarantee its effectiveness.  
 When the threshold differed between the three test-sites, we decided that the heaviest filament 
would determine the normal threshold. In those cases that the threshold differed between the 
test-sites, we could also have chosen alternative methods. For example by taking the filament 
detected in two out of three test-sites as the final threshold. However, in that case the 
thresholds would still be the same for the entire study group. When we would have taken the 
lightest filament of the three test-sites as threshold for the nerve, the threshold for the radial 
cutaneous and sural nerve would have been one filament lower (200-mg (FIN 3.61) and 2-g (FIN 
4.31) respectively). With a lower threshold, NFI will be detected earlier but more ‘false positives’ 
would occur. For this reason, we believe that it is better to use a threshold that is on the ‘safe 
side’ for the radial cutaneous and the sural nerve, particularly as injuries due to loss of 
protective sensation are less common on the dorsum of hands and feet.  
Conclusions 
Taking into account all considerations, we recommend including the assessment of the radial 
cutaneous and sural nerves for monofilament testing in routine clinical practice. Testing the 
sensory function of the dorsum of the hand and lateral foot can give additional information on 
NFI, especially since these two nerves seem to be often impaired and are some of the earliest 
nerves impaired in leprosy [26]. Additional assessment of the radial cutaneous and sural nerves 
can improve diagnosis and monitoring of NFI, and may help prevent severe NFI and disabilities 
in patients with leprosy and neuropathies caused by other diseases (e.g. diabetes). In 
conclusion, the 2-g (FIN 4.31) filament should be taken as the normal threshold when testing 
the radial cutaneous nerve while the 4-g (FIN 4.56) filament is the normal threshold for the sural 
nerve. As an exception, heavy manual labourers have a higher threshold for the sural nerve, 
namely the 10-g (FIN 5.07) filament. 
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Abstract 
Introduction  
Sensory and/or motor nerve function impairment as a consequence of neuropathy is often 
assessed using electro-neurophysiological tests. However, in low resource countries where the 
required equipment is rarely available, manual muscle strength testing (MMST) and 
monofilament testing (MFT) offer very reliable alternatives. In six leprosy programmes in four 
Asian countries, a multi-centre randomised clinical trial (RCT) was carried out to assess the 
effect of corticosteroids on neuropathy in leprosy-affected people. The sensory and motor nerve 
function was tested using MMST and MFT, including new test sites for the sural and radial 
cutaneous nerves (MFT) and the posterior tibial and common peroneal nerves (MMST). The 
reliability studies of the MMST and MFT tests of the TENLEP (Treatment of Early Neuropathy in 
LEProsy) trials are presented here.  
Methods  
Two assessors in each centre independently used the MFT and MMST in 30 leprosy-affected 
people. 
 
Results  
Reliability is good to very good for MFT in nearly all nerves. MMST also shows good to very 
good agreement, with a few exceptions.  
Conclusion  
Our study confirms that MMST and MFT can be performed reliably, and that the new tests also 
have acceptable reliability. 
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Introduction 
There are many neuropathies that may result in sensory and/or motor function impairment that 
can be assessed and evaluated with practical clinical techniques such as manual muscle 
strength testing (MMST)a and monofilament testing (MFT) [1]. Electro-neurophysiological 
assessments have an important place in the differential diagnosis and follow up of suspected 
neurological diseases but are very rarely available in low-resource countries. When clinicians are 
trained, MMST and MFT could still be a useful clinical adjunct to the electro-neurophysiological 
assessments. Various studies have reported good reliability of both MMST and MFT [2-8]. Many 
of these studies have been conducted in leprosy-endemic 
countries because of the ‘availability’ of large numbers of subjects which makes it easier to 
conduct such studies in a relatively short time. MMST and MFT, however, could also be very 
useful in assessing neuropathies due to other common diseases such as diabetes, or 
neuromuscular diseases such as hereditary motor and/or sensory neuropathies. 
This study is in part a replicate study of reliability testing. The difference, however, is that this is 
a multi-centre reliability study that includes sensory and motor tests at sites for which reliability 
had not yet been determined.  
In a randomised clinical trial (RCT), studying the efficacy of corticosteroids in the prevention and 
treatment of leprosy neuropathy, MMST and MFT were used to screen patients for intake, and 
for the follow-up of patients for the duration of the trials [9]. 
TENLEP (Treatment of Early Neuropathy in LEProsy) consists of two related multicentre, multi-
country trials. In the Sub-clinical trial, patients with normal monofilament and muscle strength 
values, but with impaired electrodiagnostic or thermodiagnostic parameters, are enrolled. The 
outcomes for a group that will receive corticosteroids for 20 weeks will be compared with the 
outcome for a placebo group. The aim is to assess whether corticosteroids may prevent the 
onset of clinically detectable nerve function loss. 
Patients with impaired nerve function of less than 6 months duration, as confirmed by MMST 
and MFT, are enrolled in the other arm of the study: the Clinical trial. In this trial, the currently 
recommended corticosteroid treatment for reaction is compared with an alternative regimen 
that is 3-4 months longer. The protocols for both trials have been published [9]. As decisions for 
enrolment and follow-up in both trials are based on the results of MMST and MFT, we felt that 
these assessments needed to show good reliability in and between the participating study 
centres. Hence, for both studies, we determined the reliability of MMST and MFT. 
 
 
                                                
a VMT (Voluntary Muscle Testing) is the more commonly accepted abbreviation for muscle testing. 
However, ‘voluntary’ muscles can also be assessed with dynamometers. To distinguish between the two, 
the first author prefers to add Manual. 
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Methods 
Following approval by local and national ethical committees, reliability was assessed in the six 
study centres where TENLEP is implemented: two each in India and Nepal and one centre each 
in Indonesia and Bangladesh. 
The level of experience of selected staff varied between and within centres; therefore all 
participating staff were trained to perform testing in a standard manner. For this purpose, a 
Standard Operational Procedure (SOP) manual was developed.   
 
Test-sites and procedures 
Table 1 shows nerves in which motor and sensory function are commonly affected and 
assessed in the diagnosis and follow up of leprosy neuropathy. 
 
Table 1- Overview of nerves and their test-sites for MMST and MFT 
Nerve Muscle strength testing Sensory testing with 
monofilaments 
   Facial Eye closure               - 
Ulnar Little finger abduction Little finger/ hypothenar 
Median Thumb abduction Thumb/ middle finger 
Radial (cutaneous) Wrist extension Radial site index/ thumb web 
Common Peroneal (CP) Foot dorsiflexion               - 
Deep branch CP Great toe extension               - 
Posterior tibial Great toe plantar flexion Great toe plantar surface/ forefoot 
Sural               - Lateral border foot 
 
Motor 
For each nerve with motor function, tests on one muscle group stimulated by that nerve were 
performed, using the Medical Research Council (MRC) grades [1]. Motor function tests for 
facial, ulnar, median, radial cutaneous and common peroneal were carried out as described 
elsewhere [1]. As a relatively new test we introduced the ‘great toe up and down’ test to assess 
the motor function of the terminal branch of the common peroneal nerve, and the posterior tibial 
nerve respectively. The great toe up test is performed when the patient is sitting with his/her 
feet flat on the ground. The patient is asked to lift the great toe only and the assessor 
determines muscle strength, applying pressure on the proximal phalanx. The great toe down 
test is also called the ‘paper grip test’ [10]. For this, an MRC score of 5 (strong), 4 (weak) or 0 
(paralysed) could be given. 
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Sensory 
For each nerve with a sensory component, three test-sites were used within the innervation 
area of that nerve. Monofilament testing was performed using five monofilaments: 200 mg, 2 g, 
4 g, 10 g and 300 g. For the foot, because of known higher thresholds, the lightest, 200 mg 
filament, was omitted. Each of three sites was then given a score based on the filament felt, the 
heaviest monofilament getting the highest score, allowing a maximum total score of 15 for the 
ulnar, median and radial nerves (4 filaments) and 12 for the foot (3 filaments). 
For the ulnar, median and posterior tibial nerves, the same sites were examined as in the INFIR 
study [11], except for the median nerve where we used the tip of the middle finger instead of 
the index finger. For the first time, the radial cutaneous and sural nerves were also assessed 
using three test-sites, which are shown in Figure 1. 
 
 
     
Figure 1- Test-sites for radial cutaneous (hand) and sural nerve (foot) monofilament testing 
Reliability testing 
To develop expertise, a large number of patients were assessed under supervision of 
experienced assessors before the reliability study was initiated. Following that period of skill 
development, both therapists were asked to randomly and independently assess a minimum of 
30 subjects, all of whom were leprosy-affected people. The testers were blind to each other’s 
results and the order of subjects was changed randomly between testers. Motor and sensory 
nerves were assessed bilaterally, effectively doubling the number of tests. 
Test results of both assessors were sent to, and analysed by the same statistician (PN). 
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Weighted Kappa’s were used to express reliability: moderate (0.41–0.6), good (0.61–0.8) and 
very good (more than 0.81). 
 
Results 
Reliability for monofilament testing for all nerves was good to very good in all centres, with the 
exception of one centre where agreement on testing the sensory function of the radial 
cutaneous nerve was moderate (Table 2).  
 
Table 3 shows that, in general, the muscle strength tests show good to very good reliability. For 
the few tests that did not show acceptable reliability the two therapists involved in each study 
centre were both requested to recheck the muscle group where disagreement was apparent, 
and to come to an agreement on the grading before making a clinical decision.  
 
Table 2- Manual Muscle Strength Test reliability (Weighted Kappa’s) 
Centre Eye 
closure 
Ulnar 
APB 
Median Radial 
wrist 
Lateral 
popliteal 
foot 
Toe up Toe 
down 
        A 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
B 1.000 0.908 0.877 0.662 0.797 0.710 0.471 
C 0.600 0.943 0.922 N/A 0.675 0.958 0.918 
D 0.575 0.641 0.257 N/A 0.869 0.756 0.688 
E 0.615 0.956 0.881 0.851 0.967 0.977 0.943 
F 0.191 0.968 0.827 0.705 0.965 0.970 0.991 
0.41-0.6= moderate agreement; 0.61-0.8=good; >0.8= very good, N/A: not applicable 
 
Discussion 
Our study confirms the findings of other studies that MMST and MFT can be reliably performed 
[2-8]. The tables show results that reflect the agreements of one pair of testers in each centre. 
As intake to TENLEP was initially slow, additional staff also had to be trained to enable the 
involvement of more clinics. Intertester reliability of new staff was also determined prior to 
intake. The tables only give results of the initial pairs of testers. Testers were encouraged to 
repeat MMST and VMT for a sample of subjects at regular intervals to maintain standards in the 
execution and interpretation of tests. 
The testing of the sural and radial cutaneous nerves for sensibility with monofilaments was a 
new development. A related study in leprosy neuropathy had shown good reliability but only 
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one test site was used for these two nerves whereas we tested three sites for all nerves in our 
study [6]. We decided to give equal value to sensory nerve function and decided on three sites 
for these two nerves that could be affected. 
 
Table 3- Monofilament test reliability (Weighted Kappa’s) 
Centre Ulnar Median Radial 
cutaneous 
Posterior tibial Sural 
      A 0.981 0.986 0.986 0.992 0.988 
B 0.948 0.945 0.932 0.982 0.960 
C 0.776 0.877 0.815 0.863 0.869 
D 0.799 0.807 0.601 0.731 0.834 
E 0.938 0.901 0.960 0.919 0.930 
F 0.987 0.986 0.989 0.993 0.993 
0.41-0.6= moderate agreement; 0.61-0.8=good; >0.8= very good 
 
New tests that were introduced for grading motor nerve function were great toe down and up 
for the posterior tibial and deep common peroneal nerve (terminal motor branch), respectively 
[9]. These tests also showed good to very good reliability in all but one study centre. These tests 
are, as yet, not routinely used in leprosy neuropathy but should be considered clinically as 
important. Isolated weakness of great toe flexion and/or extension, with normal foot 
dorsiflexion-eversion indicates nerve function impairment at ankle level or dorsal site of the foot. 
Paralysis of the intrinsic foot muscles may contribute to the onset of tissue breakdown in the 
presence of loss of protective sensation, which is often the case in leprosy neuropathy. The 
great toe down test is the only test that can reliably test the motor function of the posterior tibial 
nerve, a nerve often involved in leprosy and diabetic neuropathy. Weakness in great toe flexion 
will indicate impaired posterior tibial function at ankle level involving the intrinsic foot muscles. 
Toe flexion will still be possible because the extrinsic toe muscles are rarely involved in leprosy 
neuropathy (i.e. impairment of the posterior tibial nerve at knee level). This test was validated by 
Win et al., asking control subjects to perform the test with and without an anesthetised 
posterior tibial nerve [10]. 
 
Low reliability coefficients were recorded for eye closure (i.e. facial nerve/orbicularis oculi) in 
some centres. In cases where isolated facial nerve impairment was suspected at intake and 
during the trial and follow up, the advice given was that testers should ‘double check’ and 
agree on a grade. Differences in reliability between centres were seen, mainly for MMST, most 
likely as a consequence of differences in levels of experience. One centre even scored a perfect 
1.0 for muscle testing. This was the only centre in which both testers had lengthy experience 
with muscle grading and may illustrate the point that correct practice makes perfect. Table 3 
does not specifically mention isolated muscles with their official anatomical names. The table 
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indicates that movements are tested rather than individual muscles, which is what happens in 
most MMST tests [1,4-6]. Testing muscles in ‘isolation’ is, with rare exceptions, not possible. In 
most muscle tests there is synergistic action of multiple muscles. Most of the studies of 
reliability of MMST and MFT have been conducted with leprosy patients. This is probably 
because in many leprosy hospitals and their out-patient departments there are enough patients 
with neuropathy to be able to conduct a reliability study in a short time. We suggest, however, 
that for many other neuropathies and neuromuscular diseases these simple clinical tests of 
MMST and MFT could also be used, although it would require sufficient practice by clinicians 
using a standard protocol to achieve a reliable assessment. It is our opinion that where 
neurophysiological assessments such as nerve conduction studies and warmth detection 
thresholds, in other neurological conditions, are frequently performed alone, MMST and MFT 
could be of complementary value. 
Conclusion 
Manual muscle strength testing and monofilament testing can be reliably performed by 
experienced testers using a standard protocol. These tests can be usefully applied in diagnosis 
and follow up of neuromuscular diseases, neuropathies and suspected nerve lacerations and 
repairs, either as stand-alone procedures or as complementary procedures to electro-
neurophysiological and warmth detection assessments. 
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Abstract 
Background  
Early detection and treatment of neuropathy in leprosy is important in the prevention of 
disabilities. The INFIR study showed that 12 weeks before nerve function became abnormal 
with monofilament tests (MFT), Nerve Conduction Studies (NCS) and Warm Detection 
Thresholds (WDT) were already affected. These two methods are promising for early detection 
of neuropathy, however, they require climate-controlled rooms and highly trained staff, are very 
expensive, and are therefore not practical to use under field conditions. Our aim was to find and 
field-test alternative test methods and compare their sensitivity and specificity to detect 
neuropathy at an early stage.  
Methods  
Through a literature search we identified five alternative devices that appeared simpler, more 
affordable, portable and/or battery operated: the Neuropad®, Vibratip™, NC-
Stat®DPNCheck™, NeuroQuick and the Thermal Sensibility Tester (TST), assessing respectively 
sweat function, vibration sensation, nerve conduction, cold sensation and warm sensation. In 
leprosy patients in Bangladesh, the posterior tibial and sural nerves that tested normal for MFT 
and voluntary muscle test (VMT) were assessed with the reference standard tests NCS and 
WDT. The alternative devices were then tested on 94 nerves with abnormal WDT and/or NCS 
results and on 94 unaffected nerves. Sensitivity and specificity were the main outcomes. 
Results  
The NeuroQuick and the TST on the sural nerve showed the highest sensitivity and specificity 
(>80%), followed by the Neuropad®, NC-Stat®DPNCheck™ and Vibratip™. On the posterior 
tibial nerve the NeuroQuick and the TST also showed better sensitivity. 
Conclusions  
The NeuroQuick and TST are good candidates for further field testing for reliability and 
reproducibility, and the costs and options for further development and production should be 
studied.    
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Introduction 
Leprosy is a major cause of peripheral neuropathy in low resource countries, affecting sensory, 
motor and autonomic nerve function. Complications of neuropathy are sensory loss and muscle 
weakness. Earlier studies found that 10% to 55% of new leprosy cases presented at diagnosis 
with one or both of these clinical symptoms [1-4], and up to a fourth of the patients developed 
neuropathy during or after treatment [5]. When neuropathy remains untreated or is treated too 
late it can lead to disabilities. Worldwide over three million people are living with disabilities due 
to leprosy [6]. In the prevention of disabilities, timely detection and treatment of neuropathy is 
essential. 
Sensory nerve function impairment (NFI) is often the first symptom of leprosy neuropathy. 
Detection of sensory NFI is typically done with monofilament tests (MFT) or ballpoint tests, and 
motor function is assessed with voluntary muscle tests (VMT). It is assumed that when sensory 
impairment is clinically detectable, quite some damage has already been done to the nerves, 
the so-called subclinical neuropathy [7]. Methods to detect neuropathy in such early stages 
were studied in the INFIR (ILEP Nerve Function Impairment and Reactions) study [4]. To find the 
most sensitive methods, changes in the nerves of leprosy patients were monitored over time 
with multiple methods assessing different modalities of neuropathy. Nerve conduction studies 
(NCS) were found to be affected most frequently, followed by warm detection thresholds (WDT). 
These two methods were able to detect abnormalities in the nerves up to twelve weeks before 
MFT became abnormal. NCS assesses the large Aβ-fibres, responsible for perception of 
vibration, touch and pressure. The thermal thresholds test small myelinated Aδ- and 
unmyelinated C-fibres, which mediate pain, warm- and cold sensation and are responsible for 
the autonomic function –e.g. sweating [8-10].  
Even though NCS and WDT are very important techniques in the detection of early neuropathy, 
the devices are not optimal for use in the field of leprosy endemic areas. They are costly, require 
well trained staff and need stable environmental (temperature) conditions and stable electricity 
supply. There is a need for cheap, easy-to-use, sensitive and reliable screening tools to detect 
early neuropathy. Our aim is to find potential alternative tests methods that can detect early 
neuropathy in leprosy patients and to compare the sensitivity and specificity of these methods 
when assessed in field conditions, using NCS or WDT as reference standard test.   
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Methods 
A literature search was conducted to identify simple, portable devices used for the diagnosis of 
early neuropathy, regardless of the pathology. We covered the Embase, Medline and Cochrane 
databases and used the search engine Google, using search terms related to ‘neuropathy’, 
‘diagnosis’, ‘device’ and ‘simple’. 
This resulted in list of possible eligible devices (Appendix Table A). A final selection of devices 
was made based on the following requirements: costs less than €1500; availability; easiness of 
use- i.e. no extensive training required; and practicality and suitability for field conditions: small 
portable, battery operated devices providing direct results without the need for additional 
(computer) analyses. We also intended to select methods assessing different modalities of 
neuropathy. 
Selected alternative devices 
The final selection of devices consisted of the Neuropad® (TrigoCare International), Vibratip™ 
(McCallan Medical Limited), NC-Stat®DPNCheck™ (NeuroMetrix, Inc.), NeuroQuick (Schweers) 
and the Thermal Sensibility Tester (TST) (World Health Organization). 
The Neuropad is a patch designed to test the autonomic function of the diabetic foot by 
assessing sweat production. The colour of the patch changes from blue to pink due to a 
chemical reaction between the complex salt anhydrous cobalt-II-chloride and sweat on the skin. 
The main outcome is whether or not the patch turned completely pink after ten minutes, and 
the total time to complete colour change is recorded as well. The Neuropad is applied on the 
great toe or on the plantar surface of the foot between the first and second metatarsal head.   
The Vibratip is a pocket-sized device to test vibration sensation. This disposable, battery 
operated device produces a stimulus of 128 Hz, comparable with a tuning fork, and is activated 
by pinching. The main outcome is whether or not vibration is felt. 
The automated NC-Stat DPNCheck evaluates sensory nerve conduction of the sural nerve. This 
device offers an alternative to standard NCS and is hand-held, battery operated, fast and user-
friendly, as general health care providers can handle it with minimal training. The sural nerve is 
stimulated with a 100 mA current, and the signal is detected orthodromically by a biosensor at 
92.2 mm from the simulation probes. Conduction velocity and amplitude are the main 
outcomes.  
The portable NeuroQuick device tests cold sensation using an air flow produced by the 
integrated fan. The adjustable fan speed can be increased until the patient perceives the air 
flow. The outcome, on a 0-9 scale, is compared to a normal threshold to define whether the 
sensory nerve function is impaired.  
The Thermal Sensibility Tester has the size of a pen and assesses warm sensation. It was 
originally designed to test sensation in leprosy skin lesions [11]. Both ends of the pen have a 
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little metal disc, one side adjusts to room temperature and one becomes warm when switched 
on, with a temperature between 45° and 60°C depending on environmental temperature [12]. 
The main outcome is whether or not the difference between the warm and normal side can be 
felt.  
Patients and controls 
Leprosy patients who had normal MFT and VMT results for the posterior tibial and sural nerves 
were included when they had abnormalities in at least one sural or posterior tibial nerve with 
NCS and/or WDT test. Patients were excluded from the study when they suffered from other 
diseases that may affect the nerve function, e.g. diabetes. Patients under the age of 18 or over 
70 years were excluded as well. Patients on prednisolone treatment were excluded from 
Neuropad testing, as a rare side effect of this drug is hyperhidrosis. To assess the specificity of 
the devices we also needed to test nerves with normal NCS and/or WDT. When one of the 
body sides of the included patients had normal nerve conduction and/or WDT test results for 
the sural or posterior tibial nerve, this nerve was taken as control. At the end of the study, we 
also had to include some leprosy patients with only normal NCS and/or WDT results as control 
subject in order to acquire the calculated number of normal nerves.  
Test procedure 
The study took place in the Danish Bangladesh Leprosy Mission hospital at the Rural Health 
Program (RHP) department in Nilphamari, which is run by The Leprosy Mission International 
Bangladesh. Patients with normal VMT and MFT for sural and posterior tibial nerves were sent 
to Nilphamari RHP from the nearby field clinics. There, the subjects were assessed again with 
MFT and VMT, according to a previous described protocol [13]. In short, a standard set of 
Semmes-Weinstein monofilaments was used to assess three test-sites for each nerve, the 2g 
filament representing the normal threshold for the foot. For motor function assessment, the 0-5 
Medical Research Council (MRC) scale was used [14]. An MFT score under 3 and a VMT score 
of 5 were considered normal. 
Reference standard test 
When MFT and VMT were normal, the reference standard tests, sensory NCS and WDT tests 
were carried out. Sensory NCS were performed for the sural nerve only, because sensory NCS 
for the posterior tibial nerve is difficult and therefore we considered it unreliable. Sural NCS were 
recorded antidromically at 14 cm from the standard stimulation site. The test was done with the 
Neurocare 2000W EMG machine (BioTech Ltd, Mumbai), and a nerve was considered affected 
when either amplitude or velocity was impaired. The WDT test was carried out using TSA II 
(MEDOC, Israel) for both sural and posterior tibial nerves, on respectively the mid-lateral border 
of the foot and the plantar aspect of the great toe. Both reference standard tests were done 
bilaterally, in an air-conditioned room by two experienced assessors who showed good inter-
tester reliability (intraclass correlation coefficient of sural SNC, Velocity: 0.89; Amplitude: 0.99). 
The outcomes of NCS and WDT were compared to age-adjusted normal values that had been 
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determined earlier for the TENLEP trial at Nilphamari Rural Health Program (using the 97.5th 
percentile) [13]. However, for the posterior tibial nerve, WDT cut-off levels were set at the 
maximum temperature reached with the TSA, i.e. 50°C. Applying this cut-off, no patient was 
considered abnormal. Therefore, we redefined the abnormal threshold by using the 95th 
percentile from the normative studies of TENLEP, instead of the originally used 97.5th percentile. 
Alternative devices 
Four out of five tests were performed for the sural nerve, which was chosen because this nerve 
is the most commonly affected in leprosy [15,16] and because the NC-stat was specifically 
designed to assess the sural nerve. The Neuropad test was carried out on the posterior tibial 
nerve, since this test has been validated for the sole of the foot only. We tested the other two 
small nerve fibre tests -the NeuroQuick and the TST- on the posterior tibial nerve as well (Table 
1). Not all patients were tested with all devices, for two reasons. First, only the nerve(s) identified 
as abnormal by one of the reference standard tests and their contralateral normal side were 
assessed with the alternative devices. Second, only the alternative devices that assessed the 
same type of nerve fibre - small or large - as the abnormal reference standard test was tested 
(Table 1). For example, in a patient with abnormal sensory NCS for one sural nerve we tested 
both sural nerves with NC-Stat DPNCheck and Vibratip. The tests with the alternative devices 
were carried out on the same day as the reference standard tests, by one trained assessor who 
was blinded to the NCS and WDT results. The tests took place outside, without fan or air-
conditioning to mimic field circumstances, and were done in a random order following a 
randomization table created in Excel. Before the testing started, the assessor thoroughly 
explained and demonstrated the test procedures to the patient. 
 
The Vibratip, NeuroQuick and TST assessed the sural nerve at the mid-lateral border of the foot. 
With the Vibratip, the skin was touched twice, each time for approximately one second, and 
randomly once with vibration and once without vibration. After the second touch, the patient 
was asked during which of the two touches he felt the vibration. The test was repeated two 
more times. When the answer was correct at least two out of three times, the patient’s vibration 
sensation was recorded as normal [17]. The outcome of the Vibratip tests was compared to 
NCS. A similar procedure was followed for the Thermal Sensibility Tester: the patient’s skin was 
touched twice for about three seconds, randomly once with the warm side and once with the 
‘normal side’. After the second touch, the patient was asked which of the two touches was 
perceived as warm. The test was repeated two more times. When the answer was correct at 
least two out of three times, the patient’s warmth sensation was recorded as normal. The 
outcome of the Thermal Sensibility Tester was compared to WDT. The NeuroQuick test was 
started at fan speed level 0 and the device was then held for 5 seconds at a distance of 23 cm 
from the foot. This exact distance is shown by two crossing laser beams. When the patient did 
not perceive the air flow, the fan speed was increased by one level and held above the foot for 
another 5 seconds. This process was repeated until the airflow was perceived by the patient. 
The total procedure was repeated two more times and the average of three measurements was 
the outcome of the test. This outcome was compared to the cut-off levels  
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Table 1- Modality, nerve type and reference standard test for the alternative devices 
Test Modality    Nerve    Nerve fibre 
 
Reference standard test 
NC-Stat 
 
Conduction    Sural    Large fibre (Aβ)        NCS sural 
Vibratip Vibration    Sural    Large fibre (Aβ)        NCS sural 
NeuroQuick Cold sensation    Sural and PT    Small fibre (Aδ)        WDT sural/ PT 
TST Warm sensation    Sural and PT    Small fibre (C)        WDT sural/ PT 
Neuropad Sweat function    PT    Small fibre (C)        WDT PT 
PT= posterior tibial nerve 
 
of the normative test to determine whether it was abnormal. The reference test used for 
comparison was WDT.  
For the test with the NC-Stat DPNCheck, the patient was asked to place his lower leg on a 
chair in a position that the muscles were relaxed [18]. The skin was cleaned with alcohol, a 
biosensor was inserted in the device and gel was applied on the stimulating probes. The sural 
nerves were stimulated for 10-15 seconds, just posterior to the lateral malleolus. Both velocity 
and amplitude were read directly from the device, and were automatically corrected for skin 
temperature. The manufacturer suggests four severity categories: normal (velocity >40 m/s and 
amplitude >4 µV), mild (velocity <40 m/s, but amplitude >4 µV), moderate (amplitude 1-4 µV), 
and severe (amplitude<1 µV). The outcome of the DPNCheck was compared to NCS. The 
Neuropad, NeuroQuick and TST were assessed on the plantar side of the great toe. Similar 
procedures as described above were followed for NeuroQuick and TST. The Neuropad was 
applied after the patient had acclimatised for ten minutes with bare feet. For each Neuropad, a 
stopwatch was started immediately after application of the pad. The total time to complete 
colour change from blue to pink was recorded as outcome, or if the change was not complete, 
the colour of the patch after ten minutes was noted (blue/pink or blue). The outcome of the 
Neuropad test was compared to WDT. After all the tests had been finished, we asked the 
patient which of the five tests he valued the best and the worst and for what reasons. We also 
asked the assessor’s opinion on the practicality of the tests and we looked at the costs.  
Ethics 
This is a sub-study of the TENLEP trial, for which ethical approval was given by the Bangladesh 
Medical Research Council (BMRC/NREC/2010-2013/533). An informed written consent was 
obtained from all participants.  
Analyses 
Sample size calculations were done for an expected sensitivity of 0.60 and a confidence interval 
width of 0.20. This resulted in 92 nerves per test. A similar number of normal nerves should be 
tested to determine the specificity at 0.60.  
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A normative study was carried out for the NeuroQuick to define the cut-off for abnormality. We 
tested the posterior tibial and sural nerves of 50 healthy males and 50 healthy females between 
18 and 60 years of age. The NeuroQuick test procedure was followed as described above. As 
the outcomes for left and right body side did not differ significantly, the average of both body 
sides was used to calculate the normal thresholds. The correlation of NeuroQuick outcome with 
sex and age was tested with Spearman’s rho. Only age was significantly related with the 
NeuroQuick outcome for both nerves (sural: r= 0.64, p<0.001; posterior tibial: r=0.57, p<0.001). 
We therefore used a regression equation to calculate an age-related cut-off for abnormality. For 
the sural nerve, the NeuroQuick result was considered abnormal when larger than 
0.02*Age+3.4, and for posterior tibial when larger than 0.01*Age+3.3.  
As primary outcome for our study, the sensitivity and specificity of each alternative device were 
calculated against the appropriate reference standard test –NCS or WDT- with their 95% 
confidence intervals. Also the positive and negative likelihood ratios and area under the curve 
(AUC) were calculated for each alternative device. A p-value < 0.05 was considered to be 
statistically significant. 
 
Results  
We enrolled 209 patients, and examined a total of 95 abnormal and 89 normal sural nerves with 
NCS, 94 abnormal and 90 normal sural nerves with WDT, and 75 abnormal and 115 normal 
posterior tibial nerves with WDT. The majority of patients had PB leprosy (67%) and were still on 
MDT (55%). On average leprosy was diagnosed 11 months earlier. The patients’ demographic 
and clinical characteristics are presented in Table 2. 
All patients tested with the Vibratip were able to detect the vibration for all three touches, 
whether it was tested on an abnormal or normal nerve. For results on abnormal and normal of 
TST and NQ see Table 3. Abnormal nerve conduction was indicated by the NC-Stat DPNCheck 
in 14% of the sural nerves. One nerve was mildly affected, 18 moderately affected and seven 
severely affected. The colour of the Neuropad had changed completely after ten minutes in 90 
cases, and in 77 cases some blue was still visible. None of the pads remained completely blue. 
Mean time until complete colour change was 7.5 minutes, ranging from 2 to 10 minutes. 
Excluding the people without complete colour change, the average time to complete colour 
changes was 4.9 minutes. 
The sensitivity, specificity, positive and negative likelihood ratios of all alternative devices are 
shown in Table 3. For the sural nerve, the NeuroQuick had the highest sensitivity and specificity 
(both 86%), closely followed by the TST (respectively 83% and 82%). The two devices 
assessing large fibre neuropathy in the sural nerves, the Vibratip and NC-Stat DPNCheck, had 
poorer outcomes. The sensitivity of the Vibratip was 0%, and 100% specific. For the posterior 
tibial nerve, the NeuroQuick showed the highest sensitivity as well (93%), but a lower specificity  
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Table 2- General characteristics of the patients (n=209) 
Characteristics              
   Sex (% male)  57% 
Age (mean)  35,3 
Height (cm)  157 
Weight (kg)  51 
Time since diagnosis (months, mean)  11 
RFT (%)  46% 
RJ Classification (%) TT 2% 
 BT 89% 
 BB 1% 
 BL 4% 
 LL 4% 
 PN 1% 
WHO classification (% PB)  67% 
Smoking status (%) Never 67% 
 Current 26% 
 Former 7% 
RFT: Released from anti-leprosy treatment; RJ: Ridley-Jopling; WHO: World Health Organisation 
 
than the TST. The sensitivity and specificity of the Neuropad were average (56% and 60%). The 
highest positive likely hood ratio was seen in the NeuroQuick for the sural nerve: 6.0 (3.6-10.0). 
Patients’ and assessor’s preferences 
Sixty-eight patients were tested with at least four out of the five tests. More than half (53%) 
indicated a preference for the TST, mainly because they found it easy to feel. The second 
favourite test was the Neuropad (25%), also because it was easy as it does not require any 
response from the patient. The Vibratip and the NeuroQuick followed with 13% and 9%. When 
asked which test was least preferred, 54% answered the NC-Stat DPNCheck. The main reason 
was that it was too painful. The second least preferred test was the NeuroQuick (24%), since it 
was too difficult and third the Neuropad (22%), because it was seen as time consuming. 
The assessor indicated he preferred the TST and Neuropad, because they are easy to carry 
out. He pointed out that for the patient the TST and the Vibratip are the best, since the warmth 
and vibration are easily detected. Finally, the assessor reported that the TST and Vibratip are 
the fastest tests to perform.  
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Table 3- Outcomes of the alternative devices when compared to the reference standard test  
(95% confidence interval); NCS: Nerve Conduction Studies; TST: Thermal Sensibility Tester; WDT: Warm Detection 
Thresholds; AUC: area under the curve; PLR: positive likelihood ratio; NLR: negative likelihood ratio 
 
Costs 
We have not performed a cost-effectiveness analysis, though we would like to present the costs 
of the devices (Table 4). The retail price for Neuropads for clinics is $11 per test, containing two 
pads. The Vibratip is a disposable device and can be used thousands of times [19]. The list 
price for the NC-Stat DPNCheck is the highest of the alternative devices in our study, $1000 for 
the device and another $20 per sensor, which can be used to assess both left and right sural 
nerve in one patient. The TST and NeuroQuick are not available for purchasing, and therefore 
the prices are unknown. A paper published in 1989 describes that the cost of a TST was about 
$35 [12].  
 
 
 
 
Alternative 
devices 
 Reference standard test  
 Abnormal Normal Sensitivity Specificity AUC PLR NLR 
Sural NCS (n) 95 89      
        NC-Stat 
DPNCheck 
Abnormal 15 11 16% 
(9-25) 
88% 
(79-94) 
0.52 
(0.43-0.60) 
1.3 
(0.6-2.6) 
1.0 
(0.9-1.1) Normal 80 78 
Vibratip Abnormal 0 0 0% 
(0-4) 
100% 
(96-100) 
0.50 
(0.41-0.58) 
- 1.0 
(1.0-1.0)  Normal 95 89 
Sural WDT (n) 94 90      
        TST Abnormal 78 16 83% 
(74-90) 
82% 
(73-89) 
0.83 
(0.76-0.89) 
4.7 
(3.0-7.4) 
0.2 
(0.1-0.3)  Normal 16 74 
NeuroQuick Abnormal 81 13 86% 
(78-92) 
86% 
(77-92) 
0.86 
(0.80-0.92) 
6.0 
(3.6-10.0) 
0.2 
(0.1-0.3)  Normal 13 77 
Posterior tibial WDT (n) 75 115      
        Neuropad Abnormal 42 35 56% 
(44-67) 
61% 
(51-72) 
0.59 
(0.51-0.67) 
1.5 
(1.1-2.1) 
0.7 
(0.5-1.0)  Normal 33 57 
 Missing  23      
TST Abnormal 60 50 83% 
(72-91) 
57% 
(47-66) 
0.70 
(0.63-0.76) 
1.9 
(1.5-2.4) 
0.3 
(0.2-0.5)  Normal 12 65 
NeuroQuick Abnormal 67 68 93% 
(85-98) 
41% 
(32-50) 
0.67 
(0.60-0.74) 
1.6 
(1.3-1.9) 
0.2 
(0.1-0.4)  Normal 5 47 
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Table 4- Overview of the costs of the alternative devices 
Device Price per unit Additional costs 
   Neuropad 
 
$11 * - 
 
Thermal Sensibility Tester 
 
- 
$35 in 1980’s 
2x AA battery 
NeuroQuick 
 
- 
Not available on the market 
2x AA battery 
 
Vibratip 
 
$9* + packaging costs - 
 
NC-Stat DPNCheck $1,000 $20 per sensor 
*Prices were calculated from other currencies at 25/2/2016. The original price for Neuropad was €10 and Vibratip was 
£6.50 
 
Discussion 
It is important to detect leprosy neuropathy at an early stage, as it can progress to nerve 
function impairment and subsequently may lead to disabilities. In the INFIR study, 20-50% of 
the newly diagnosed leprosy patients either had subclinical neuropathy at diagnosis or 
developed this during follow up [20]. Of the patients who have subclinical neuropathy, around 
16% developed clinical NFI in the INFIR study. In TENLEP, preliminary data show that this 
occurred in 8% of the subclinical patients. And although treatment of subclinical neuropathy has 
not been successful [21,22], knowing the subclinical status of a patient’s nerves is actually very 
valuable. Because in the patients that do develop clinical NFI, treatment with prednisolone can 
be immediately started. In this study we aimed to compare simple methods for detecting early 
leprosy neuropathy in field settings. We found that the NeuroQuick and TST are promising 
screening methods, especially for the sural nerve, since they show high sensitivity and 
specificity and are positively perceived by both patients and assessor.  
Both the NeuroQuick and the TST examine small fibre function. The INFIR study found however 
that there was variation between the patients in the first affected modality and type of nerve 
fibre -large or small [23]. First of all, this indicates that the processes and patterns of neuropathy 
are different for each individual. Second, this has consequences for the assessment of early 
neuropathy. Adding a second test method that assesses large fibre function is recommended. 
Unfortunately, the two devices in our study testing large fibres, the NC-stat DPNCheck and the 
Vibratip, are not suitable for early detection of leprosy neuropathy. So far NCS are the only 
reliable option for detection of early large fibre neuropathy.  
None of the alternative devices included in our study were new. The TST was used in leprosy to 
assess sensitivity of leprosy skin lesions [11]; the Neuropad, NeuroQuick, Vibratip and NC-stat 
DPNCheck have been used before for diagnosis of diabetes neuropathy. Studies in diabetes 
patients showed generally good sensitivity and specificity for the detection of neuropathy 
[17,24-29]. Although both small and large fibres are involved in diabetes neuropathy and in 
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leprosy neuropathy, diabetes neuropathy is often symmetrical [30] and the order of affected 
modalities is somewhat different between the two diseases. In diabetes for example, cold 
perception was found to be the most sensitive thermal test [31], where in leprosy warm 
detection was more sensitive [20]. Furthermore, the tests in diabetes patients have been 
performed in a completely different setting and environment, namely western hospital settings. 
Therefore, it was necessary to test the devices in a leprosy endemic country with a subtropical 
climate, in a field setting with high temperatures and humidity. It is interesting to see that the 
TST, designed for testing in high environmental temperatures, showed good results. The 
temperature of the warm-end of the TST adapts to the ambient temperature, when between 
15°C and 45°C. A graph with the correlation is depicted on the device.  
The accuracy of the reference standard test, to which the new tests are compared, is an 
important point to take into consideration. When the reference standard test is not 100% 
accurate, this has an effect on the sensitivity and specificity estimates [32]. NCS have been 
compared with nerve biopsies and were found to be accurate [33]. In addition, NCS are more 
reliable because they are independent of the patient’s response and therefore objective. The 
WDT test, on the other hand, has never been compared to a gold standard in leprosy 
neuropathy. Furthermore, it requires a response from the subject and is therefore less reliable. 
Perkins et al. describe that variances of 50% and higher can occur in thermal thresholds testing. 
However, since we use very high cut-off levels for normality (97.5%), we are confident that the 
sural nerves tested abnormal in our study are in fact abnormal. This is less the case for the WDT 
of the posterior tibial though. We could not rely on the upper thresholds for the posterior tibial 
nerve, since they mainly lay outside the measurement range of the TSA (50°C). Therefore, we 
used a lower cut-off by taking the 95th percentile, but even with that method it was very difficult 
to include abnormal nerves. 
We made an effort to select the most promising devices for this study. The appendix contains a 
table presenting the reasons for inclusion and exclusion of the different options. Since in leprosy 
sensory function generally is affected before motor function we did not include any assessments 
for motor nerves. Several other tests might be worthwhile to look at in future studies. We 
intended to include the NerveCheck (PhiMed Europe), which is a portable device that assesses 
four modalities: cold, warm, pain and vibration sensation [34]. Unfortunately, at the time of our 
study no NerveCheck device was available for field testing. Second, it might be interesting to 
look at skin wrinkling as an autonomic function test. Although the duration of the test takes long 
- 30 minutes - the results are quite promising in diabetes neuropathy [35,36]. 
In conclusion, based on our results the Neuropad, NCstat and Vibratip do not qualify for further 
testing for detection of early leprosy neuropathy. For both the NeuroQuick and TST, however, 
we recommend that three different aspects should be further studied. First, the options for 
further development and possible production on a larger scale should be examined. Second, 
repeatability and reproducibility should be determined for these two tests, and preferably 
assessed in different populations as well. Finally, additional testing of the accuracy on the hands 
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can give more information on the usability of the two tests in detecting early leprosy neuropathy 
in field settings, as upper extremity neuropathy is common as well.  
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Appendix    
Table A- Results literature search and selection 
Included tests Modality Reason selected 
NeuroQuick Cold sensation Portable, battery operated  
Neuropad Sweat function Easy, direct results, no training 
NC-Stat DPNCheck Nerve conduction Portable, battery operated 
Vibratip Vibration Portable, battery operated 
Thermal Sensibility Tester Warm sensation Portable, battery operated 
Excluded tests Modality Reason not selected  
NerveCheck Warm, cold, pain and vibration 
sensation 
Portable, battery operated, not 
available at the moment of this study 
Tiptherm Cold sensation Weakest performance compared 
with other tests 17 
Neurometer Nerve conduction Expensive 
Biothesiometer Vibration Expensive 
Neurotip Touch sensation Low expected sensitivity, 
comparable to MFT 
Neuropen Pain sensation Pain sensation loss is at a later stage 
than touch sensation loss 37,38 
Sudoscan Sweat function Expensive 
EzScan Sweat function Expensive 
Bumps Touch sensation Low sensitivity, comparable to MFT 
LDI-flare Axon reflex–induced flare after 
heating skin (Doppler Imager) 
Not portable, power needed 
NervePace Nerve conduction Assesses motor latencies, while 
sensory conduction is more often 
affected in leprosy neuropathy 
Neurosentinel Nerve conduction Similar to DPNCheck, only assessed 
Median nerve, which is less often 
affected in leprosy neuropathy 
Thermotropic liquid Chrystal 
strip assessment 
Skin temperature Works when only one body side is 
affected (need to be compared to 
normal side) 
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Abstract 
Background  
While prednisolone is commonly used to treat recent nerve function impairment (NFI) in leprosy 
patients, the optimal treatment duration has not yet been established. We evaluated whether a 
32-week prednisolone course is more effective than a 20-week course in restoring and 
improving nerve function.   
Methods  
In this multi-centre, triple-blind, randomized controlled trial, leprosy patients who had recently 
developed clinical NFI (<6 months) were allocated to a prednisolone treatment regimen of either 
20 weeks or 32 weeks. Prednisolone was started at either 45 or 60 mg/day, depending on the 
patient’s body weight, and was then tapered. Throughout follow up, motor NFI was assessed 
by voluntary muscle testing and sensory NFI by monofilament testing. The primary outcome 
was the proportion of patients with improved or restored nerve function at week 78, tested with 
a Chi-Square test in an intention-to-treat analysis. As secondary outcomes, we analysed 
improvements between baseline and week 78 on the Reaction Severity Scale, the SALSA Scale 
and the Participation Scale. Serious Adverse Events and the need for additional prednisolone 
treatment were monitored and reported. 
Results  
We included 868 patients in the study, 429 in the 20-week arm and 439 in the 32-week arm. At 
78 weeks, the proportion of patients with improved or restored nerve function did not differ 
significantly between the groups: 78.1% in the 20-week arm and 77.5% in the 32-week arm 
(p=0.821). Nor were there any differences in secondary outcomes, except for a significant 
higher proportion of Serious Adverse Events in the longer treatment arm.  
Conclusion  
In our study, a 20-week course of prednisolone was as effective as a 32-week course in 
improving and restoring recent clinical NFI in leprosy patients. Twenty weeks is therefore the 
preferred treatment duration.  
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Introduction  
Leprosy is an infectious disease caused by Mycobacterium leprae. Since the introduction of 
antibiotic multidrug treatment (MDT) in the 1980’s, the number of leprosy diagnoses has 
decreased dramatically and the disease was even declared eliminateda at a global level in the 
year 2000. Nevertheless, in 2014 a total of 213 000 new leprosy patients were diagnosed 
worldwide [1].  
The main complication of leprosy is neuropathy, which often causes sensory and motor nerve 
function impairment (NFI). Untreated NFI can result in deformities of the hands and feet, and 
may also affect the eyes. NFI can develop before MDT has started, but it can also arise during 
MDT and even several years after leprosy treatment has been completed [2,3]. The risk of 
developing new NFI within two years of starting MDT can be as high as 65% [4].  
To prevent disabilities and deformities in leprosy patients, it is very important to detect and treat 
neuropathy early. Neuropathy is commonly treated with prednisolone [5]. Although ideally 
prednisolone therapy is adjusted to individual needs and response, this is not always feasible in 
field clinics, which often lack the treatment expertise of referral centres [6]. In these situations, 
the WHO recommends a standardized prednisolone treatment for 12 weeks [7]. 
Even though observational studies suggest that prednisolone can improve nerve function in 60-
70% of nerves [2, 8-10], this effect has never been established in randomized controlled trials 
[11]. There are indications, however, that a longer treatment duration may be more effective 
than the WHO standardized treatment. In an RCT in India, type 1 reaction (T1R) patients on a 
20-week course required less additional prednisolone than patients on a 12-week course [12]. 
Further research is needed to establish the optimal prednisolone regimen specifically for leprosy 
patients with NFI. 
For this reason, we set up the study entitled “Treatment of Early Neuropathy in Leprosy” 
(TENLEP), aimed at determining whether a longer period of prednisolone treatment gives better 
results in the prevention of permanent NFI. In the Clinical trial, we evaluated whether a 32-week 
prednisolone course is more effective than a 20-week course in restoring and improving recent 
clinical neuropathy (<6 months) [13].  
 
  
                                                
a Elimination is defined as a prevalence of less than 1 case per 10 000 inhabitants 
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Methods 
The TENLEP study was a multicentre, triple blind parallel-group clinical trial, conducted in six 
referral centres in India, Nepal, Bangladesh and Indonesia. A detailed description of the TENLEP 
study can be found in the study protocol paper [13].  
Patients 
Leprosy patients between 15 and 60 years of age with any recent peripheral NFI - onset less 
than 6 months ago - were eligible for the trial. NFI was established with voluntary muscle testing 
(VMT) and/or monofilament testing (MFT). Patients were excluded if they were pregnant, already 
receiving prednisolone treatment, suffered from other conditions that may affect the peripheral 
nervous system, or presented with a single skin lesion on the trunk as the only sign of leprosy. 
The sample size was calculated to be able to detect ‘restored or improved’ nerve function in 
70% of the intervention group, compared to an assumed proportion of 60% in the control 
group. This one-tailed hypothesis, using 80% power, 5% significance and allowing for 20% loss 
to follow-up, lead to a sample size of 720 patients. During the trial period, however, the loss to 
follow-up turned out to be higher than 20%. We therefore extended the inclusion period to 
reach the calculated sample size. 
Treatment  
Prednisolone dose started at 45 mg/day for patients with low weight (≤50 kg) and at 60 mg/day 
for patients with high weight (>50 kg). The prednisolone dose was then slowly tapered during 
the treatment period [13], maintaining a plateau of 0.4-0.5mg/kg for 20 weeks in the 32-week 
arm. To check the chemical composition of the prednisolone and placebo tablets, a random 
selection of packages from both treatment groups was evaluated at the start of the trial by the 
manufacturer (Rubicon), and an independent Indian laboratory (Medibios Laboratories). After 20 
months the composition was checked again by the Royal Dutch Society of Pharmacists 
(KNMP). Treatment adherence was checked every month either verbally or by checking the 
medication package of the previous month.  
Randomization and blinding 
Patients were randomly allocated to either 20 or 32 weeks of oral prednisolone, using a 
separate computer-generated blocked randomization sequence for each centre and weight 
group. This sequence was prepared by the project’s statistician (PN), and the manufacturer 
labelled the trial drug packages accordingly. Every new patient received the next available 
numbered package. Patients and research staff were kept unaware of the assigned treatment 
group. Additionally, the statistician was kept blinded until all data analyses were performed. The 
key to treatment allocation was only broken if a patient had serious adverse events (SAE) or 
required individualized treatment for a reaction or worsening NFI. 
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Assessments 
In each centre, monofilament testing and voluntary muscle testing were carried out by two 
trained assessors, except in the Indonesian centre where ten assessors have performed the 
tests. Reliability studies at baseline generally showed good inter-tester reliability [14]. For every 
patient the sensory function of six nerves and the motor function of seven nerves were 
assessed on both left and right body side, adding up to a total of 26 assessments. Sensory 
function was tested on three test-sites for each nerve, using a standard set of Semmes-
Weinstein monofilaments, with the 200 mg filament representing the normal threshold for the 
hand, and the 2g filament for the foot. For motor function assessment, the 0-5 Medical 
Research Council (MRC) scale was used [15]. The exact test methods and -sites are described 
in the protocol paper [13]. When the total monofilament score for a nerve was 3 or more, the 
sensory nerve function was considered impaired. A motor nerve scoring less than 5 on the 
Medical Research Council scale was also regarded as impaired. Follow-up assessments for 
VMT and MFT were carried out monthly during the treatment period (up to week 32), and at 
week 52 and 78. At baseline and the end of the study a Screening of Activity Limitation and 
Safety Awareness (SALSA) scale [16] and a Participation (P) scale [17] were completed for each 
patient. In addition, reaction severity was monitored with a Reaction Severity Scale (RSS) [18] at 
baseline, week 32, 52 and 78. When a patient did not show up for their follow-up appointment, 
a telephone call or in some cases a home visit was made in an effort to get the patient visit the 
clinic for assessments. When indicated in advance, a patient was allowed to miss one 
assessment, and the medication was provided for eight weeks. 
When a patient’s nerve function had deteriorated during the trial treatment period -the first 32 
weeks-, the trial treatment was stopped and the patient received a tailored prednisolone 
treatment. Patients who developed new NFI or who experienced NFI worsening after the 32-
week treatment period were also given additional prednisolone, as indicated by a medical 
doctor. When determining whether this additional treatment was needed, the definition of 
deteriorated MFT used was: an increase of 6 points or more on the score per nerve since the 
last assessment, or an increase of 3 points or more on the score per nerve that was confirmed 
on the consecutive assessment. VMT deterioration was defined as: a reduction in VMT score by 
two or more points or a reduction of 1 point on two consecutive assessments. Patients who 
developed serious adverse events (SAE) were taken off trial treatment as well, and their 
complications were treated. Patients who received additional prednisolone or developed SAE 
were still followed up in the trial, and data were collected at 78 weeks. 
Primary and secondary outcomes 
The primary study outcome was the proportion of patients with restored or improved nerve 
function (of all nerves) measured by MFT and/or VMT at 78 weeks. We established for each 
nerve whether it had been restored (normal function), improved (but not restored), unchanged 
or deteriorated. For the primary outcome, the MFT score was considered improved when the 
total score per nerve had decreased with at least three points. Deterioration was defined as an 
increase of at least three points in MFT score. For VMT the score was considered improved or 
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deteriorated when increased or decreased by one point on the MRC scale. Since the primary 
outcome was at patient level, we calculated a composite score by subtracting the number of 
deteriorated nerves from the number of restored and improved nerves. A patient’s nerve 
function was considered completely restored when all nerves had returned back to normal 
function. Improved nerve function was defined as a positive composite score, i.e. more restored 
and improved nerves than deteriorated and unchanged nerves. 
For the secondary outcomes we looked at six variables. First, we compared the proportion of 
restored, improved, unchanged, deteriorated and fully impaired patients between the groups at 
week 78 for each specific nerve -e.g. ulnar. This was done for all 13 nerves. Second, a count of 
impairments was calculated per patient by giving each impaired nerve a score of 1, and adding 
the scores up for all nerves, leading to a maximum possible score of 26. The scores were 
compared between the intervention and control groups, and the change over time was 
assessed. Third, change in reaction severity was monitored with the RSS. The patient was 
considered improved when the score reduced with at least 3 points on the sum score or at 
least 2 points on any individual item of the scale. Fourth, the improvement in SALSA-scale and 
P-scale scores between baseline and week 78 was evaluated. For the SALSA-scale and P-
scale, a patient was considered improved when classified in a better category, e.g. extreme, 
severe, moderate, and mild. Fifth, we compared the difference in proportion of patients with 
Serious Adverse Events (SAE) between the intervention and control group. Last, we looked at 
the proportion of patients needing additional prednisolone and analysed whether there was a 
difference in timing, dose and duration of the provided additional prednisolone treatment. 
Data analysis  
Data were entered at each centre in an Access Database and then combined to be analysed in 
Stata. Data were analysed according to the modified intention-to-treat principle: data of all 
randomized patients who matched the inclusion criteria were analysed for week 78, whether 
they had finished treatment or not, including all patients lost to follow-up. To handle missing 
data of patients lost to follow-up, the last observation carried forward method was used. For 
patients who received additional prednisolone, the assessment recorded at the time when 
additional was first prescribed was carried forward. Only nerves with new impairments (<6 
months) were included in the analyses. The primary and secondary outcomes were analysed 
using a Chi-Square test. A difference between treatment groups was considered significant 
when the p-value was < 0.05.  
Ethics 
Written informed consent was taken from all patients. Ethical permission was obtained in-
country. In India from the Indian Council of Medical Research and the Ethics Committee of the 
Foundation for Medical Research, Mumbai; in Nepal from the Nepal Health Research Council 
(NHRC); in Indonesia from the Komite Etik Penelitian Kesehatan RSUD Dr. Soetomo Surabaya; 
in Bangladesh from the Bangladesh Medical Research Council- National Research Ethics 
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Committee. The trial was registered in the Netherlands Trial Register (NTR2300) and in the 
Clinical Trials registry India (CTRI/2011/09/002022 and 23). 
 
Results 
Participants 
A total of 875 leprosy patients were enrolled in the trial, of whom 432 were randomized to the 
20-week arm and 443 to the 32-week. Patients were recruited between February 2012 and 
October 2013, and the last follow-up data were collected in July 2015. The flow diagram in 
Figure 1 illustrates the number of patients followed up and the reasons for drop out. Seven of 
the randomized patients were excluded in the final analyses: one patient who had missing 
baseline MFT assessments and six patients who did not meet the inclusion criteria of having 
recent NFI. The number included in the analyses reported here was therefore 868. 
Baseline data 
Baseline demographic and clinical characteristics of the patients are shown in Table 1. 
Differences in demographic and clinical characteristics did not reach statistical significance 
between the groups. The most important characteristics are also presented per centre in Table 
2. At baseline, sensory function was more often impaired than motor function: for both groups 
the median number of nerves with impaired sensory function was 3, ranging from 0-12, while 
the median number of nerves with impaired motor function was 1 (0-13). The proportions of 
sensory and motor impairment per nerve are shown in Figure 2. 
Number analysed 
Of the 868 patients enrolled in the study, the trial treatment period of 32 weeks was completed 
by 281 (65.5%) in the 20-week arm and 293 (66.7%) in the 32-week arm. Complete follow-up 
data until week 78 were collected for 230 (82%) of the patients of the 20-week arm and 219 
(75%) patients of the 32-week arm. At week 78, follow-up data were also collected for 233 
additional patients who did not complete trial treatment due to new NFI, new or recurrent 
reactions, SAEs or patients who were temporarily lost to follow-up. For the intention-to-treat 
analyses, the primary and secondary outcomes were analysed using the data of all patients who 
met the inclusion criteria (n=868). A separate per protocol analysis was carried out including 
only patients who had completed treatment (n=574). 
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Figure 1- Flow diagram of number of patients enrolled, randomized, treated and followed-up  
 
 
 
 
 
 
 
 
 
3 did not meet exclusion 
criteria 
1 missed baseline data 
3 did not meet exclusion 
criteria 
    
875 patients randomized  
432 patients assigned to 20 weeks 
7 additional prednisolone 
12 serious adverse events 
110 lost to follow-up 
3 other 
38 additional prednisolone 
4 serious adverse events 
96 lost to follow-up 
293 completed treatment 281 completed treatment 
2 died 
8 moved away  
1 died  
13 moved away 
429 patients enrolled to 20 weeks 
Treatm
ent period (32 weeks) 
3 died 
4 moved away 
9 lost to follow-up 
1 died 
10 moved away 
9 lost to follow-up 
56 additional prednisolone 
2 SAE 
Follow-up period (46 weeks) 
443 patients assigned to 32 weeks 
439 patients enrolled to 32 weeks 
30 additional prednisolone 
1 SAE 
230 completed 
follow-up at 78 
weeks 
107 completed 
follow-up at 78 
weeks 
230 completed 
follow-up at 78 
weeks 
122 completed 
follow-up at 78 
weeks 
678 patients in analysis of week 78 
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Table 1- Baseline demographics and clinical characteristics of the 868 patients 
 20 weeks 
(n= 429) 
32 weeks 
(n= 439) 
   Gender (female) 101  (23.4%) 90  (20.4%) 
Age (mean ±SD) 34.7  (12.1) 34.3  (12.1) 
Literate (%) 241  (56.5%) 247  (56.3%) 
MB/PB (% MB) 339  (79.2%) 357  (81.0%) 
RJ classification      
TT 9  (2.1%) 20  (4.6%) 
BT 212  (49.4%) 203  (46.2%) 
BB 61  (14.2%) 55  (12.5%) 
BL 67  (15.6%) 70  (16.0%) 
LL 40  (9.3%) 51  (11.6%) 
PN 40  (9.3%) 40  (9.1%) 
Average smear (mean ±SD) 0.8  (1.4) 0.9  (1.5) 
Disability grade      
0 171  (39.9%) 165 (37.6%) 
1 158  (36.8%)  176  (40.1%) 
2 100  (23.3%) 98  (22.3%) 
T1R      
Mild 66  (15.4%) 59  (13.4%) 
Severe  14  (3.3%) 24  (5.5%) 
T2R     
Mild 11  (2.6%) 14  (3.2%) 
Severe 2  (0.5%) 6  (1.4%) 
MB: Multibacillary; PB: Paucibacillary; RJ: Ridley-Jopling; T1R: Type 1 Reaction; T2R: Type 2 Reaction 
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Table 2- Intake per research centre 
Centre Number 
of 
patients 
Gender 
(% 
female) 
Mean 
age 
Low 
weight 
group (%) 
20-week 
arm (%) 
Area 
       Anandaban hospital 
Nepal 
57 26% 36.7 37% 47% Kathmandu 
       Foundation for Medical 
Research India 
82 15% 31.8 34% 49% Mumbai 
       JALMA  
India 
230 17% 31.5 53% 50% Agra and 
surroundings 
       Lalgadh hospital   
Nepal 
166 28% 34.3 45% 50% Rural south-east 
Nepal 
       Nilphamari  
Bangladesh 
232 22% 39.1 51% 50% Rural north-west 
Bangladesh 
       Dr. Soetomo hospital 
Indonesia 
101 25% 31.9 46% 48% Surabaya and 
Madura 
 
 
Primary outcome 
An overview of the primary and secondary outcomes and their definitions are presented in Table 
3. The proportion of patients with restored or improved nerve function at week 78 was similar in 
both groups: 78.1% in the 20-week arm and 77.5% in the 32-week arm (p=0.821). At week 32 
and week 52, this outcome was not significantly different between the two groups either. Figure 
3 shows the proportion of patients in each category of improvement. In the 20-week arm, more 
patients showed completely restored nerve function than in the 32-week arm, 23.5% against 
18.7%. The per-protocol analysis, leaving out treatment non-compliers, resulted in an overall 
slightly higher proportion of patients with improved and restored nerves. However, again no 
significant difference was found between the groups: 81.9% in the 20-week arm and 81.7% in 
the 32-week arm (p=0.960). The percentage of patients with full restored nerve function in this 
specific group is higher in the 20-week arm than in the 32-week arm, 26.4% against 20.5%.   
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Figure 2- Baseline impairments for sensory and motor nerves   
Secondary outcomes 
Table 4 presents the outcomes per nerve, for six sensory and seven motor nerves. The 
proportion of improved and restored motor nerves was overall higher than for sensory nerves. 
The motor function of median, lateral popliteal, radial and trigeminal nerves improved most 
between baseline and week 78. Although the last three nerves were involved in only small 
number of patients. The sensory function of the radial, median and ulnar nerves had the highest 
proportion of improvement and restoration. The average count of impairments at baseline, week 
32, week 52 and week 78 is shown in Table 5. 75.7% of the patients in the 20-week arm 
showed an improvement in count of impairment, compared to 70.8% in the 32-week arm 
(p=0.149). Table 5 also presents the results of the Reaction Severity scale, the SALSA scale 
and the P-scale for every assessment point. The proportion of patients with improved in 
Reaction Severity Scale score at week 78 was higher in the 32-week arm (70%) than in the 20-
week arm (65%), but this difference was not statistically significant (p=0.09). After 78 weeks, 
also the day-to-day situation for patients improved: the scores of both SALSA and P-scale 
improved between baseline and week 78, but did not differ between the treatment groups at 
either point in time. The absolute change over time also did not differ significantly (p=0.638 for 
SALSA and p=0.543 for P-scale).  
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Table 3- Overview of primary and secondary outcomes 
 Outcome Definitions 
   Primary 
outcome 
Proportion of patients with 
restored or improved nerve 
function 
Using a composite score. 
Restored: all nerves back to normal function 
Improved: more restored and/or improved nerves 
than unchanged and/or deteriorated nerves 
Unchanged: same number of nerves impaired 
Deteriorated: more deteriorated nerves than 
improved and/or restored nerves 
   
Secondary 
outcomes 
Proportion of restored, improved, 
unchanged, deteriorated and fully 
impaired nerves for each specific 
nerve – e.g. ulnar nerve 
 
For six sensory nerves and seven motor nerves 
 Count of impairments Per patient 26 nerves were assessed. Each 
impaired nerve adds 1 point to the total score 
   
 Improvement Reaction Severity 
Scale 
Improvement: reduction in RSS of 3 or more 
points on the total score, or a reduction of 2 or 
more points on any individual item of the scale 
   
 Improvement in SALSA-scale and 
P-scale 
Improvement: classified in a better category 
(extreme, severe, moderate, mild, none) 
   
 Proportion of patients with Serious 
Adverse Events 
 
   
 Proportion of patients needing 
additional steroids for treatment of 
reaction or worsening NFI 
 
 
Additional prednisolone, to treat new or deteriorating NFI and reactions, was required in 68 
(16%) patients in the 20-week arm and 65 (15%) patients in the 32-week arm. This difference 
was not statistically significant. Interestingly, the majority (38/68) of these patients in the 20-
week arm needed additional prednisolone between week 21 and week 32, while in the 32-week 
arm additional prednisolone was given mostly between week 33 and 52 (56/65). The additional 
prednisolone given before week 32 was in 78% of the cases because of a reaction- with or 
without accompanying worsening NFI-, while the additional prednisolone given after week 32 
was more often for deteriorating NFI without reaction (55% of the cases needing additional 
prednisone did not have other reaction symptoms). Figure 4 shows the survival time until the 
first course of additional prednisolone. The dose and duration of additional prednisolone 
treatment was not significantly different between the two groups. 
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Figure 3- Percentage of patients with restored, improved, unchanged and deteriorated nerve function 
impairment at week 78 as primary outcome   
Adverse events 
There were seven deaths, 3 in the 20-week arm and 4 in the 32-week arm, but none was 
related to the prednisolone treatment. Serious adverse events occurred in both groups, but 
were more often reported in the intervention group: 12 cases (2.7%) in the 32-week arm and 4 
cases (0.9%) in the 20-week arm [19]. This difference was statistically significant (p=0.04). The 
main reported SAE’s were hypertension (6), diabetes (6), and peptic ulcer (2). Minor side effects 
were reported in 66% in the intervention group and 68% in the control group. Detailed results 
will be reported separately. 
Additional analyses  
We used logistic regression to assess the association between clinical and demographic data 
recorded at baseline and the primary outcome of improved or restored nerve function. The 
characteristics that showed a significant correlation with the primary outcome were weight 
group and BMI, gender, WHO disability grade and Eye Hand Foot (EHF) score. A patient with a 
higher BMI had higher odds on improved or restored nerve function at 78 weeks (OR= 1.09 
(1.04-1.14)). The high weight group (≥50 kg) had a 1.43 (1.09-1.86) higher probability of a 
positive primary outcome than the low weight group. Furthermore, women were 1.46 (1.06-
2.10) times more likely to have a restored or improved nerve function than men. The subgroup 
analysis also showed that patients having a grade 1 or 2 impairment at baseline were less likely 
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Table 4- Outcomes per nerve at week 78 
 Arm  Restored Improved Unchanged Deteriorated 
Sensory  n % % % % 
       Trigeminal    20 weeks 22 59.1 - 36.4 4.5 
               32 weeks 16 75.0 - 6.3 18.8 
       Ulnar  20 weeks 330 43.0 23.3 13.6 20.0 
 32 weeks 380 39.7 26.6 12.6 21.1 
       Median  20 weeks 260 46.5 18.5 13.1 21.9 
 32 weeks 283 37.1 26.5 12.0 24.4 
       Radial 20 weeks 218 46.3 26.6 11.0 16.1 
 32 weeks 224 42.9 23.2 12.1 21.9 
       Posterior tibial* 20 weeks 394 35.0 22.6 20.3 22.1 
 32 weeks 448 31.0 30.4 20.8 17.9 
       Sural* 20 weeks 459 25.3 30.1 24.2 20.5 
 32 weeks 520 25.6 28.1 33.3 13.1 
Motor  n % % % % 
       Eye closure 20 weeks 83 50.6 18.1 21.7 9.6 
 32 weeks 71 59.2 18.3 12.7 9.9 
       Ulnar 20 weeks 322 39.1 18.3 26.7 15.8 
 32 weeks 334 33.5 21.0 31.7 13.8 
       Median 20 weeks 132 52.3 3.8 17.4 26.5 
 32 weeks 134 53.7 8.2 20.9 17.2 
       Radial 20 weeks 37 70.3 2.7 5.4 21.6 
 32 weeks 40 62.5 2.5 12.5 22.5 
       Lateral 
 
20 weeks 81 61.7 11.1 17.3 9.9 
 32 weeks 89 57.3 7.9 22.5 12.3 
       Posterior tibial 
up 
20 weeks 172 52.3 10.5 22.1 15.1 
32 weeks 162 48.1 9.3 30.2 12.3 
       Posterior tibial 
down 
20 weeks 188 51.1 1.6 25.5 21.8 
32 weeks 202 55.0 1.5 29.2 14.4 
*Difference between arms is statistically significant  
109 
 
Table 5-Secondary outcomes: count of impairment, severity scale, salsa scale, p-scale 
(Mean (SD)); NS: not significant 
 
 
 
 
 n 20 weeks n 32 weeks Test 
statistic 
Count of impairments      
  Baseline sensory  429 3.55 (2.98) 439 3.74 (2.91) NS 
  Baseline motor     429 2.11 (2.40) 439 2.16 (2.29) NS 
Total count 429 5.66 (4.48) 439 5.90 (4.27) NS 
  Week 78 sensory  338 2.33 (2.80) 343 2.63 (3.03) NS 
  Week 78 motor   338 1.15 (1.88) 343 1.35 (1.90) p<0.05 
Total count 338 3.48 (4.22) 343 3.98 (4.38) NS 
  Difference baseline-week 78 338 2.11 (3.73) 343 1.68 (3.34) NS 
Reaction Severity Scale      
  Baseline  426 7.26 (9.15) 438 7.22 (6.79) NS 
  Week 32 425 4.21 (6.09) 437 4.16 (5.66) NS 
  Week 52 427 3.93 (5.81) 437 4.59 (6.18) NS 
  Week 78 422 3.97 (5.96) 432 4.50 (6.16) NS 
  Difference baseline-week 78 420 3.35 (7.47) 432 2.75 (4.62) NS 
SALSA scale      
  Baseline 402 27.77 (10.26) 412 27.08 (9.03) NS 
  Week 78 269 23.49 (7.93) 272 23.92 (8.41) NS 
  Difference baseline-week 78 269 1.62 (8.96) 272 1.37 (8.74) NS 
P-Scale      
  Baseline  402 13.02 (12.79) 412 11.57 (11.74) NS 
  Week 78 269 9.41 (9.87) 273 9.43 (10.21) NS 
  Difference baseline-week 78 269 0.04 (15.42) 273 -1.38 (13.27) NS 
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to have restored or improved nerve function at week 78 (OR Grade 1: 0.73 (0.54-0.98) and OR 
Grade 2: 0.19 (0.12-0.28)). A higher EHF score also reduced the odds of a good outcome (OR: 
0.73 (0.67-0.80). Neither WHO nor Ridley-Jopling classification had influence on improvement 
of the nerve function, nor did skin smear, nor the presence or absence of severe Type 1 or Type 
2 reaction at baseline. 
 
Discussion 
Our study demonstrated that a 32-week course of prednisolone is not more effective than a 20-
week course in restoring and improving recent clinical nerve function impairment in leprosy 
patients. This result is not in accordance with our hypothesis that a longer prednisolone regimen 
would be more beneficial. This was based on the results of Rao et al., who found that T1R 
patients on a 20-week prednisolone course required significantly less additional prednisolone 
than patients receiving a 12-week course. The theory underlying this hypothesis was that a 
longer prednisolone treatment suppresses the immune system long enough for the antigenic 
load to sufficiently decrease [20,21]. Nevertheless, in both treatment arms in our study, a large 
group of patients showed improvement and recovery of nerve function, indicating that 20-week 
prednisolone treatment is sufficient for most patients. Nerve function improved in around 78% 
of the patients, and 24-30% of these patients recovered completely. Unfortunately, there was 
also a group of patients that had a reaction or had deteriorating NFI, for which additional 
prednisolone was still required. Notably, the proportion of patients needing additional 
prednisolone was similar in both groups (15% and 16%). The total duration and dose of the 
additional prednisolone treatment did not differ between the groups. However, we did see a 
difference in timing of the need for additional prednisolone. New NFI and reactions were 
primarily reported in the weeks after prednisolone treatment had ended, thus after 20 weeks 
and 32 weeks respectively for the control and intervention arm. A similar rebound effect was 
observed in the TRIPOD study and in the study of Rao et al. [12,22]. The longer prednisolone 
treatment in our study seems to merely postpone the immune response in some patients. 
The group of patients needing additional prednisolone differed at baseline from the group that 
did not need extra prednisolone. This former group had significantly more MB patients -mainly 
BL and LL-, had higher average skin smear, had a higher EHF score, had T1R and T2R more 
often at baseline and showed more often signs of neuritis and reactions, i.e. inflamed and raised 
skin lesions, peripheral oedema, nerve pain and tenderness. An even longer prednisolone 
course than assessed in this study might be beneficial for these patients, as it seems that the 
immune response against dead M. leprae bacilli is too persistent to be permanently suppressed 
by a 32-week prednisolone course [23]. New studies with even longer prednisolone treatments 
are needed in an attempt to find the best treatment for recent NFI in this specific group of 
patients. 
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The mechanisms behind nerve damage in leprosy are generally not well understood, because it 
is difficult to study. Nerve biopsies can give some insight in the pathophysiology of neuropathy, 
but are limited to a single point in time and do not provide information about the onset and 
further development of impairment [20]. Several mechanisms are described in literature though. 
The first mechanism is demyelination of the nerves. In cell cultures, demyelination has been 
shown to occur when M. leprae invades the Schwann cells [24-26]. This process can take place 
in an early stage, when the immune system has not been activated yet. After the immune 
system gets involved, demyelination can also be induced by cytokines [27-31]. The second 
mechanisms, shown in Schwann cell cultures, is the direct attack and damaging of Schwann 
cells by T-cells [32-34], destroying the nerves. The last mechanism of nerve damage in leprosy 
is mechanical. The high pressure in the nerve due to oedema, a characteristic sign of 
inflammation, can lead to axonal loss. The pressure can also close blood vessels and cause 
ischemia [20,35]. Damaged nerves can regenerate when the inflammation is under control. 
However, the duration of the inflammation may influence how well the nerve can regrow [36]. In 
addition, scar formation is often seen around the damaged nerves, hindering regeneration [35]. 
Prednisolone can reduce the inflammation, and therefore reduce oedema and pressure, and 
stop the killing of Schwann cells. In addition, prednisolone reduces scar formation [37], giving 
the damaged nerves time and space to regenerate.  
 
Figure 4- Survival until first course of additional prednisolone for all cases (n=868) 
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Observational studies have shown that prednisolone improves nerve function [2,8-10]. And even 
though prednisolone is generally considered an important drug for improving NFI, it is not 
known to what extent prednisolone is responsible for the reported improvements in these 
observational studies. Its effectiveness has never been confirmed in placebo controlled 
randomized controlled trials, such as the TRIPOD studies [22,38]. Additionally, the high 
proportion of patients experiencing spontaneous nerve function improvement should be 
considered [22,39,40]. Previous studies have found that 33%-75% of impairments improved 
spontaneously, depending of the severity of NFI and the type of nerve [39,41]. Even in patients 
with old NFI, receiving a placebo, 51% showed improvement [40]. A placebo controlled RCT 
could be an important next step to investigate the actual effect of prednisolone on the treatment 
of recent NFI (without reaction). Alternatives for prednisolone should be studied as well, 
however, so far no treatments have been proven effective. Azathioprine and cyclosporine are 
immunosuppressants used to treat reactions, but their effect is limited [42,43]. These drugs 
have not been studied in the treatment of NFI by itself. Nerve decompression, a surgical method 
to relieve the pressure on the nerves, is used to improve neuropathy in leprosy. Evidence from 
controlled randomized on the effectiveness of this method trials is lacking as well [44].  
The strongest point of our study is the multi-centre, multi-country set up. We included patients 
from rural and urban areas, PB and MB patients, and patients with or without reaction 
symptoms. With some confidence we can therefore generalize our results. In addition, our RCT 
was unique in maintaining a middle plateau for a longer time with a relatively high dose of 
prednisolone. We are also the first to assess three points for the sural and radial cutaneous 
nerves for MFT. Adding the sural and radial cutaneous nerves to the Composite Nerve Score 
increased its reliability. One limitation in this study was the high loss to follow-up. The 
percentage of patients lost to follow-up exceeded the Evidence Based Medicine cut off of 20%, 
leading to a loss of validity [45]. At 78 weeks, we collected data of 72% of the patients in the 
20-week arm and 78% of the patients in the 32-week arm; including patients who did not finish 
trial treatment because of SAE, the need for additional prednisolone or temporary lost-to-follow 
up. However, we tried to limit the effects of the high loss to follow up. First, we prolonged the 
intake period to increase the number of patients in the trial, so we could reach the required 
power. Second, we analysed our data according to the intention to treat principle, using the last 
observation carried forward approach. This should limit the bias related to the non-random loss 
of patients. The disadvantage of an intention-to-treat analyses is that patients who do not finish 
treatment are included as well. Their results will dilute the outcome, but this situation is similar to 
what would have happened in non-controlled conditions in a field clinic. Consequently, it is likely 
that our outcome is conservative and therefore the actual improving effect of prednisolone on 
NFI might be even larger. A second limitation is that the duration of NFI was self-reported. 
Patients were included in the study when the duration of NFI was maximum 6 months. 
However, one can wonder whether estimation of duration of impairments by the patients 
themselves is reliable. When the delay in prednisolone treatment is too long (>6 months), the 
damage to the nerve is considered to be irreversible. From previous studies [5,46] it seems that 
NFI of shorter duration has better chances on improvement. It could therefore be that in some 
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patients nerves do not improve because the actual duration of NFI is much longer than the self-
reported duration. Unfortunately, there is no reliable method to establish the duration of NFI.  
In conclusion, we hypothesized that the 32-week prednisolone treatment would be more 
beneficial in improving nerve function than the 20-week treatment. The results of this study 
show that this is not the case; the 32-week and 20-week regimens were equally effective. In 
absence of published RCT data on shorter duration - 16-weeks would be a good candidate- in 
a similar patient group, we conclude that a 20-week course is sufficient to improve nerve 
function in 78% of patients with recent NFI. Future studies should focus on the group of 
patients who do not seem to benefit from prednisolone treatment of this duration. To help better 
treat this group, it is important to unravel the pathophysiology of nerve function impairment and 
to study the actual effect of prednisolone on immune function as it relates to NFI. Understanding 
the mechanisms behind NFI can lead to alternative, more effective solutions for the treatment of 
NFI and the prevention of irreversible impairments and subsequent disabilities. 
 
  
114 
 
References 
1. World Health Organization, Weekly Epidemiological Record. 2014. 89(36): p. 389-400. 
 
2. Saunderson, P., The pattern of leprosy-related neuropathy in the AMFES patients in 
Ethiopia: definitions, incidence, risk factors and outcome. Leprosy Review, 2000. 71(3): p. 
285-308. 
 
3. Rosenberg, N.R., W.R. Faber, and M. Vermeulen, Unexplained delayed nerve impairment 
in leprosy after treatment. Leprosy Review, 2003. 74(4): p. 357-365. 
 
4. Croft, R.P., et al., A clinical prediction rule for nerve function impairment in leprosy 
patients-revisited after 5 years of follow-up. Lepr Rev, 2003. 74(1): p. 35-41. 
 
5. Naafs, B., Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve 
damage. International journal of leprosy and other mycobacterial diseases : official organ 
of the International Leprosy Association, 1996. 64(4 Suppl): p. S21-28. 
 
6. Britton, W.J., The management of leprosy reversal reactions. Leprosy Review, 1998. 
69(3): p. 225-234. 
 
7. World Health Organization, WHO Expert Committee on Leprosy- Seventh report, in World 
Health Organization technical report series No. 874. 1998: Geneva. 
 
8. Britton, W.J. and D.N.J. Lockwood, Leprosy. Lancet, 2004. 363(9416): p. 1209-1219. 
 
9. Croft, R.P., J.H. Richardus, and W.C.S. Smith, Field treatment of acute nerve function 
impairment in leprosy using a standardized corticosteroid regimen - First year's 
experience with 100 patients. Leprosy Review, 1997. 68(4): p. 316-325. 
 
10. Schreuder, P.A.M., The occurrence of reactions and impairments in leprosy: Experience in 
the leprosy control program of three provinces in northeastern Thailand, 1978-1995. III. 
Neural and other impairments. International Journal of Leprosy, 1998. 66(2): p. 170-181. 
 
11. van Veen, N.H., et al., Corticosteroids for treating nerve damage in leprosy. Cochrane 
Database Syst Rev, 2007(2): p. CD005491. 
 
12. Sundar Rao, P.S.S., et al., Multi-centre, double blind, randomized trial of three steroid 
regimens in the treatment of type-1 reactions in leprosy. Leprosy Review, 2006. 77(1): p. 
25-33. 
13. Wagenaar, I., et al., Two randomized controlled clinical trials to study the effectiveness of 
prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: 
the TENLEP study protocols. BMC Neurology, 2012(1471-2377 (Electronic)). 
 
14. Brandsma, J.W., et al., Reliability of clinical nerve function assessment in peripheral 
neuropathies. Leprosy Review, 2014. 85(1): p. 29-35. 
 
15. O'Brien, M.D., Aids to the examination of the peripheral nervous system. The Guarantors 
of Brain. Vol. 5th edition. 2010: Elsevier Health Sciences. 
 
115 
 
16. The SALSA Collaborative Study Group. Screening Activity Limitation and Safety 
Awareness Users Manual V1.1. 2010 [cited 2012 September 28th]; Available from: 
http://www.ilep.org.uk/fileadmin/uploads/Documents/Infolep_Documents/Salsa/SALSA_
manual_v1.1pdf.pdf. 
 
17. van Brakel, W.H. Participation Scale Users Manual v. 6.0 2010 [cited 2012 September 
28th]; Available from: 
http://www.ilep.org.uk/fileadmin/uploads/Documents/Infolep_Documents/Participation_S
cale/Participation_Scale_Users_Manual_v._6.0.pdf. 
 
18. Walker, S.L., et al., Development and validation of a severity scale for leprosy type 1 
reactions. PLoS Neglected Tropical Diseases, 2008. 2(12). 
 
19. Post E., W.I., Brandsma W., Nicholls P., Richardus J.H., Prednisolone Adverse Events in 
the Treatment of Leprosy Neuropathy. In preparation, 2016. 
 
20. Scollard, D.M., R.W. Truman, and G.J. Ebenezer, Mechanisms of nerve injury in leprosy. 
Clinics in Dermatology, 2015. 33(1): p. 46-54. 
 
21. Lockwood, D.N.J., Steroids in leprosy type 1 (reversal) reactions: Mechanisms of action 
and effectiveness. Leprosy Review, 2000. 71(SUPPL.): p. S111-S114. 
 
22. van Brakel, W.H., et al., The prognostic importance of detecting mild sensory impairment 
in leprosy: A randomized controlled trial (TRIPOD 2). Leprosy Review, 2003. 74(4): p. 300-
310. 
 
23. Shetty, V.P., et al., Persistence of Mycobacterium leprae in the peripheral nerve as 
compared to the skin of multidrug-treated leprosy patients. Leprosy Review, 1992. 63(4): 
p. 329-336. 
 
24. Oliveira, R.B., et al., Expression of toll-like receptor 2 on human schwann cells: A 
mechanism of nerve damage in leprosy. Infection and Immunity, 2003. 71(3): p. 1427-
1433. 
 
25. Rambukkana, A., et al., Contact-dependent demyelination by Mycobacterium leprae in 
the absence of immune cells. Science, 2002. 296(5569): p. 927-31. 
 
26. Tapinos, N., M. Ohnishi, and A. Rambukkana, ErbB2 receptor tyrosine kinase signaling 
mediates early demyelination induced by leprosy bacilli. Nature Medicine, 2006. 12(8): p. 
961-966. 
 
27. Constantin, G., et al., Induction of adhesion molecules on human Schwann cells by 
proinflammatory cytokines, an immunofluorescence study. Journal of the Neurological 
Sciences, 1999. 170(2): p. 124-130. 
 
28. Fujioka, T., D.L. Kolson, and A.M. Rostami, Chemokines and peripheral nerve 
demyelination. Journal of NeuroVirology, 1999. 5(1): p. 27-31. 
 
29. Andrade, P.R., et al., Inflammatory Cytokines Are Involved in Focal Demyelination in 
Leprosy Neuritis. J Neuropathol Exp Neurol, 2016. 
 
116 
 
30. Shetty, V.P., Pathomechanisms of Nerve Damage, in IAL Textbook of Leprosy, H. Kumar 
and B. Kumar, Editors. 2010, Jaypee Brothers Medical Publishers (P) Ltd.: New Delhi. 
 
31. Khanolkar-Young, S., et al., Tumor necrosis factor-alpha (TNF-α) synthesis is associated 
with the skin and peripheral nerve pathology of leprosy reversal reactions. Clinical and 
Experimental Immunology, 1995. 99(2): p. 196-202. 
 
32. Lockwood, D.N. and P.R. Saunderson, Nerve damage in leprosy: A continuing challenge 
to scientists, clinicians and service providers. International Health, 2012. 4(2): p. 77-85. 
 
33. Ford, A.L., W.J. Britton, and P.J. Armati, Schwann cells are able to present exogenous 
mycobacterial hsp70 to antigen-specific T lymphocytes. Journal of Neuroimmunology, 
1993. 43(1-2): p. 151-160. 
 
34. Steinhoff, U., et al., Mycobacterium leprae renders Schwann cells and mononuclear 
phagocytes susceptible or resistant to killer cells. Infection and Immunity, 1991. 59(2): p. 
684-688. 
 
35. Job, C.K., Pathology and pathogenesis of leprous neuritis; a preventable and treatable 
complication. International Journal of Leprosy and Other Mycobacterial Diseases, 2001. 
69(2 SUPPL.): p. S19-S29. 
 
36. Burnett, M.G. and E.L. Zager, Pathophysiology of peripheral nerve injury: a brief review. 
Neurosurg Focus, 2004. 16(5): p. E1. 
 
37. Naafs, B., Treatment of reactions and nerve damage. International Journal of Leprosy, 
1996. 64(4 SUPPL.): p. S21-S28. 
 
38. van Veen, N.H., et al., Corticosteroids for treating nerve damage in leprosy. A Cochrane 
review. Lepr Rev, 2008. 79(4): p. 361-71. 
 
39. Croft, R.P., et al., The treatment of acute nerve function impairment in leprosy: Results 
from a prospective cohort study in Bangladesh. Leprosy Review, 2000. 71(2): p. 154-168. 
 
40. Richardus, J.H., et al., Treatment with corticosteroids of long-standing nerve function 
impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev, 2003. 74(4): p. 
311-8. 
 
41. Smith, W.C., et al., Steroid prophylaxis for prevention of nerve function impairment in 
leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ, 2004. 328(7454): p. 1459. 
 
42. Lambert, S.M., et al., Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in 
the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, 
Controlled Pilot Studies in Ethiopia. PLoS Neglected Tropical Diseases, 2016. 10(2). 
 
43. Lambert, S.M., et al., A Randomized Controlled Double Blind Trial of Ciclosporin versus 
Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in 
Ethiopia. PLoS Negl Trop Dis, 2016. 10(4): p. e0004502. 
 
44. van Veen, N.H., et al., Decompressive surgery for treating nerve damage in leprosy. 
Cochrane Database Syst Rev, 2009(1): p. CD006983. 
 
117 
 
45. Oxford Centre for Evidence-based Medicine. Levels of Evidence. 2009 [cited 2016 4th of 
April]; Available from: http://www.cebm.net/oxford-centre-evidence-based-medicine-
levels-evidence-march-2009/. 
 
46. Becx-Bleumink, M., D. Berhe, and W. Mannetje, The management of nerve damage in the 
leprosy control services. Lepr Rev, 1990. 61(1): p. 1-11. 
 
 
 
 
  
 
  
 
 
  
 
 
Chapter 7 
 
 
Prednisolone adverse events in the treatment  
of leprosy neuropathy 
 
 
 
 
 
 
Erik Post 
Inge Wagenaar 
J Wim Brandsma 
Cita Rosita Sigit Prakoeswa 
Krishna Tamang 
Deanna Hagge 
Robert Bowers 
Sajid Husain 
Vanaja Shetty 
Peter Nicholls 
Jan Hendrik Richardus 
 
 
 
 
Submitted to Leprosy Review
120 
 
Abstract 
Introduction  
Corticosteroids (prednisolone) are the mainstay in the treatment of leprosy reactions, including 
neuropathy. However, these drugs have adverse effects for which patients need to be carefully 
monitored.  
Methods  
In a double-blind randomized controlled trial (RCT), treatment effectiveness of a 20-week 
prednisolone regimen was compared with a longer and more intensive 32-week course to 
assess whether the latter would be more effective to restore nerve function. In a parallel double-
blind RCT, patients with subclinical neuropathy received either a course of 20 weeks 
prednisolone or placebo to assess if the former could prevent the development of clinical 
neuropathy. In both trials, the occurrence of serious adverse events (SAE) was an important 
secondary outcome. In both trials, patients were assigned to a prednisolone starting dose 
according to weight: high weight (≥50 kg) started at 60mg and low weight (<50 kg) started at 
45mg. 
Results  
In the Clinical trial, 868 patients enrolled, of whom 16 (1.8%) developed a serious adverse event 
(SAE). There were twelve SAEs in the longer treatment arm (n=439, event rate of 2.7%), and 
four in the shorter arm (n=429, event rate of 0.9%) (p=0.041). In the Subclinical neuropathy trial 
4/364 (1.1%) developed an SAE, of which one in the placebo arm. In both trials, minor adverse 
events were very common and varied greatly in occurrence of event and between centres. 
Discussion/conclusion  
When searching for the optimum dose and duration of prednisolone in the treatment and 
prevention of neuropathy in leprosy patients, one has to weigh possible advantages of 
prednisolone treatment against the possible serious adverse events. Our trials have not shown 
significant benefits of a longer prednisolone treatment for clinical neuropathy than 20 weeks, nor 
the effectiveness of 20 weeks of prednisolone in the prevention of clinical neuropathy in case of 
subclinical neuropathy. At the same time, our trials did show a significantly increased 
percentage of SAE in the longer treatment arm, be it with an overall low event rate. 
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Introduction 
Leprosy is a disease of skin and nerves. Leprosy neuropathy is a major complication that may 
lead to permanent disability when untreated. Nerve function impairment (NFI) might be 
prevented if neuropathy is diagnosed in time and the patient is given a course of an 
immunosuppressive drug such as prednisolone [1-4].  
The World Health Organization has recommended regimens for the treatment of neuropathy 
taking into account age (child/adult) and type of ‘reactional’ neuropathy, typically a 12-weeks 
regimen [5]. In case of a type 1 reaction, ILEP advises a 12-weeks regimen for PB cases, and a 
24-weeks regimen for MB cases. For type 2 reaction, this is a short course of 6 weeks [6].  
Many studies have shown both benefits and limitations of treating leprosy neuropathy with 
corticosteroids using different treatment regimens, with variations in dose and duration [1-3,7]. 
These studies have shown that treatment durations longer than proposed in the WHO guideline 
are more effective.  
Outside the field of leprosy, the adverse events of corticosteroids have been well documented 
for the treatment of diverse pathologies [8]. 
A recently concluded randomized, double-blind clinical trial compared the effectiveness of a 
longer, 32 weeks course of prednisolone with the commonly accepted treatment regimens of 
20 weeks in improving and restoring clinically established recent sensory and/or motor loss [9].  
In a parallel randomised, double-blind and placebo-controlled trial, prednisolone was given for 
20 weeks to patients who had only subclinical nerve impairment, as assessed by nerve 
conduction studies (NCS) and/or Warmth Detection Thresholds (WDT) [10-12]. The aim of the 
study was to determine whether prednisolone treatment would prevent clinical function loss in 
leprosy patients as established by Voluntary Muscle Testing (VMT) and Monofilament Testing 
(MFT). These two trials are known as the TENLEP trials (Treatment of Early Neuropathy in 
LEProsy) [13]. This study reports on possible steroid induced serious and minor adverse events 
in the two TENLEP trials. 
 
Methods 
The trials took place in six centres in four leprosy endemic countries: India (2), Nepal (2), 
Bangladesh and Indonesia. Eligible patients were assessed with Voluntary Muscle Tests (VMT), 
Monofilament Tests (MFT), Nerve Conduction Studies (NCS), and Warmth Detection Tests 
(WDT). Reliability and normative studies were carried out prior to screening for possible 
inclusion. Patients, between the ages of 15 and 60, were eligible for enrolment, irrespective of 
the leprosy classification. More detailed information regarding in- and exclusion criteria can be 
found in the protocol article [13]. Patients were monitored for 78 weeks, whereby assessments 
were carried out monthly until completion of the intervention period at 20 or 32 weeks, followed 
by assessments at week 52 and week 78. 
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Table 1- The types of adverse events as recorded in this study 
 
In both trials the medication provided is prednisolone. Adverse events were recorded as listed in 
Table 1. The option ‘other’ adverse events was included to leave room for the clinicians to 
report for example extremely rare adverse events.    
In the Clinical trial , patients in the treatment arm received prednisolone for 32 weeks, in tablets 
of 5 mg [13]. The control arm followed a regimen of 20 weeks and received placebo tablets to 
keep the number of tablets equal to that in the treatment group. The dose in both the 
intervention and control arm started at 1 mg/kg/day (either 45 or 60 mg/day depending on body 
weight being under or above 50kg respectively) and was tapered down over 32 and 20 weeks, 
respectively (see Figure 1). Contrary to previous trials, the middle range of the prednisolone 
dose was maintained at a high level (0.44 mg/kg/day) for a longer period (12 weeks).  
In the Subclinical trial, patients received either prednisolone or placebo for 20 weeks in tablets 
of 5 mg [13]. The prednisolone dose started at 1 mg/kg/day (either 45 or 60 mg/day depending 
on weight class), and was be tapered down over 20 weeks. Figure 1 shows the timeline and 
dosage. The total dosage of prednisolone over 20 weeks will be 2.8 grams for patients under 
50 kg body weight, and 3.7 grams for patients over 50 kg body weight. 
Prior to enrolment, patients were screened for underlying morbidities such as diabetes and 
osteoporosis. Patients with these diagnoses were not enrolled in the trial. All patients were de-
wormed before starting the trial medication. 
 
A distinction was made between minor and serious adverse events. Adverse events were only 
counted once, even when they occurred multiple times in one patient or were recorded on 
multiple visits. When minor adverse events were noticed these were treated and the patient 
continued in the trial. When serious adverse events were noticed or leprosy ‘reactions’ or other 
complications occurred, patients were taken off trial treatment and continued on individualised 
treatment. 
Serious Adverse Events (SAE) Minor Adverse Events (MAE) 
  Peptic ulcer Gastric pain 
Diabetes Moon face 
Tuberculosis Acne 
Hypertension Fungal infection (local) 
Psychosis Weight gain 
Glaucoma Other 
Cataract  
Corneal ulcer  
Worm infestation  
Other  
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Figure 1 A- Timeline prednisolone dose for patients under 50 kg in the Clinical trial. Figure 1 B- Timeline 
prednisolone dose for patients under 50 kg in the Subclinical trial 
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Data from the participating centres were send to PN and were analysed with Stata. 
Informed written consent was obtained from each patient, who could withdraw from the 
treatment at any time. In India, ethics approval was obtained from the Indian Council of Medical 
Research and the Ethics Committee of the Foundation for Medical Research, Mumbai; in Nepal 
from the Nepal Health Research Council (NHRC); in Indonesia from the Komite Etik Penelitian 
Kesehatan RSUD Dr. Soetomo Surabaya; in Bangladesh from the Bangladesh Medical 
Research Council - National Research Ethics Committee. The trial was registered in the 
Netherlands Trial Register (NTR2300) and in the Clinical Trials registry India 
(CTRI/2011/09/002022 and 23).  
 
Results   
A total of 868 patients were enrolled in the Clinical trial and 364 patients in the Subclinical trial. 
In both trials there were no statistically significant differences in demographics nor assignment 
to the treatment arms [9,14]. We refer to these papers for primary outcomes and detailed 
information regarding classification and ‘flow’ of patients through the trial phase. 
 
Table 2 summarises the serious- and minor adverse events from both trials. In the Subclinical 
trial, with a prednisolone (20 weeks) and a placebo arm, only four SAEs were noticed: three 
patients with hypertension and one patient with TB, the latter who had been assigned to the 
placebo arm. All SAEs in the Subclinical trial were reported by one centre, and all were in the 
high weight group. 
 
In the Clinical trial, with two treatment arms 16 SAE were recorded. Table 3 shows the SAEs 
per centre and trial arm. It is noticeable that not all possible SAEs, as listed in Table 1, did occur 
in our cohort. In addition, it can be seen that there is considerable variation between the centres 
in the number of SAEs reported. All SAEs were reported within the period that prednisolone was 
given. More SAEs were reported from the longer treatment arm, namely 12 of the 16 (p=0.041). 
Of these 16, 11 were in the high weight group (p=0.378).  
 
The minor adverse events are reported in Tables 4 and 5. In both trials, minor adverse events 
were very common: 49% of the patients in the Subclinical trial and 67% of the patients in the 
Clinical trial showed one or more MAEs. MAEs varied greatly in occurrence of event and 
between centres, e.g. in the Subclinical trial: moon face (2-68%), and acne (8-61%). Minor 
events were also noticed in the placebo arm, e.g. moon face: 0-53% (Table 4). 
The same great variation in numbers of minor adverse events between the centres is also 
noticeable for the Clinical trial (Table 5). In both trials and all arms differences could be seen 
between the high and low weight groups, however, the differences were not clearly in one 
direction. The high weight group in the Subclinical trial 44% had an MAE and in the Clinical trial 
66%. In the low weigh groups, this was 56% and 69%, respectively. 
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Table 2- Relative risk, confidence intervals and p-values of adverse events in both trials 
  RR: relative risk; CI: confidence interval; †One- sided p-value; * statistically significant difference 
 
Discussion  
The TENLEP trials were conducted to a) assess the effectiveness of a relatively longer course of 
prednisolone than normally practiced in the treatment of recent NFI and b) to assess if a 20-
week course of prednisolone would reduce the incidence of clinical NFI in patients with 
subclinical neuropathy [13]. The results of these trials are reported elsewhere [9,14]. An 
important secondary outcome was the occurrence of adverse events due to prednisolone. Do 
hypothesised benefits outweigh the possible increase in incidence of prednisolone related 
serious adverse events?   
The Clinical trial did not show a significant beneficial effect of 32 weeks prednisolone in the 
treatment of NFI compared to the ‘standard’ 20-week course. Likewise, the treatment in the 
Subclinical trial was not significantly more effective than a placebo in the prevention of NFI. 
 
Our studies have shown that serious adverse events do occur, but that the overall event rate of 
SAE was very low. A longer duration of prednisolone (32 weeks), however, did significantly 
increase the event rate of SAEs. If our trials had shown significant benefits of the longer 
treatment, a longer course could be recommended considering the small numbers of SAE. 
 
It should be noted that patients in our Clinical trial not only received prednisolone for a longer 
duration then commonly practiced in leprosy, the total amount of prednisolone was higher as 
well. This was not only because of the longer duration, but also because we maintained a 
‘middle-medium plateau’ dose for a relative longer time before tapering down (Figure 1). The 
plateau dose remained above the ‘critical’ dose of 25mg as recommended by Naafs except for 
the last three weeks [1].  
 
 Clinical Trial 20-week arm 
n=429 
32-week arm 
n=439 
RR CI p-value†             
      Serious Adverse Events 4 12 2.9 (0.95-9.02) 0.041* 
Minor Adverse Events 284 300 1.0 (0.94- 1.13) 0.275 
 Subclinical Trial 20-week arm      
n=181 
Placebo           
n=182 
RR CI p-value†            
      Serious Adverse Events 3 1 3.0 (0.32-28.73) 0.309 
Minor Adverse Events 102 75 1.4 (1.10-1.70) 0.003 
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Table 3- Serious adverse events in the Clinical trial 
 20-week arm  32-week arm  
               Centre A B C D E A B C D E 
           Peptic ulcer    1†   1#    
           Diabetes    1# 1#   1# 3†##  
           Tuberculosis           
           Hypertension    1#  1#  2†# 2††  
           Psychosis        1# 1#  
           Glaucoma           
           Cataract           
           Corneal ulcer           
           Worm infestation           
           Other           
Centre F did not report any SAE; † In low weight group, #In high weight group 
 
Despite the somewhat higher dose used in our trials, SAE event rates were quite similar to 
those in the TRIPOD trials, at less than 3% [15]. All patients developing SAE did so during the 
trial treatment period of 32 weeks. In both trials, when patients had deteriorating nerve function 
or reactions, they received additional prednisolone. None of those patients developed SAE.  
 
In one of the centres, many patients were recalled for an additional physical examination after 
the 72 weeks follow up period, but within 120 weeks after enrolment in the trial. An additional 
three patients were diagnosed with cataract and two with hypertension. Hypertension can have 
multiple causes and is not likely to be related to the use of prednisone many months after the 
use of prednisolone. 
 
Regarding cataract, there seems to be a relationship between prednisolone treatment and a 
specific type of cataract, sub-capsular. This specific type was diagnosed in two of the patients. 
The aetiology of steroid induced posterior subcapsular cataracts is explained by James [16]. 
One study in lepromatous leprosy patients in India found that cataract develops in 3% per 
person year and 7% per person year in lepromatous patients over 40 years of age. There was, 
however, no significant association with oral steroids [17]. Leprosy patients are ‘at risk’ because 
of the generally long duration of the disease and often present subclinical intra-ocular 
inflammation [2,17]. Further prospective studies are recommended to investigate the late 
occurrence of cataract and its possible relation to prednisolone. 
 
Minor adverse events have been reported in another placebo controlled trial, and similar to our 
study, the MAEs were present in the placebo arm, though less frequent [15]. It appears, 
therefore, that some of the minor adverse events that can be attributed to prednisolone also 
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Table 4- Minor Adverse Events in Subclinical trial per treatment arm for each centre 
 n 
(total) 
n 
(20-week) 
MAE 
20-week  
MAE 
Placebo  
MAE 
Total 
   n  n  n  
         Moon face         
A 61 30 1 (3%) 0 (0%) 1 (2%) 
B 136 68 56 (82%) 36 (53%) 92 (68%) 
C 48 24 4 (17%) 0 (0%) 4 (8%) 
D 118 59 3 (5%) 1 (2%) 4 (3%) 
            
Acne            
A 61 30 3 (10%) 2 (6%) 5 (8%) 
B 136 68 52 (76%) 31 (46%) 83 (61%) 
C 48 24 5 (21%) 1 (4%) 6 (13%) 
D 118 59 7 (12%) 3 (5%) 10 (8%) 
            
Fungal infection            
A 61 30 1 (3%) 2 (6%) 3 (5%) 
B 136 68 8 (12%) 4 (6%) 12 (9%) 
C 48 24 1 (4%) 2 (8%) 3 (6%) 
D 118 59 3 (5%) 1 (2%) 4 (3%) 
            
Gastric pain            
A 61 30 0 (0%) 0 (0%) 0 (0%) 
B 136 68 7 (10%) 4 (6%) 11 (8%) 
C 48 24 0 (0%) 0 (0%) 0 (0%) 
D 118 59 19 (32%) 21 (36%) 40 (34%) 
 
happen due to other causes, co-incidentally. Some, like moon face, depend on subjective 
clinical judgement. MAEs can be treated or will resolve when prednisolone treatment is 
stopped. However, they can be aesthetically unacceptable and therefore need careful 
explanation [18]. 
This study had some limitations to take into consideration. First, even though the trial was 
double-blind, experienced leprosy physicians and field-staff may suspect that patients are on 
the prednisolone arm through for example the appearance of moon-face features, or acne, 
which happens in many patients [3]. This knowledge could influence the clinical observation, 
besides alertness and conscientiousness, in the recording of minor adverse events. However, 
this seems to be contradicted by the finding that minor adverse event were also noticed in the 
placebo group, confirming findings by others [15]. Second, in both arms of the Clinical trial there 
were a considerable proportion of patients who were lost to follow-up. This was seen in both 
the 20-week (96/429 (22.4%) and the 32-week (110/439= 25.1%) prednisolone arms. One 
possible reason for loosing patients to follow-up is the occurrence of side effects of the 
treatment, and therefore the number of SAE could potentially have been higher than reported 
[8,19]. 
128 
 
Obvious differences are seen in the incidence of minor adverse events between the project 
sites. It should be born in mind that the studies took place in six hospitals in four countries with 
structurally differing leprosy programs. Difference in access to services and illness behaviour, 
changes in staff and commitment may be an explanation for diversity in therapy adherence and 
reporting and noticing of, especially, minor adverse events. In addition, one could wonder 
whether these variations could be attributed to ethnic differences [20]. 
One ‘beneficial’ adverse event that is known but little researched is the dependency on 
prednisolone [21]. Prednisolone supposedly may cause euphoria, which may result in patients 
requesting the drug, even purchasing prednisolone themselves. Fardet mentions many different 
mental consequences [18], not systematically recorded in our study, but euphoria is not listed. 
This effect was not studied in our cohorts either.  
The search for alternative, more effective drugs continues, but none has been shown to be 
superior yet to prednisolone in terms of better outcomes and fewer adverse events [22,23]. 
Hence, corticosteroids remain ‘first choice’ in neuropathy and ‘reactional’ phases in leprosy 
whether skin, nerve, or both are involved. More research is needed, though, into the effect of 
prednisolone in the prevention and treatment of NFI and often concomitant other signs of 
leprosy reactions, not only in delineation of leprosy- and patient specific characteristics that 
determine response but also in alternative drug regimens. 
The TENLEP studies are two of very few studies that have looked systematically in randomized 
trials into the adverse events of corticosteroids in the treatment of leprosy neuropathy. Outside 
leprosy, adverse events due to corticosteroids have been extensively reviewed by Fardet for 
many other clinical conditions [8,18]. Because of its completeness and clinical grouping, the 
classification of adverse events as developed by Fardet seems most suitable to follow in future 
leprosy clinical projects using steroids or other immune-suppressive drugs [8,24]. 
Though it is important to have a protocol, a ‘guiding’ (guideline) document, for the treatment of 
nerve function impairment, ideally treatment for reaction/NFI should be patient-centred. This is 
not always practical under field conditions with integrated services and declining leprosy 
expertise. Nevertheless, ideally, “.. treatment should be tailored to the individual patient. ... 
response carefully assessed and adapted to changing circumstances, immediately if necessary” 
[1]. 
When searching for the optimum dose and duration of prednisolone in the treatment and 
prevention of neuropathy in leprosy patients, one has to weigh possible advantages of 
prednisolone treatment against the possible serious adverse events. The documented 
advantages of prednisolone for the treatment of recent nerve function impairment, to a reported 
70-80% improvement [7], outweigh the disadvantages of SAEs, especially with the low rates in 
our study.   
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Table 5- Minor Adverse Events in Clinical trial per treatment arm for each centre 
 n 
(total) 
n 
(20-week) 
MAE 
20-week  
MAE 
32-week  
MAE 
Total 
   n  n  n  
         Moon face         
A 82 40 3 (8%) 1 (2%) 4 (5%) 
B 230 115 99 (86%) 97 (84%) 196 (84%) 
C 166 83 12 (14%) 11 (13%) 23 (14%) 
D 232 116 24 (21%) 31 (27%) 55 (24%) 
E 101 48 13 (27%) 15 (28%) 28 (28%) 
F 57 27 23 (85%) 29 (97%) 52 (91%) 
             Acne             
A 82 40 7 (18%) 6 (14%) 13 (16%) 
B 230 115 98 (85%) 97 (84%) 195 (85%) 
C 166 83 14 (17%) 15 (18%) 29 (17%) 
D 232 116 15 (13%) 22 (19%) 37 (16%) 
E 101 48 20 (42%) 15 (28%) 35 (35%) 
F 57 27 7 (26%) 8 (27%) 15 (26%) 
             Fungal infection             
A 82 40 0 (0%) 0 (0%) 0 (0%) 
B 230 115 11 (10%) 15 (13%) 26 (11%) 
C 166 83 4 (5%) 11 (13%) 15 (9%) 
D 232 116 24 (21%) 28 (24%) 52 (22%) 
E 101 48 13 (27%) 20 (38%) 33 (33%) 
F 57 27 6 (22%) 6 (20%) 12 (21%) 
             Gastric pain             
A 82 40 0 (0%) 0 (0%) 0 (0%) 
B 230 115 19 (17%) 14 (12%) 33 (14%) 
C 166 83 0 (0%) 0 (0%) 0 (0%) 
D 232 116 54 (47%) 51 (44%) 105 (45%) 
E 101 48 16 (33%) 15 (28%) 31 (31%) 
F 57 27 7 (26%) 11 (37%) 18 (32%) 
              
 
  
130 
 
References 
1. Naafs, B., J.M. Pearson, and H.W. Wheate, Reversal reaction: the prevention of 
permanent nerve damage. Comparison of short and long-term steroid treatment. Int J 
Lepr Other Mycobact Dis, 1979. 47(1): p. 7-12. 
 
2. Rao, P.S., et al., Multi-centre, double blind, randomized trial of three steroid regimens in 
the treatment of type-1 reactions in leprosy. Lepr Rev, 2006. 77(1): p. 25-33. 
 
3. Sugumaran, D.S., Steroid therapy for paralytic deformities in leprosy. Int J Lepr Other 
Mycobact Dis, 1997. 65(3): p. 337-44. 
 
4. Croft, R.P., et al., The treatment of acute nerve function impairment in leprosy: results 
from a prospective cohort study in Bangladesh. Lepr Rev, 2000. 71(2): p. 154-68. 
 
5. World Health Organisation, WHO Model Prescribing Information: Drugs Used in Leprosy. 
1998. p. 28. 
 
6. ILEP, How to Recognise and Manage Leprosy Reactions. 2002. 
 
7. van Veen, N.H., et al., Corticosteroids for treating nerve damage in leprosy. Cochrane 
Database Syst Rev, 2016(5): p. Cd005491. 
 
8. Fardet, L., et al., Corticosteroid-induced adverse events in adults: frequency, screening 
and prevention. Drug Saf, 2007. 30(10): p. 861-81. 
 
9. Wagenaar I., P.E., Brandsma J.W., Effectiveness of 32 versus 20 weeks of prednisolone 
in leprosy patients with recent nerve function impairment: a randomized controlled trial. In 
prepration, 2016. 
 
10. McKnight, J., Reference values for nerve function assessments among a study population 
in northern India - ii: Thermal sensation thresholds. Neurology Asia, 2010. 15(1): p. 27-38. 
 
11. McKnight, J., Reference values for nerve function assessments among a study population 
in northern India - iii: Sensory and motor nerve conduction. Neurology Asia, 2010. 15(1): 
p. 39-54. 
 
12. van Brakel, W.H., et al., Early diagnosis of neuropathy in leprosy--comparing diagnostic 
tests in a large prospective study (the INFIR cohort study). PLoS Negl Trop Dis, 2008. 
2(4): p. e212. 
 
13. Wagenaar, I., et al., Two randomized controlled clinical trials to study the effectiveness of 
prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: 
the TENLEP study protocols. BMC Neurol, 2012. 12: p. 159. 
 
14. Post E., W.I., Brandsma J.W., A 5-month prophylactic prednisolone course is not 
effective in preventing clinical neuropathy in leprosy patients with subclinical neuropathy. 
In prepration, 2016. 
 
131 
 
15. Richardus, J.H., et al., Adverse events of standardized regimens of corticosteroids for 
prophylaxis and treatment of nerve function impairment in leprosy: results from the 
'TRIPOD' trials. Lepr Rev, 2003. 74(4): p. 319-27. 
 
16. James, E.R., The etiology of steroid cataract. J Ocul Pharmacol Ther, 2007. 23(5): p. 
403-20. 
 
17. Daniel, E. and P.S. Sundar Rao, Evolution of vision reducing cataract in skin smear 
positive lepromatous patients: does it have an inflammatory basis? Br J Ophthalmol, 
2007. 91(8): p. 1011-3. 
 
18. Fardet, L., et al., Corticosteroid-induced clinical adverse events: frequency, risk factors 
and patient's opinion. Br J Dermatol, 2007. 157(1): p. 142-8. 
 
19. Morin, C. and L. Fardet, Systemic glucocorticoid therapy: risk factors for reported adverse 
events and beliefs about the drug. A cross-sectional online survey of 820 patients. Clin 
Rheumatol, 2015. 34(12): p. 2119-26. 
 
20. Wood, A.J. and H.H. Zhou, Ethnic differences in drug disposition and responsiveness. 
Clin Pharmacokinet, 1991. 20(5): p. 350-73. 
 
21. Swinburn, C.R., et al., Evidence of prednisolone induced mood change ('steroid 
euphoria') in patients with chronic obstructive airways disease. Br J Clin Pharmacol, 
1988. 26(6): p. 709-13. 
 
22. Naafs, B. and C.L. van Hees, Leprosy type 1 reaction (formerly reversal reaction). Clin 
Dermatol, 2016. 34(1): p. 37-50. 
 
23. Lambert, S.M., et al., A Randomized Controlled Double Blind Trial of Ciclosporin versus 
Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in 
Ethiopia. PLoS Negl Trop Dis, 2016. 10(4): p. e0004502. 
 
24. Liu, D., et al., A practical guide to the monitoring and management of the complications of 
systemic corticosteroid therapy. Allergy Asthma Clin Immunol, 2013. 9(1): p. 30. 
  
  
 
  
 
 
  
 
 
Chapter 8  
 
 
Diet-related risk factors for leprosy:  
A case-control study 
 
 
 
 
 
 
 
 
 
Inge Wagenaar 
Lisanne van Muiden 
Khorshed Alam 
Robert Bowers 
Md. Anwar Hossain 
Kolpona Kispotta 
Jan Hendrik Richardus 
 
 
 
 
 
PLoS Neglected Tropical Diseases 9(5): e0003766 
134 
 
Abstract 
Introduction  
Food shortage was associated with leprosy in two recent studies investigating the relation 
between socioeconomic factors and leprosy. Inadequate intake of nutrients due to food 
shortage may affect the immune system and influence the progression of infection to clinical 
leprosy. We aimed to identify possible differences in dietary intake between recently diagnosed 
leprosy patients and control subjects.   
                                                                                                                                                              
Methods  
In a leprosy endemic area of Bangladesh, newly diagnosed leprosy patients and control 
subjects were interviewed about their socioeconomic situation, health and diet. Dietary intakes 
were recorded with a 24-hour recall, from which a Dietary Diversity Score (DDS) was calculated. 
Body Mass Index (BMI) was calculated and Household Food Insecurity Access Scale (HFIAS) 
was filled out for every participant. Using logistic regression, a univariate, block wise 
multivariate, and an integrated analysis were carried out.      
                                               
Results  
52 leprosy cases and 100 control subjects were included. Food shortage was more common, 
dietary diversity was lower and household food insecurity was higher in the patient group. 
Patients consumed significantly less items from the DDS food groups ‘Meat and fish’ and ‘Other 
fruits and vegetables’. Lower food expenditure per capita, lower BMI, lower DDS and absence 
of household food stocks are the main factors associated with an increased risk of having 
leprosy.   
 
Conclusion  
Low income families have only little money to spend on food and consequently have a low 
intake of highly nutritious non-rice foods such as meat, fish, milk, eggs, fruits and vegetables. 
Development of clinical leprosy could be explained by deficiencies of the nutrients that these 
foods normally provide. 
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Introduction 
Leprosy, an infectious disease caused by Mycobacterium leprae, affects skin and nerves and 
can lead to deformities of the hands, feet and face. The disease remains a public health 
problem in underdeveloped areas in the world, and is therefore known as a disease of the poor. 
Our understanding of risk factors for the transmission of M. leprae and the development of 
leprosy disease is not complete. One of the reasons is the long incubation period, which is on 
average 2-5 years. It is therefore difficult to investigate causal relationships between 
circumstances at the time of infection and the onset of clinical symptoms years later. The most 
important known determinant for contracting leprosy is being a household contact of a leprosy 
patient, which carries a five to eight times higher risk of contracting leprosy [1,2]. The specific 
risk factors that determine the risk for contacts include the Ridley-Jopling leprosy classification 
of the index patient, physical distance to the patient and age of the contact [3]. However, in 
endemic regions the majority of new leprosy patients are not close contacts of a known leprosy 
case [4,5]. Another possible risk factor is poverty, although not all poor countries have high 
leprosy prevalence rates. It is even the case that Brazil, an economically emerging country, has 
one of the highest new case detection rates in the world [6]. It remains unclear which aspects of 
poverty are associated with leprosy susceptibility and the progression to clinically detectable 
disease. Two recent case-control studies investigating socioeconomic factors in relation to 
leprosy found that food shortage was associated with leprosy. The setting of one of these 
studies was a poor, high leprosy endemic area in Brazil [7]. Among other factors, having 
experienced food shortage at any time in life was related to leprosy. The other study was set in 
two leprosy endemic districts in Bangladesh. In this study, food shortage in the past year was 
the only factor significantly associated with the clinical manifestation of leprosy [8]. 
The definition of food shortage used in the Bangladesh study was: ‘the period in which a family 
had to reduce the number of meals a day, or reduce the intake of foods other than rice’. This is 
most likely to occur when rice prices are high, household food stocks depleted and income is 
low due to lack of labour opportunities. Multiple studies in Bangladesh documented that this 
situation typically arises in the period between September and the end of November, just before 
the major harvest Aman in December [9-12].   
Food shortage worsens the often already inadequate intake of micro- and macronutrients. 
Nutritional deficiencies impair the immune system and thus the defence of the body against 
infections [13,14]. The risk of contracting subclinical M. leprae infection is not necessarily 
increased by food shortage, but it could facilitate the progression from infection to the clinical 
presentation of leprosy.  
The findings of the two above-mentioned studies raise many questions regarding the exact 
mechanisms behind the relationship between food shortage and leprosy. Literature on this 
subject is scarce, and to further examine this relationship we designed a case-control study in 
rural Bangladesh during an expected period of food shortage. The aim was to assess possible 
differences in dietary intake between recently diagnosed leprosy patients and control subjects 
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without the disease that could lead to hypotheses on immunological mechanisms underlying the 
clinical development of leprosy. 
 
Methods 
Study population and sampling 
This case-control study was conducted in October and November 2013 in northwest 
Bangladesh, in the mainly rural and agricultural Nilphamari and Rangpur districts. These are 
among the poorest regions in Bangladesh [15], and leprosy is still endemic in this area. In 
2012, 512 new leprosy cases were found in these districts, which have a total population of four 
million (data from the Rural Health Program, Nilphamari).  
Data of all patients diagnosed with leprosy in the first half of 2013 were gathered from the Rural 
Health Program database in Nilphamari, which is run by The Leprosy Mission International, 
Bangladesh (TLMIB). Our aim was to include an equal number of men and women, to have an 
even age distribution and take in only one person (case or control) per household. Furthermore, 
we only included patients aged between 18 and 50 years and with help of field staff we pre-
selected patients with a low risk of stigma possibly caused by a home visit. Of the 180 patients, 
92 were eligible for this study, 64 were outside the age bracket criterion and 24 were excluded 
to avoid the risk of stigma of a home visit. Controls were selected from a random cluster 
sample of the population, originally composed for the COLEP study [16]. Out of the 13 sub-
districts in the area, 20 clusters were formed, each containing 1000 randomly selected people 
[17]. We selected three clusters that could be reached within approximately one hour by 
motorcycle from the TLMIB Leprosy Center in Nilphamari; two clusters in Nilphamari district, of 
which one rural and one suburban, and one rural cluster in Rangpur district. From each cluster, 
34 controls were randomly selected using a computerized sampling method, with an even 
distribution of men and women. Controls were excluded if they or a household member had 
ever been diagnosed with leprosy and if they were under 18 or over 50 years of age. When a 
control subject was not available at the time of our first visit, we made two more attempts. If the 
control subject was still not available the third time, a neighbour of similar age was invited to 
participate.  
Ethics 
Ethical approval for the study protocol was given by the institutional review board of TLMI 
Bangladesh, Nilphamari. Informed written consent was obtained from all participants.  
Data collection 
Data on patients and controls were collected by means of a structured questionnaire, a 24-hour 
dietary recall and anthropometric measures. The questionnaires for cases and controls were 
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developed in English, translated separately by two translators to Bengali and each of them 
translated their colleague’s version back to English. The translations were discussed and the 
questionnaire was optimized. The questionnaire was pre-tested on patients and controls and 
adjusted where necessary. The questions of the Household Food Insecurity Access Scale 
(HFIAS) were kindly provided in Bengali by the International Centre for Diarrheal Disease 
Research, Bangladesh (ICDDR,B). Data were collected during household visits by two staff 
members of the TLMIB Nilphamari Training Center, both were trained field workers fluent in 
Bengali and English.  
The questionnaire focused on demographic, socioeconomic and health data of the subjects 
and their households. The questions dealt with the occupation of the income generator, 
household size (defined as the number of people eating in the house), average income and 
income variation, self-classification on a poverty scale (very poor to rich), land ownership, food 
expenditure, any health problems other than leprosy in the past year and the presence of a 
BCG scar. If a patient’s income had changed since the diagnosis of leprosy, the pre-diagnosis 
income was used in the analyses. Income and food expenditure were then calculated per 
capita. Second, the HFIAS was administered [18]. This validated tool monitors problems with 
food access, dietary modifications and concerns about food insecurity over the past four 
weeks. Finally, subjects were asked questions about their history of food shortage, their 
household food stocks, and details of their coping mechanisms such as reducing the number 
or variety of meals. For the sake of comparability, these questions and the definition of food 
shortage were based on the study of Feenstra et al. [8]. Dietary intakes were assessed by a 24-
hour recall, following the Food and Agriculture Organization (FAO) guidelines for measuring 
individual dietary diversity [19]. Subjects were asked to list the foods consumed during the 
previous day, starting from waking up in the morning. Details of all meals and snacks, 
consumed inside and outside the house during the full day, were recorded in chronological 
order. To be as accurate as possible, subjects were prompted about drinks, snacks and 
food consumed in and outside the house. Recipes of mixed meals were obtained to 
ascertain that all ingredients were recorded. The 24-hour recalls were carried out on 
weekdays, with exception of atypical holidays. Therefore, no interviews were held in the week 
after Eid al-Adha (Festival of Sacrifice). Also, two focus group discussions were held with 
women to gather information on commonly used ingredients and preparation methods.   
Weight of subjects was measured using a portable scale and assessed to the nearest 0.5 kg. 
Subjects were asked to remove shoes. Height was measured with a measuring tape while the 
subject was standing barefooted with his/her back straight against a wall. Body mass index 
(BMI) was calculated as weight (kg)/ height2 (m). Subjects were identified as underweight when 
their BMI was lower than 18.5 kg/m2. From the 24-hour recalls, the Dietary Diversity Score 
(DDS) was calculated [19]. The DDS is a simple count of the food groups consumed by the 
subject, and is increasingly used to measure dietary quality [20,21]. Nine food groups were 
included in this study: ‘Starchy staples’, ‘Dark green leafy vegetables’, ‘Other vitamin A rich 
fruits and vegetables’, ‘Other fruits and vegetables’, ‘Organ meat’, ‘Meat and fish’, ‘Eggs’, 
‘Legumes, nuts and seeds’ and ‘Milk and milk products’. Vitamin A rich fruits and vegetables 
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were defined as containing a minimum of 60 RAE/100 g (RAE stands for retinol activity 
equivalents) [19]. The condiments garlic and chilies were not counted, because the amount 
consumed per person was likely to be very low. The possible score ranged from 0 to 9. A score 
≥5 was considered as adequately diverse [22].  
Analysis 
Before statistical analysis, a framework was built using four blocks comprised of several related 
variables: Demographic factors (age, sex, religion, district, and household size); socioeconomic 
factors (income, food expenditure, poverty classification, occupation, and land ownership); 
health factors (diseased in the last year, BCG scar, and BMI); and diet-related factors (HFIAS, 
DDS, food shortage in the past year, food shortage at any time in life, and household food 
stocks). 
 Statistical analyses were performed using SPSS (version 22, SPSS Inc., Chicago, IL). All 
analyses were done using logistic regression, with case/control as dependent variable. 
Income and food expenditure were log transformed to normalize their distribution. To reduce 
the effect of matching, age and sex were continuously adjusted for in the univariate, multivariate 
per block and integrated analyses. Univariate analysis was carried out first, and the variables 
significantly (p<0.10) associated with leprosy were included in a multivariate backward 
stepwise logistic regression per block. The variables that remained statistically significant (p 
≤0.05) in these multivariate analyses were considered as the main result. Finally, for the 
integrated analysis, the significant variables of each block (p<0.10 in the Wald Chi Square 
test) were combined and again backward stepwise logistic regression was carried out, this 
time using a p-value of <0.05 as statistically significantly contributing to the model. 
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Table 1- Demographic, socioeconomic and health characteristics (% or mean (±SD)) 
  Cases                                                     
(n=52) 
Controls        
(n=100) 
Sex  Male 29 (56%) 48 (48%) 
      
Age Mean (years) 35.0 ± 9.5 33.3 ± 10.4 
 15-29 25.0 % 37.0 % 
 30-44 32.7 % 27.0 % 
 45-60 42.3 % 36.0 % 
      
District Nilphamari 
 
27 (51.9%) 67 (67.0%) 
 Rangpur 25 (48.1%) 33 (33.0%) 
      
Household size Mean 4.6 ±1.4 5.2 ± 2.1 
      
Income  Household mean (BDT) 5115 ± 3621 8177 ± 6398 
 Per capita mean (BDT)  1180 ± 886 1766 ± 2011 
      
Income variation  Mean (BDT) 3827 ± 2852 5234 ± 5719 
      
Food expenditure  Household mean (BDT) 4545 ± 2323 6540 ± 3435 
 Per capita mean (BDT) 1046 ± 530 1340 ± 841 
      
Land owned  Landowner 8 (15.4%) 34 (34.0%) 
 Mean size (m2) 387 ±1214 3161 ± 6820 
      
BMI Mean (kg/m2) 20.3 ± 3.1 21.6 ± 3.0 
 Underweight 25.0 % 14.0 % 
 Normal weight 67.3 % 72.0 % 
 Overweight 7.7 
 
% 14.0 % 
      
Leprosy Paucibacillary 34 (65.4%) -  
 Multibacillary 18 (34.6%) -  
      
Disability grade 0   37 (71.2%) -  
 1   9 (17.3%) -  
 2   6 (11.5%) -  
BMI=Body Mass Index, categories: underweight <18.5, normal: 18.5-25, overweight: >25; BDT: Bangladesh Thaka,               
100 BDT= ± $1.28 
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Results 
Fifty-two leprosy cases and 100 control subjects were interviewed during home visits. The 
majority of the leprosy patients had paucibacillary (PB) leprosy (65%), was released from 
multidrug treatment (56%) and had no leprosy-related disabilities (71%). Seventy-one percent of 
the controls were acquainted with at least one person diagnosed with leprosy, in most cases a 
neighbour (59%). Other demographic and socioeconomic characteristics of the patient and 
control groups are shown in Table 1. In general, the socioeconomic variables for the patient 
group were less favourable.  
Table 2 provides detailed data on food shortage, food security and coping mechanisms, from 
which it becomes evident that leprosy patients are once more in a disadvantaged position. The 
average DDS was significantly lower in the patient group, who consumed significantly less items 
from the groups ‘Meat and fish’ and ‘Other fruits and vegetables’ than the control group did 
(Figure 1). Control subjects consumed more items from the groups ‘Milk and milk products’ and 
‘Eggs’ as well, but in this regard there was no significant difference with the patient group. 
Adequate dietary diversity (DDS ≥5) was reached by 25% of the control subjects and 17.3% of 
the patients. Food insecurity, measured by HFIAS, was more severe in the patient group, with a 
mean score of 10.2 and 6.4 for patient and control group, respectively (p=0.003). Figure 2 gives 
the proportions and the severity of food insecurity for each item of the scale for both groups. 
Food stocks were present in 74% of the controls’ households, lasting on average for 32 days, 
and in 51% of the patients’ households, sufficient for 15 days on average.  
Food shortage, at any time in life as well as in the past year, was reported by many people in 
both groups, but significantly more often by patients (p= 0.03). Food shortage was most 
common in the months of September to November leading up to the major harvest in 
December, Aman. Income was reported to be the lowest of the year during these months by 
79% of the subjects. Forty-one percent of interviewees who experienced food shortage in 
September-October last year reported food shortage as well in the period March-April, before 
the rice harvest in May/June, Boro. Food shortage in the past year lasted a mean of 101 days, 
during which one consumed less of certain food products or eliminated these from the diet, and 
often took fewer meals per day. Note that while control subjects mainly reduced their intake of 
most foods, patients had to eliminate foods more often. Intake of fish and meat was affected 
most frequently.  
Regardless of being a case or control, people who had had to cope with food shortage in the 
past year had a DDS of 3.14 (±1.1) versus 4.59 (±1.3) in people without food shortage 
(p<0.001). Food insecurity was significantly higher among the people suffering from food 
shortage: their HFIAS score was on average 10.8, versus 0.6 for people not experiencing food 
shortage (p<0.001).  
 
 
141 
 
Table 2- Details on food shortage, coping mechanisms and household food stocks 
  Cases          (n=52) Controls  (n=100) 
      DDS   3.2  ± 1.1 3.8  ± 1.4 
      Experienced food shortage at any time in life  96.2    % 84.0 % 
      Experienced food shortage in past year  80.8 % 64.0 % 
   Average duration of food shortage (days)  106 ± 118 99 ± 124 
   Experienced food shortage in      
      March/April  5.7 % 5.4 % 
      September/October  54.3 % 57.1 % 
      Both periods   40.0 % 37.5 % 
   Coping mechanisms      
      Reduced variety  16.7 % 29.7 % 
      Reduced number of meals  -  3.1  
      Reduced both variety and number of meals  83.3 % 67.2 % 
   Changes in consumption of food items      
      Fish No change 9.5  % 1.6 % 
 Reduced 
 
38.1 % 64.5 % 
 Eliminated 52.4 
 
% 33.9 % 
            Meat No change 7.1 % -  
 Reduced 28.6 % 51.6 % 
 Eliminated 64.3 % 48.4 % 
            Vegetables No change 57.1 % 75.8 % 
 Reduced 38.1 % 22.6 % 
 Eliminated 4.8   % 1.6 % 
            Fruits No change 50.0 % 53.2 % 
 Reduced 19.0 % 25.8 % 
 Eliminated 31.0 % 21.0 % 
            Lentils No change 73.8 % 72.6 % 
 Reduced 14.3 % 24.2 % 
 Eliminated 11.9 % 3.2 % 
            Egg No change 59.5 % 51.6 % 
 Reduced 19.1 % 35.5  % 
 Eliminated 21.4 % 12.9 % 
            Milk No change 66.7 % 53.2 % 
 Reduced 14.3 % 32.3 % 
 Eliminated 19.0 % 14.5 % 
HFIAS    10.2 ± 7.4 6.4 ± 7.0 
   Food secure  19.2 % 33.0 % 
   Mildly food insecure  3.8 % 9.0 % 
   Moderately food insecure  25.0 % 31.0 % 
   Severely food insecure  51.9 % 27.0 % 
      Household food stock present  51.9 % 74.0 % 
   Mean duration food stock (days)  14.9  ± 
 
32.0  ± 56.1 
DDS: Dietary Diversity Score, HFIAS: Household Food Insecurity Access Scale, categories following Coates et al. (2007) 
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Figure 1- Proportion of leprosy patients and controls consuming items from the 9 food groups  
 
The results of the univariate and multivariate analysis are summarized in Table 3, and are 
addressed below per block.  
Block 1: Demographic factors 
Both religion and household size were significantly related to leprosy in the demographic block 
(p<0.10). Hindus were two times more likely to be in the patient group. A larger household was 
associated with a lower risk on leprosy.  
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Figure 2- Frequency-of-occurrence for each Household Food Insecurity Access Scale item for 
leprosy patients and controls 
Block 2: Socioeconomic factors 
All variables in this block showed a significant association with leprosy in the univariate analysis. 
A higher income, land ownership, working as a farmer or a businessman and being part of a 
low/middle or middle income classified household lead to a decreased risk of leprosy. In the 
multivariate analysis of this socioeconomic block, step by step income per capita, land 
ownership, and self-classification were removed. The factors that remained significant were 
food expenditure per capita (p<0.05) and occupation (p<0.10). 
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Block 3: Health factors 
BCG vaccination coverage was almost similar in both groups, and therefore did not show a 
relation to leprosy. BMI was the only significant factor in the uni- and multivariate analysis 
(p<0.05); a lower BMI increased the risk of leprosy.   
Block 4: Diet-related factors 
In the univariate analysis, higher HFIAS, food shortage experienced in the past year and at any 
time in life were significantly associated with an increased risk of leprosy, while higher DDS and 
household food stocks reduced the chance of having leprosy. In the multivariate analysis of this 
block, only DDS and household food stocks remained significant (p<0.05). 
Integrated analysis 
In addition to the analyses per block, we considered relationships between the blocks. 
Therefore, all significant factors from each of the four blocks were analysed together in a final 
integrated analysis, presented in Table 4. After stepwise elimination of the least significant 
factors, two factors remained significantly associated with leprosy: food expenditure (log) and 
household size (p≤0.05).  
 
Discussion 
In this study, we set out to identify factors through which food shortage may have an effect on 
the development of leprosy, and in particular addressed the question whether recently 
diagnosed leprosy patients and controls had different dietary intakes. Our findings show that 
leprosy patients have a less favourable position with regard to socioeconomic, health and 
nutritional factors than a control population. Lower food expenditure per capita, lower BMI, 
lower dietary diversity score (DDS) and absence of household food stocks were the main 
factors associated with an increased risk of having leprosy.  
Food shortage experienced in the past year was significantly associated with leprosy in the 
univariate analysis, but not in the multivariate analysis. In our study, the proportions of patients 
and control subjects experiencing food shortage in the past year were higher than in the study 
of Feenstra et al.: 80.8% vs. 47.8% for patients and 64.0% vs. 35.7% for the controls, 
respectively. This is remarkable because the studies were carried out in the same geographical 
area, used the same definition of food shortage, and no important changes were seen in 
income and food availability over the four years [23]. In the study of Feenstra et al., food 
shortage was only one item of an extensive socioeconomic questionnaire, however, while the 
focus of our questionnaire was entirely on diet and food insecurity. This could possibly explain 
the higher percentages observed in our study.  
145 
 
Dietary Diversity Score 
Traditionally, a Bengali diet consists mainly of rice. Previous studies found that people from 
Bangladesh get between 74% and 86% of their energy intake from rice [12,22,24]. This 
suggests that consumption of nutritious non-rice foods is relatively low, which may explain the 
low DDSs found in our study. These studies demonstrated that the amount of rice a person 
consumes remains stable during the year, independent of rice price and season [12,25]. As a 
result, in the period September-November, when rice prices are high and income is low, 
expenditures on highly nutritious, generally more expensive, food products are likely to be lower. 
Consequently, dietary diversity scores are lower during these periods. To our knowledge, this is 
the first published study investigating the DDS in leprosy patients, and therefore there is no data 
to compare our results with. However, dietary diversity studies carried out among Bangladeshi 
women found a mean DDS of 3.6 ±1.1 and 3.4 ±1.1, which are very close to our findings of 3.2 
±1.1 and 3.8 ±1.4 for patient and controls, respectively [22,26].  
For the DDS, the condiments chilies and garlic were not counted, in spite of the fact that they 
are used in almost all dishes according to the women participating in our focus group 
discussions. Still, the amounts consumed per person were likely to be very low, and therefore 
the contribution to the diet and dietary diversity should be negligible [22]. 
Food expenditure  
Food expenditure was another important factor associated with leprosy. However, per capita 
food expenditure and per capita income were highly correlated (Spearman’s correlation 
coefficient: 0.81, p<0.001) and additional analyses demonstrated that income and food 
expenditure are interchangeable in the block- and integrated analysis. The association with 
leprosy could therefore be just through poverty in general, which is a risk factor often associated 
with leprosy [27]. Two studies in Bangladesh have linked food expenditure and income to 
dietary diversity, a variable that was statistically significantly related to leprosy in our study 
[24,28]. In the study of Thorne-Lyman et al., household dietary diversity increased with 
increasing food expenditure, and primarily the intakes of animal source foods and fruits 
increased strongly with higher food expenditures. Our control population had significantly higher 
food expenditures, and accordingly had higher intakes of these food groups.  
Household size 
The second variable that remained statistically significant in the integrated analysis was 
household size. A larger household size gives a lower risk on leprosy. In the study of Feenstra et 
al., mean household size was larger in the control group as well, although this was not 
statistically significant. In theory, however, a larger household could increase the risk of leprosy, 
since it increases the chance of transmission. Nevertheless, in an Indonesia-based study an 
increased risk was found only for households larger than seven people [29], while in our study 
no more than 9 of 152 households counted more than seven people; two (3.8%) in the patient 
group and seven (7%) in the control group.  
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Table 3- Results of univariate logistic regression and multivariate logistic regression per block 
Factors 
 
 
 
 
 
 
 
 
 
Cases 
 
 
Controls Univariate† Multivariate 
  n=52 n=100 OR (95% CI) p-value OR (95% CI) p-value 
Block 1: Demographic factors          
  Age (years) 35.0 
 
± 9.5 33.3 ± 10.4 1.02 (0.99-1.05) 0.269    
            Sex Male 29 (56%) 48 (48%)       
 Female 
 
23 (44%) 52 (52%) 0.69 (0.35-1.37) 0.294    
            Religion Muslim 40 (77%) 88 (88%)       
 Hindu 12 (23%) 12 (12%) 2.21 (0.90-5.38) 0.082# 2.23 (0.92-5.46) 0.079 
 
            Household size  4.6  ± 1.4 5.2 ± 2.1 0.83 (0.67-1.02) 0.075# 0.82 (0.66-1.02) 0.073 
Block 2: Socioeconomic factors 
   
 
   
 
   
      
         Income per capita (log) 2.96 ± 0.27 3.12 ± 0.30 0.10 (0.03-0.44) 0.002*    
           Food expenditure per capita (log) 2.98 ± 0.17 3.08 ± 0.18 0.02 (0.00-0.22) 0.001* 0.03  (0-0.36) 0.006* 
 
 
           Self-classification      0.005*    
  Very poor 17 (33%) 14 (14%) 1.00      
  Poor 21 (40%) 29 (29%) 0.61 (0.24-1.50)     
  Low/middle 11 (21%) 35 (35%) 0.26 (0.10-0.69)  
 
   
  Middle  3 (6%) 22 (22%) 0.11 (0.03-0.47)     
   Rich 0 (0%) 0 (0%) -
 
 
     
            Occupation      0.025*   0.058 
  Laborer 26 (50%) 28 (28%) 1.00   1.00   
  Shopkeeper 10 (19%) 13 (13%) 0.84 (0.31-2.27)  
 
1.28 (0.44-3.80)  
  Other 8 (15%) 25 (25%) 0.32 (0.12-0.86)  0.44 (0.16-1.22)  
  Farmer 5 (10%) 19 (19%) 0.28 (0.09-0.86)  
 
0.24 (0.07-0.83)  
  Business 3 (6%) 15 (15%) 0.19 (0.05-0.76)  0.31 (0.07-1.34)  
            Land      0.042*    
  Landless 41 (79%) 58 (58%) 1.00      
  Land leaser 3  (6%) 8 (8%) 0.49 (0.12-1.99)     
 
 
 Land owner 8 (15%) 34 (34%) 0.34 (0.14-0.81)     
Block 3: Health factors          
 Disease other than leprosy No 24 (46%) 49 (49%)       
  Yes 28 (54%) 51 (51%) 1.12 (0.57-2.22) 0.742 
 
   
            BCG vaccination No 26 (50%) 46 (46%)       
  Yes   26 (50%) 
 
54 (54%) 0.89 (0.45-1.76) 0.743    
            BMI (kg/m2)  20.3 ± 3.1 21.6 ± 3.0 0.87 (0.77-0.98) 0.020* 0.87 (0.77-0.98) 0.020* 
Block 4: Diet-related factors          
 HFIAS (score 0-27) 
 
 10.2 ± 7.4 6.4 ± 0.19 1.08 (1.03-1.13) 0.003*    
             DDS (score 0-9)  3.2 ± 1.1 3.8 ± 1.4 0.67 (0.50-0.89) 0.007* 0.71 (0.52-0.96) 0.024* 
             Recent food shortage No 10 (19%) 36 (36%)       
  Yes 42 (81%) 64 (64%) 2.42 (1.07-5.47) 0.034*    
            Ever food shortage No 
 
2 (4%) 16 (16%)       
  Yes 50 (96%) 84 (84%) 4.30 (0.93-19.77) 0.061#    
           
 Household food stocks No 25 (48%) 26 (26%)   
 
    
  Yes 27 (52%) 74 (74%) 0.38 (0.19-0.78) 
 
0.008* 0.45 (0.22-0.95) 0.036* 
 
†Adjusted for age and sex; BCG: Bacillus Calmette-Guérin; BMI: Body Mass Index; HFIAS:  Household Food Insecurity Access 
Scale; DDS: Dietary Diversity Score; * statistically significant at 0.05 level; # statistically significant at 0.10 level
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Table 4- Results of the integrated logistic regression analyses containing the significant 
               variables of the multivariate analysis per block  
 
Factors Before backward elimination After backward elimination 
 OR
† 
(95% CI) p-value OR† (95% CI) p-value 
       Age 1.00 (0.97-1.05) 0.797 1.02 (0.98-1.05) 0.424 
       Sex Male 1.00   1.00   
 Female 0.45 (0.20-1.00) 0.050 0.52 (0.25-1.10) 0.086 
        Religion Muslim 1.00      
 Hindu 1.41 (0.52-3.88) 0.502    
 Household size 0.76 (0.55-1.04) 0.084 0.68 (0.52-0.89) 0.005* 
       Food expenditure  0.02 (0.00-0.45) 0.014* 0.005 (0.00-0.08) <0.001* 
       Occupation   0.294    
 Labourer 1.00      
 Shopkeeper 2.08 (0.62-6.98)     
 Farmer 0.47 (0.12-1.89)     
 Business 0.66 (0.13-3.25)     
 Other 0.59 (0.20-1.72)     
        BMI 0.90 (0.78-1.04) 0.163    
       DDS 0.83 (0.58-1.18) 0.299    
       Household food 
stocks 
No 1.00      
Yes 0.66 (0.29-1.50) 0.320    
†Calculated OR’s are adjusted for all other variables in the column, * statistically significant at 0.05 level; BMI: Body Mass 
Index; DDS: Dietary Diversity Score 
Effect of nutrition on leprosy 
The exact role of malnutrition on susceptibility to leprosy and the development to a clinical stage 
remains unclear [30,31]. A recent review on micronutrients and the immune response in leprosy 
emphasizes this knowledge gap, as only few studies in this field have been carried out and 
most of the evidence is derived from other diseases, mainly tuberculosis. Apart from this, 
previous studies are based either on blood analyses, or focussed on diets of (cured) leprosy 
patients after they developed clinical leprosy. In both cases, it is difficult to determine if leprosy 
is a cause or a consequence of nutritional deficiencies [32-36]. Mycobacterium leprae is an 
intracellular micro-organism, thus a cell-mediated immune response is important in the defence 
of the human host [37]. Protein-energy malnutrition, as well as inadequate intake of vitamins 
and/or minerals are linked to a reduced cell-mediated immunity [38]. With lower intakes of 
several food groups during food shortage periods, deficiencies may have put leprosy patients in 
our study at risk for a reduced cell-mediated immunity.  
Another interesting theory that could possibly apply to leprosy is that of immune reconstitution, 
a well-known phenomenon in HIV after anti-retroviral therapy [39,40]. When the immune 
response is restored after a period of suppression, the immune system will start to respond to 
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infections present in the body. We hypothesize that, when food intake is improved after a long 
period of food shortage and nutrient deficiencies, the body may start to respond to M. leprae, 
causing the development of clinical disease.  
This study has some limitations. First, data were collected referring to the period after the 
diagnosis of leprosy, which makes it hard to determine a causal relationship. However, the 
interviews were held shortly after diagnosis (maximum of nine months) and we specifically asked 
for changes in the patients’ diet and income after diagnosis, to be able to correct for this 
difference. Second, a cross-sectional design was employed because we aimed to collect data 
during a food shortage period. We assumed that the persons experiencing food shortage this 
year have also experienced this in the previous years and that their diets did not change over 
time. Ideally, a longitudinal study, collecting detailed data on diet and health, and taking blood 
samples to determine nutrient absorption, should be carried out to compare long-term data of 
the persons who developed leprosy with data of persons who did not. However, this will be a 
lengthy and expensive process. A third limitation is that most of the data were self-reported 
through questionnaires, introducing recall and response biases. Especially for very poor people 
with an unstable income their average income is difficult to estimate. By asking the same 
questions to cases and controls we tried to limit the effect on our results. In addition to the 24-
hour recall, biomarkers for micro- and macronutrients in blood, urine and/or faeces can be 
analysed to assess dietary intake more objectively [41]. However, we decided not to use this 
method because collection and analyses of biomarkers is laborious and costly, especially 
because a high number of nutrients need to be analysed since the key nutrients are unknown. 
Fourth, the DDS might have been over or underestimated as it was based on one 24h-recall, 
which may not be representative of the usual diet. We tried to get the most reliable information 
possible by avoiding a recall for atypical days such as religious holidays. Furthermore, in 
developing countries diets tend to have a low day-to-day variability, thus one 24h-recall may be 
enough to get a good idea of the usual diet. In addition, when comparing population groups, a 
single dietary recall should give an accurate estimation of the intake of a whole group [42]. The 
DDS informs about the last 24 hours, while we extrapolated this to the diet before leprosy was 
diagnosed. Only few patients indicated that their food intake was different from that of last year, 
before diagnosis, however. Data of these patients were kept in the analyses, because there was 
little difference in the numbers of people who consumed more (4 patients) and who consumed 
less (5 patients) than in the period before they were diagnosed.  
In conclusion, this study adds to the current knowledge on food shortage, nutrition and leprosy. 
We found that DDS and household food stocks are the most important diet-related factors 
associated with leprosy in Bangladesh. Furthermore, BMI and food expenditure per capita have 
a strong association with leprosy in our study. People living in poverty have less money available 
to spend on food. This results in a low consumption of animal source foods, fruits and 
vegetables. Deficiencies of the nutrients that these types of foods provide could result in an 
impaired immune response, which may be an explanation for the development of clinical 
leprosy. It is evident that little research has been carried out on the association between leprosy 
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and nutrition, and that the immunological pathway leading to the clinical development of leprosy 
and the influence of nutrition should be studied further. Our results can be a starting point to 
elucidate the relation between nutrition and leprosy.  
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Chapter 9  
 
 
General discussion 
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In this thesis, methods to improve the detection and treatment of leprosy neuropathy were 
studied in order to prevent irreversible nerve function impairment and disabilities. Also, 
nutritional risk factors that could be related to the development of clinical leprosy were 
assessed. In this section, I will answer the research questions posed in the introduction by 
discussing the key findings of the previous chapters. Also, some practical implications and 
recommendations for future studies will be given. 
 
Research Question 1 
How can the detection of nerve function impairment in leprosy at field level be improved?  
Answer: 
Detection of NFI can be improved by including the radial cutaneous and in particular the sural 
nerve in routine sensory testing. These two nerves are often affected and are affected in an 
early stage. This can lead to a higher sensitivity for earlier detection of NFI in general. 
Furthermore, NFI can be detected even earlier in the field when using portable warm and cold 
sensation tests such as the Thermal Sensibility Tester and the NeuroQuick.  
Leprosy patients are at risk of developing nerve function impairment, even after they have been 
treated with multidrug therapy [1-3]. Since sensory and motor nerve function can lead to severe 
disabilities and deformities of hands, feet and eyes, it is very important that NFI is detected at an 
early stage so that it can be treated with prednisolone and nerve function can be restored. In 
the TENLEP study, we followed the recommendation of the INFIR study to include the sural and 
radial cutaneous nerves in the assessments in our TENLEP trials. The sensory function of the 
sural and radial cutaneous was assessed with monofilaments on three test-sites for the first 
time. We established the normal monofilament threshold values for the sural and radial 
cutaneous nerves (Chapter 3), so that these tests can be applied routinely in the field. In 
Chapter 4 we determined that the monofilament assessment of the sural and radial cutaneous 
nerves can be performed reliably when executed by trained staff. 
The sural and radial cutaneous nerves are rarely examined in clinical practice, because 
impairment of these nerves is not likely to lead to ulceration or burns due to the position of the 
area they innervate - the lateral border of the foot for the sural nerve, and the dorsal side of the 
hand for the radial cutaneous nerve. In the INFIR study, however, the sural nerve was the 
second most affected nerve when assessed with MFT [4]. Furthermore, the sural and radial 
cutaneous nerves were affected most frequently when assessed for subclinical neuropathy by 
nerve conduction studies [4]. These two nerves may not be so relevant from a practical point of 
view, but they can function as sensitive sentinels for NFI in general. Including the sural and radial 
cutaneous in the clinical assessment routinely would likely lead to earlier detection of NFI and 
early treatment can prevent further damage to more significant peripheral nerves. 
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The significance of assessing the sural and radial cutaneous was originally demonstrated in 
INFIR study, and subsequently confirmed in the TENLEP study. Adding the sural and radial 
cutaneous nerves to the Composite Nerve Score increased its reliability (Chapter 6).  
Other methods that may improve early detection of NFI were discussed in Chapter 5. In patients 
with subclinical neuropathy, new, portable devices were compared with the standard reference 
tests Warm Detection Threshold and Nerve Conduction Studies. The Thermal Sensibility Tester 
(TST) and the NeuroQuick showed high sensitivity and specificity for the detection of subclinical 
neuropathy. The TST assesses warm sensation and was originally designed to test sensation in 
leprosy skin lesions. One of the ends becomes warm when switched on, with a temperature 
between 45°C and 60°C depending on environmental temperature. The NeuroQuick tests cold 
sensation using an air flow produced by the integrated fan. The adjustable fan speed can be 
increased until the patient perceives the air flow.  
Both the NeuroQuick and the TST examine small fibre function. The INFIR study found, 
however, that there was variation between patients in which modality and type of nerve fibre - 
large or small - was first affected [5]. This variation should be covered when testing for early 
neuropathy and therefore we recommend adding a second test method that assesses large 
fibre function. Unfortunately, the two devices in our study testing large fibres, the NC-stat 
DPNCheck and the Vibratip, are not very suitable for early detection of leprosy neuropathy. So 
far nerve conduction studies are the only reliable option for detection of early large fibre 
neuropathy.  
Monofilaments as well as the portable TST and the NeuroQuick are very useful to detect 
neuropathy under field conditions. They are relatively cheap compared to TSA and the 
monofilament test is reliable. Reliability for the TST and the NeuroQuick needs to be assessed 
further. It is important to underline that for these methods some training is required and 
therefore it is important to regularly carry out a quality control such as reliability testing. 
To improve early detection of NFI we recommend including the radial cutaneous and in 
particular the sural nerve in routine sensory testing, especially in referral centres. Also, the use of 
early, subclinical detection methods such as Thermal Sensibility Tester and/or the NeuroQuick 
is advised. Good training protocols should be developed to support a reliable execution of the 
testing. Suggestions for further research are: 
§ For the Thermal Sensibility Tester and the NeuroQuick study, reliability tests should be 
done. Test-retest and inter-rater reliability should be studied in preferable different leprosy 
populations. 
§ The sensitivity and specificity of the Thermal Sensibility Tester and the NeuroQuick test 
should be determined for testing on the hands. 
§ The search for devices should be continued, to find alternative portable, battery operated 
tests that accurately and reliably detect subclinical large fibre neuropathy. 
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Research Question 2 
How can irreversible nerve function impairment best be prevented in leprosy? 
Answer: 
A prednisolone course of 20 weeks was sufficient to improve or restore nerve function in the 
majority of leprosy patients with recent nerve function impairment (NFI). Longer prednisolone 
treatment could be a solution for the 15% of patients who needed additional prednisolone due 
to reactions or new NFI.  
While prednisolone is commonly used to treat recent nerve function impairment (NFI) in leprosy 
patients, the optimal treatment duration has not yet been established [6]. As early treatment is 
stimulated in leprosy neuropathy, the detection and treatment of subclinical neuropathy would 
be a logical step. However, the first results of studies into prophylactic treatment or treatment of 
subclinical neuropathy are not very promising [7,8]. The TENLEP study on clinical neuropathy 
was designed to evaluate whether a 32-week prednisolone course is more effective than a 20-
week course in restoring and improving nerve function (Chapter 6). We found that there was no 
difference in the percentage of patients with restored and improved nerve function between the 
two courses. Both treatment groups showed improvement rates of 78%, with 24-30% of these 
patients recovering completely. Unfortunately, in other patients the immune response against 
(dead) M. leprae bacilli seems too persistent to be permanently suppressed, even by a 32-week 
prednisolone course [9]. In both groups, around 15% of patients needed additional 
prednisolone due to reaction or new NFI.  
Our study provides insight in the characteristics of this group of patients that needed additional 
treatment with prednisolone, as they were different than the group that did not need extra 
prednisolone. At baseline, the former group contained significantly more MB patients - mainly 
BL and LL-, had higher average bacterial index (BI), had a higher EHF score, suffered more 
often from both type 1 and type 2 reactions, and more often showed signs of neuritis and 
reactions, i.e. inflamed and raised skin lesions, peripheral oedema, nerve pain and tenderness. 
This information can be an important addition to the Clinical Prediction Rule, developed by Croft 
et al. to determine which patients have a high risk of developing NFI [10]. Three risk levels - low, 
medium and high - were defined in their study, where MB patients with NFI at baseline have the 
highest risk of developing NFI within 2 years of diagnosis. Our result can strengthen the Clinical 
Prediction Rule, by defining the group that need extra surveillance when on treatment for NFI. 
People at risk for ‘resistance’ of prednisolone treatment are quite similar to the people at risk for 
new NFI, i.e. MB patients with previous reaction or nerve function impairment problems. 
Future studies should focus on this group of patients who do not seem to benefit from 
prednisolone treatment of the duration assessed in the TENLEP study. First, it is important to 
unravel the immunological and pathophysiological mechanisms behind NFI and to study the 
actual effect of prednisolone on NFI. Second, an even longer prednisolone course could be 
beneficial for this group. Naafs et al. found that some leprosy patients may need up to 20 
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months of treatment [11]. However, the TENLEP study showed that longer prednisolone leads 
to more Serious Adverse Events (Chapter 7). An option would be to test longer, low-dose 
steroid courses, as is practiced for the treatment of autoimmune diseases, such as rheumatoid 
arthritis (4.5-10 mg/day for 2 years) [12] or autoimmune hepatitis (5-12 mg/day for 3 years) [13]. 
Third, an effort should be made to develop alternative drugs. Currently, prednisolone is the drug 
of choice for the treatment of NFI, but other anti-inflammatory drugs are available as well, mainly 
as second line treatment for reactions [14]. Clofazimine, thalidomide, cyclosporine and 
azathioprine have been studied for reactions, but so far their effect is not as durable as 
prednisolone.  
As non-drug option, surgical treatment is available for patients with severe nerve inflammation, 
i.e. nerve decompression. This might be an alternative method to restore NFI in some patients. 
Through an incision of the thickened nerve sheath, pressure on the nerve due to oedema is 
relieved [15]. However, so far there is not enough evidence of the effectiveness of surgical nerve 
decompression [16].  
In conclusion, for a large group of patients, a 20-week course of prednisolone is sufficient to 
improve or restore nerve function. It is important to have a better understanding on which 
patient characteristics determine the outcome of prednisolone treatment. In addition, the 
pathophysiology of NFI needs to be unravelled. So far, an alternative for prednisolone is lacking 
and there is no sufficient evidence that surgical treatment is beneficial. Recommendations for 
further research are: 
§ Validate the characteristics of the group of patients not responding to a 20-week or 32-
week course of prednisolone.  
§ Assess longer, low-dose prednisolone courses in the group not responding to a 20 or 32-
week course of prednisolone for the treatment of NFI. 
§ Continue the search for alternative drugs for the treatment of NFI. 
§ Carry out a – preferably multicentre - trial to establish the effect of surgical nerve 
decompression. 
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Research Question 3 
Which nutritional factors possibly underlie the development of clinical leprosy? 
Answer: 
Leprosy patients are more likely to have a low dietary diversity. Reduced intake of meat, fish, 
fruits and vegetables leads to protein-energy malnutrition and/or inadequate intake of vitamins 
and minerals. These nutrient deficiencies could reduce the body’s immune response towards 
M. leprae, and therefore give way to the development of clinical leprosy.  
 
The risk factors for contracting leprosy and the further development into the clinical stage of the 
disease are largely unknown. Recently, two studies linked food shortage to the clinical 
manifestation of leprosy [17,18]. We investigated this association further by studying whether 
during a period of food shortage the dietary intake differed between recently diagnosed leprosy 
patients and control subjects (Chapter 8). Food shortage was defined as ‘the period in which a 
family had to reduce the number of meals a day, or reduce the intake of foods other than rice’. 
Our study took place in a leprosy endemic region in Bangladesh, where food shortage is mainly 
experienced in the period between September and the end of November, just before the major 
rice harvest in December. Our findings show that leprosy patients have a less favourable 
position with regard to socioeconomic, health and nutritional factors than a control population 
from the same area. Leprosy patients had a lower dietary diversity and were more often and 
more severe food insecure. They consumed less meat, fish, fruits and vegetables, and to a 
lesser extent eggs, milk and milk products, than the control group. Furthermore, food stocks 
were lower and more often absent in households of leprosy patients. Most likely, this is 
explained by the lower food expenditure in patients’ households, a factor highly correlated with 
income. Using a retrospective study makes it difficult to study the causal relation between food 
shortage and leprosy, as the association could work both ways - food shortage could cause 
leprosy, or leprosy could cause food shortage. However, by interviewing patients shortly after 
diagnosis and asking for changes compared to last year we were reasonably certain that our 
outcomes were a good representation of the situation in the previous year.  
 
The exact role of malnutrition on leprosy susceptibility and the further development to a clinical 
stage remains unclear [19,20]. The risk of contracting subclinical M. leprae infection is not 
necessarily increased by food shortage, but malnourishment can cause progress of a latent 
infection into a clinical, active disease [21]. The cell-mediated immunity plays an important role 
in the response against M. leprae [22], and this immune function can be deteriorated by protein-
energy malnutrition as well as micronutrient deficiencies [23]. Considering our finding that 
leprosy patients had significant lower intake of protein sources, such as meat and fish, and 
micronutrient sources as fruit and vegetables, a reduced cell-mediated immunity seems a likely 
intermediary step towards the development of clinical leprosy. There is hardly any evidence for 
this theory though, because of the complex interactions between the different deficiencies, 
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environmental factors such as hygiene, safe water, housing, access to health services, and the 
previous described two-way causal relationship. It is therefore important to better understand 
the mechanisms and interactions of the mentioned factors on the development of clinical 
leprosy, and to find ways to influence these factors through e.g. vaccination, improved nutrition, 
and general socioeconomic support. Such support, in particular targeted at high risk groups for 
leprosy, would be an important addition to leprosy control programs. 
 
Looking at the evidence so far, it is crucial that future research is focused on preventing clinical 
leprosy, especially because once nerves are clinically impaired, it is difficult to achieve complete 
recovery of nerve function (Chapter 6). Interrupting the transmission of M. leprae is the most 
promising intervention. Other possible sources of infection should be investigated and 
eliminated, for example reservoirs outside the human body such as soil, water, and armadillo’s 
(in the America’s) [24]. Also early diagnosis and treatment of leprosy is key to prevent further 
transmission of leprosy. Therefore, sensitive diagnostic tests need to be developed that can 
detect subclinical leprosy [25]. Additionally, prophylactic treatment of leprosy contacts can 
interrupt transmission. Studies targeting leprosy contacts show good results up to two years 
after chemoprophylaxis with single dose rifampicin [26].  
 
In conclusion, the nutritional status of poor people living in leprosy endemic regions needs to be 
improved in order to reduce the chance that clinical leprosy develops after subclinical infection. 
This should be done by increasing their dietary diversity and food security. As long as 
transmission of M. leprae is ongoing, efforts should be made to prevent the development of 
clinical leprosy, and therefore we need to understand the mechanisms better. 
Recommendations for further research are: 
§ Study the immunological pathway and mechanisms leading to the clinical development of 
leprosy and the factors that can influence this 
§ Investigate if and how improving nutrition status of poor people living in leprosy endemic 
regions reduces leprosy prevalence and transmission 
§ Improve methods to detect subclinical leprosy  
 
Challenges in studying leprosy 
Leprosy prevalence has fallen significantly in the previous decades, mainly because of the 
introduction of multidrug therapy [27] and improved case finding [28]. However, the new case 
detection rate is still substantial - around 250.000 per year-, and has barely decreased over the 
last decade. The diminished decline can be very well explained by the knowledge gaps that still 
exist, even though leprosy is one of the oldest diseases known. The first uncertain factor is the 
method of M. leprae transmission, which is of course very important in relation to the number of 
new cases. Most likely, people get infected through nasal droplets via the respiratory tract [29]. 
In some cases, it might also be possible that M. leprae enters the body through abraded skin 
[27,30]. A second major factor is that no specific leprosy vaccine is available that can prevent 
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clinical leprosy, although much research has been done on this subject. Furthermore, there is 
not yet a reliable test available for early diagnosis and detection of subclinical disease. 
Establishing which person with subclinical infection would continue to progress to clinical 
disease and providing subsequent treatment would reduce the time a person is infectious and 
can spread the disease to others. Third, we do not completely understand the immunological 
pathways involved in leprosy infection and the reasons why some infected people develop 
clinical leprosy and others do not. It is most likely related to genetic differences [31,32], social 
distance, nutritional status, health status, and hygiene. Fourth, the immune mechanisms leading 
to NFI are largely unknown, as pointed out before in this thesis. And methods to identify high 
risk patients for NFI are lacking as well. Last, no ideal treatment regimen has been established 
to treat nerve function impairment and reactions. 
The reason why so little is known about leprosy is because the disease is difficult to study. To 
explain, I will list some biological characteristics of M. leprae and mention epidemiological and 
social reasons. Because of the slow multiplication of M. leprae, the incubation time of leprosy is 
usually long. In extreme cases, symptoms appear after 20 years, but in most patients the 
incubation time is between 2 and 5 years [33]. This makes it nearly impossible to determine 
when and under which circumstances the disease was contracted, hence the knowledge gap 
on transmission of leprosy. A second characteristic that interferes with studying the pathology 
of leprosy is that M. leprae cannot be cultured in vitro. Furthermore, no suitable animal model is 
available for vaccine testing and to study pathogenesis. Experiments are performed on nude 
mice and armadillo’s, but mice do not live long enough to follow the effects of the slowly 
growing M. leprae [34], and armadillo’s develop mainly lepromatous infections.  
Also from an epidemiologically point of view it is hard to study leprosy, as the incidence is 
relatively low. To study the pathology and transmission of the disease in humans, prospective 
studies are preferred, as the long incubation time makes retrospective studies less reliable. 
Since leprosy is such a rare disease many people need to be followed for a long time to get 
good results. This is time consuming and costly. In addition, because of the low prevalence it is 
very challenging to produce possible new vaccines cost-effectively. Last, but not least, a large 
social problem influences the success to study leprosy: stigma. Fear of stigma may lead to 
refusal to participate in scientific studies. And more importantly, stigma leads to delayed 
diagnosis and thus to a longer period of infectiousness and more severe and irreversible 
neuropathy.  
All the above challenges in studying leprosy and in developing effective preventive and curative 
measures for leprosy and related disability are a main cause of the steady new case detection 
rate of leprosy and of the steady numbers of new cases with grade 2 disability in many endemic 
countries. Fortunately, progress is being made, and large multicentre studies such as TENLEP 
help increase our insight into the many difficult issues in leprosy that need to be addressed in 
order to achieve elimination of the disease and its related disabilities. 
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Recommendations 
From the results and experience of the studies described in this thesis, I developed a set of 
recommendations to improve detection and treatment of neuropathy in the field: 
§ The sural and radial cutaneous nerves should be included in standard routine 
monofilament assessment  
§ Use more sensitive methods to detect neuropathy in an earlier stage. The portable 
Thermal Sensitivity Tester and NeuroQuick are promising devices for this goal 
§ Implement nutrition support for poor people during food shortage periods in leprosy 
endemic regions to increase dietary diversity 
Furthermore, the results reported in this thesis lead to new questions and identified the need for 
more research and new studies. The topics that need to be studied further are: 
§ The sensitivity and specificity of the Thermal Sensibility Tester and the NeuroQuick test 
should be determined for testing on the hands 
§ The reliability of the Thermal Sensibility Tester and the NeuroQuick should be examined. 
Test-retest and inter-rater reliability should be studied in preferable different leprosy 
populations 
§ The search for devices should be continued, to find alternative portable, battery-
operated tests that accurately and reliably detect subclinical large fibre neuropathy 
§ The characteristics of the group of patients not responding to a 20-week or 32-week 
course of prednisolone need to be determined in more detail 
§ Assess longer, low-dose prednisolone courses in the group of patients that is not 
responding to a 20- or 32-week course of prednisolone for the treatment of NFI. 
§ Set up studies on nutrition in new leprosy patients and test serum levels of different 
micronutrients in blood around first symptoms  
§ Investigate if and how improving nutrition status of poor people living in leprosy endemic 
regions reduces leprosy prevalence and transmission 
§ Study the immunological pathway and mechanisms leading to the clinical development 
of leprosy and the factors that can influence this 
§ Continue the search for alternative drugs for the treatment of NFI 
§ Carry out a multi-centre trial to establish the effect of surgical nerve decompression 
§ Focus on finding methods to prevent leprosy (early detection of leprosy (infection), 
prophylaxis, identify all ways of transmission (soil/water)) 
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Summary 
In this thesis, methods were studied that could improve the detection and treatment of leprosy 
neuropathy, in order to prevent irreversible nerve function impairment and disabilities. Also, 
nutritional risk factors that could be related to the development of clinical leprosy were assessed 
Leprosy is an infectious disease caused by the bacteria Mycobacterium leprae. The disease is 
often seen as a disease of the poor, especially since nowadays leprosy is mainly prevalent in 
low resource countries. 89% of the newly detected patients are found in eight countries: 
Bangladesh, Brazil, Democratic Republic of Congo, Ethiopia, India, Indonesia, Nepal and 
Nigeria, with India alone contributing as much as 60%. According to the WHO, leprosy is 
officially eliminated worldwide, meaning that there is less than 1 patient per 10 000 people. 
Unfortunately, for certain regions in the mentioned countries this is not the case yet, and leprosy 
is still being spread. The disease is transmittable, but not everyone who comes into contact with 
the bacillus will get leprosy. Whether the disease develops depends on multiple variables; it is 
assumed that genes, general health status, nutrition, hygiene and social distance to a patient 
play a role.  
Leprosy affects the skin and the nerves, but the results of the nerve damage makes that the 
disease is considered harmful. Neuropathy may lead to nerve function impairments, for sensory 
as well as motor nerves. When sensory function is impaired, leprosy patients often do not feel 
when they burn themselves or have a wound, and in addition, they do not take good care of the 
wounds because they do not feel the pain. As a result of impaired motor function, muscles in 
the hand and feet can weaken. Both motor and sensory nerve function impairments can result 
in disabilities. Therefore, it is very important to detect nerve function impairment in an early stage 
so it can be treated. In general, it is assumed that impaired nerve function of less than 6 months 
will improve when treated with prednisolone. The optimal duration of prednisolone treatment, 
however, is unknown.  
We have set up a study to investigate whether a longer than usual treatment with prednisolone 
has a more profound effect on the improvement of nerve function impairment. This study is 
known as the TENLEP study (Treatment of Early Neuropathy in LEProsy). Results of this and 
other studies are described in this thesis. The aim of this thesis was to answer the following 
research questions: 
1. How can the detection of nerve function impairment in leprosy at field level be 
improved? 
2. How can irreversible nerve function impairment best be prevented in leprosy? 
3. Which nutritional factors possibly underlie the development of clinical leprosy? 
Chapter 1 gives an introduction in the disease leprosy and extensive information on 
neuropathy. The four studies in the second part focus on methodology. In chapter 2, I describe 
the details of the protocol of the two randomized controlled TENLEP trials that we have carried 
out in six leprosy centres in four Asian countries. In the Clinical trial we assessed whether a 
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longer treatment with prednisolone, 32 weeks compared to 20 weeks, shows better results in 
the improvement of recent nerve function impairment. Additionally, in a parallel, placebo 
controlled trial, we studied whether prednisolone can prevent nerve function impairment in 
patients with subclinical neuropathy. This trial is named the Subclinical trial. 
In the following three chapters I attempt to answer the first research question. In chapter 3, a 
study is described in which we determined the normal values for the monofilaments test of the 
radial cutaneous and sural nerves, by testing people without leprosy in India and Nepal. Earlier 
research has shown that these two nerves are the first affected nerves in leprosy neuropathy. 
Patients rarely have wounds in the innervation areas of the radial cutaneous and sural nerves 
however, therefore these nerves are seldom included in routine sensory testing. This is a missed 
opportunity, because the additional information can lead to earlier detection and treatment of 
nerve function impairment. To be able to interpret the outcomes of monofilament tests in 
leprosy patients, it is important to know what the threshold of normal sensitivity is in people 
without leprosy. We established that the purple 2-g monofilament is the normal threshold for de 
radial cutaneous nerve and the red 4-g filament is normal threshold for the sural nerve.  
For the monofilament test (MFT) and voluntary muscle test (VMT), we have done reliability 
studies in the six leprosy centres. These studies are described in chapter 4. We can conclude 
that monofilament tests of the radial cutaneous nerve and sural nerve can be done reliably by 
trained staff. Chapter 5 presents a study into alternative methods to detect nerve function 
impairment in an earlier stage. In this study we carry out diagnostic accuracy tests for five 
different ‘gadgets’ in 209 leprosy patients who have subclinical neuropathy. These five tests 
have been selected on their usefulness in the field: they are portable, battery operated, 
affordable and easy to carry out without much training. The five gadgets all examine the sensory 
nerves, but test different modalities: the Neuropad® tests sweat function, the Vibratip™ 
examines sensitivity for vibration, the NC-Stat®DPNCheck™ tests the nerve conduction, the 
NeuroQuick examines cold sensation and the Thermal Sensibility Tester (TST) tests warm 
sensation. The tests were performed on the sural nerve and/or the posterior tibial nerve. 
Additional assessments with two gold standard tests, the Warm Detection Threshold with the 
TSA II and Nerve Conduction with electromyography machines, allowed us to calculate the 
sensitivity and specificity of each gadget. The NeuroQuick and the TST showed the best results 
and we recommend to verify the reliability of these two tests. Using this type of gadgets would 
be a very good way to improve the early detection of nerve function impairment in leprosy 
patients in the field.  
The third part contains three chapters that present the results of various studies. Chapter 6 
describes the most important results of the Clinical TENLEP trial, and discusses the second 
research question. In the Clinical trial, we compared in 868 leprosy patients a prednisolone 
treatment of 32 weeks and 20 weeks. By testing the nerve function with MFT and VMT monthly 
during the 32 weeks of the treatment period and at 52 and 78 weeks, we gained good insight 
into the effect of the two treatments. Our study shows that the two treatment durations lead to 
a similar result: in 78% of the patients nerve function was improved or restored. Also the 
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secondary outcomes, such as the Participation scale, the Activity limitation scale and Reaction 
Severity scale, did not differ between the two treatments. Chapter 7 presents the Serious and 
Minor Adverse Events (SAE and MAE) of prednisolone treatment for both TENLEP trials. 
Examples of SAEs are: high blood pressure, diabetes, peptic ulcer and tuberculosis. For 20 
weeks as well as 32 weeks of prednisolone treatment, the percentage of patients developing an 
SAE was low, 0.9% and 2.7% respectively. The patients who followed the longer treatment 
duration had significantly more SAEs though. Taking into account the results of chapter 6, i.e. 
the longer treatment was not more beneficial, the 32-week treatment is not worth the increased 
SAE risk.   
The study in chapter 8 answers the third research question. In an earlier study in Bangladesh, a 
recent period of food shortage was associated with the development of clinical leprosy. We 
aimed to further explore this relationship in a case-control study in Bangladesh, in which we 
compared the diet and food security of 52 recently diagnosed leprosy patients with a healthy 
control population of 100 people from the same region. By interviewing controls and patients, 
data was collected on dietary intake in the last 24 hours, household food security, income, and 
food expenditure. Our study showed that food shortage was more common in households of 
leprosy patients, and that the dietary diversity and food security were lower. Patients reported a 
lower food expenditure, had a lower body mass index and had less household food stocks. 
Because patients could spend less money on food, they had a lower intake of highly nutritious 
non-rice foods such as meat, fish, milk, eggs, fruits and vegetables. It could be that because of 
the low intake of micronutrients, the immune system, which might give opportunity for clinical 
leprosy to develop.  
 In the last part of this thesis the conclusions and recommendations are addressed. In chapter 
9 the findings of the different studies are discussed and the research questions are answered. 
Even though leprosy is one of the oldest diseases known, many aspects of the disease are not 
completely understood. It is complicated to study M. leprae, because the bacteria cannot be 
cultured in vitro and the incubation time of leprosy is long (between 2 and 5 years on average). 
For these reasons, it is not completely clear how the disease is transmitted, how and when the 
immune system responds to the bacilli and how neuropathy and reactions develop. In addition, 
no specific leprosy vaccine is available that can prevent clinical leprosy. These challenges in 
studying leprosy and in developing effective preventive and curative measures for leprosy are a 
main cause of the steady new case detection rate of leprosy and of the steady numbers of new 
cases with grade 2 disability in many endemic countries. Fortunately, progress is being made, 
and large multicentre studies such as TENLEP help increase our insight into the many difficult 
issues in leprosy that need to be addressed in order to achieve elimination of the disease and its 
related disabilities. 
From the results and experience of the studies described in this thesis, I developed a set of 
recommendations to improve detection and treatment of neuropathy in the field: 
§ The sural and radial cutaneous nerves should be included in standard routine 
monofilament assessment  
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§ Use more sensitive methods to detect neuropathy in an earlier stage. The portable 
Thermal Sensitivity Tester and NeuroQuick are promising devices for this goal 
§ Implement nutrition support for poor people during food shortage periods in leprosy 
endemic regions to increase dietary diversity 
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Samenvatting 
In dit proefschrift beschrijf ik verschillende methodes om neuropathie in leprapatiënten vroeg op 
te sporen en te kunnen behandelen, zodat permanente, onomkeerbare verslechterde werking 
van de zenuwen voorkomen kan worden. Ook heb ik verschillende risicofactoren op het gebied 
van voeding bestudeerd in relatie tot de ontwikkeling van klinische lepra.  
Lepra is een infectieziekte die wordt veroorzaakt door de bacterie Mycobacterium leprae. Het 
wordt vaak gezien als een ziekte van de armen, zeker nu lepra vooral voorkomt in lage-
inkomenslanden. 89% van de nieuw gediagnosticeerde leprapatiënten komen uit acht landen: 
Bangladesh, Brazilië, Democratische Republiek Congo, Ethiopië, India, Indonesië, Nepal en 
Nigeria, waarvan India veruit de grootste bijdrager is met ongeveer 60%. Officieel is lepra 
wereldniveau geëlimineerd, wat wil zeggen dat er minder dan 1 patiënt per 10.000 inwoners 
voorkomt volgens de Wereldgezondheidsorganisatie (WHO). Helaas geldt dit nog niet voor 
bepaalde regio’s in bovengenoemde landen en er vindt daar dus nog steeds verspreiding 
plaats. De ziekte is besmettelijk, maar niet iedereen die besmet is krijgt het. Bij het wel of niet 
krijgen van lepra spelen genen, algemene gezondheidsstatus, voeding, hygiëne en sociale 
afstand tot een patiënt een rol.  
De leprabacterie tast de huid en zenuwen aan, maar de gevolgen van de zenuwbeschadiging 
maakt dat lepra als ernstige ziekte beschouwd wordt. Zenuwbeschadiging kan leiden tot 
verslechterde functie van de zenuwen, zowel sensorisch als motorisch. Door verslechterde 
sensorische functie voelen leprapatiënten vaak niet dat ze zich verbranden of een wond 
hebben, en verzorgen de wonden minder goed omdat ze geen pijn voelen. Door verslechterde 
motorische functie kunnen de spieren in de handen en voeten soms verzwakken. Door beide 
soorten beschadiging kan de patiënt gehandicapt raken. Het is dus van belang om eventuele 
zenuwbeschadiging snel op te merken en te behandelen. In het algemeen wordt aangenomen 
dat als een verslechterde zenuwfunctie binnen 6 maanden behandeld wordt met prednisolon de 
functie verbeterd kan worden. De optimale duur van een prednisolonbehandeling voor 
verslechterde zenuwfunctie is echter onbekend. 
We hebben een onderzoek opgezet om antwoord te vinden op de vraag of een langer dan 
gebruikelijke behandeling met prednisolon een grotere verbetering van de zenuwfunctie tot 
gevolg heeft. Dit onderzoek heeft de naam TENLEP gekregen (Treatment of Early Neuropathy in 
LEProsy).  
De resultaten van dit en andere onderzoeken zijn beschreven in dit proefschrift. Het doel van dit 
proefschrift is om de volgende vragen te beantwoorden: 
1. Hoe kan de opsporing van verslechterde zenuwfunctie in lepra in ‘het veld’ verbeterd 
worden? 
2. Hoe kan onomkeerbare verslechterde zenuwfunctie het beste voorkomen worden? 
3. Welke aan voeding gerelateerde factoren hebben invloed op het ontwikkelen van 
klinische lepra? 
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Hoofdstuk 1 geeft een inleiding in de ziekte lepra en uitgebreide informatie over neuropathie. 
De vier studies in het tweede deel focussen op methodologie. In hoofdstuk 2 beschrijf ik de 
details van het protocol van de twee gerandomiseerde, gecontroleerde TENLEP-studies die we 
hebben uitgevoerd in zes lepracentra in vier Aziatische landen. In de Klinische studie vergelijken 
we of een langere behandelduur met prednisolon, 32 vergeleken met 20 weken, betere 
resultaten laat zien in de verbetering van verslechterde zenuwfunctie. Daarnaast bestuderen we 
in een parallelle, placebo-gecontroleerde studie, genaamd de Subklinische studie of 20 weken 
prednisolon verslechterende zenuwfunctie kan voorkomen in leprapatiënten met subklinische 
zenuwbeschadiging. 
De volgende drie hoofdstukken geven antwoord op de eerste onderzoeksvraag. In hoofdstuk 
3 beschrijven we een onderzoek waarbij we van twee zenuwen de gevoeligheid bepalen met 
een monofilament test bij mensen zonder lepra in India en Nepal. Uit eerder onderzoek is 
gebleken dat de nervus radialis en de nervus suralis de eerst aangedane zenuwen zijn bij lepra 
neuropathie. Maar doordat verwondingen bijna nooit voorkomen in de innervatiezone van deze 
zenuwen worden de nervus radialis en de nervus suralis vaak overgeslagen bij de routinetesten. 
Dit is een gemiste kans, omdat deze zenuwen juist extra informatie geven die de vroege 
opsporing van verslechterde zenuwfunctie kunnen bevorderen. Om de bevindingen van de 
monofilament test bij patiënten te kunnen interpreteren hebben we daarom in deze studie 
vastgesteld wat de grens van de normale waarde voor de monofilament test is. Het paarse 2-
grams filament is de normaalwaarde voor de nervus radialis en het rode 4-grams filament is 
normaal voor de nervus suralis.  
Voor de monofilament- en spiertesten hebben we betrouwbaarheidsstudies uitgevoerd in de 
zes lepracentra; deze staan beschreven in hoofdstuk 4. We kunnen daaruit concluderen dat 
monofilament testen van de nervus radialis en de nervus suralis betrouwbaar uitgevoerd kunnen 
worden door getrainde staf. Hoofdstuk 5 beschrijft een studie naar alternatieve methodes om 
verslechterde zenuwfunctie vroeg op te kunnen sporen. In de studie doen we diagnostische 
nauwkeurigheidstesten met vijf verschillende ‘gadgets’ bij 209 leprapatiënten met subklinische 
neuropathie. Deze testen zijn geselecteerd omdat ze draagbaar, batterij-gevoed, betaalbaar en 
makkelijk uitvoerbaar zijn en daarmee geschikt zijn voor gebruik tijdens veldwerk. De vijf 
verschillende gadgets testen de sensorische zenuwen via verschillende modaliteiten: de 
Neuropad® test zweetfunctie, de Vibratip™ test vibratiegevoeligheid, de NC-
Stat®DPNCheck™ test de zenuwgeleiding, de NeuroQuick test de gevoeligheid voor kou en de 
Thermal Sensibility Tester (TST) test de gevoeligheid voor warmte. Door de gadgets te 
vergelijken met twee gouden standaarden, de warmtedetectiegrens met de TSA II en 
zenuwgeleiding met een elektromyografie apparatuur, konden we de sensitiviteit en specificiteit 
van de gadgets berekenen voor de nervus suralis en nervus tibialis posterior. De NeuroQuick en 
de TST lieten veruit de beste resultaten zien en we adviseren dat voor deze twee testen de 
betrouwbaarheid wordt geëvalueerd. Dit soort gadgets zou een erg goede manier zijn om de 
vroege opsporing van verslechterde zenuwfunctie door lepra in het veld te verbeteren. 
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Het derde deel omvat drie hoofdstukken waarin de resultaten van verschillende studies worden 
gepresenteerd. Hoofdstuk 6 beschrijft de belangrijkste resultaten van de Klinische TENLEP-
studie en gaat daarbij in op de tweede onderzoeksvraag. In de Klinische studie vergeleken we in 
868 patiënten of een prednisolonbehandeling van 32 weken beter is dan van 20 weken in de 
verbetering en volledige genezing van verslechterde zenuwfunctie. Door de zenuwfunctie van de 
patiënten maandelijks te testen met monofilament- en spiertesten tijdens de 32 weken van de 
behandelfase en vervolgens op 52 en 78 weken, kregen we een goed beeld van het effect van 
de twee behandelingen. Uit onze studie blijkt dat beide behandelingen hetzelfde resultaat 
geven, namelijk dat in 78% van de patiënten de verslechterde zenuwfunctie verbeterde of 
volledig genas. Dit betekent dat het geven van een langere behandeling geen extra verbetering 
oplevert. Ook de secundaire uitkomsten, zoals de schalen die participatie, activiteit-
beperkingen, en ernst van reacties meten, verschilden niet tussen de twee behandelduren. 
Hoofdstuk 7 beschrijft de ernstige en minder ernstige ongewenste voorvallen, ofwel 
bijwerkingen, van het gebruik van prednisolon binnen de TENLEP-studies. Onder ernstige 
ongewenste voorvallen vallen onder andere hoge bloeddruk, diabetes, maagzweer of 
tuberculose. Bij beide behandelduren, 20 en 32 weken, is het percentage patiënten dat ernstige 
ongewenste voorvallen krijgt erg laag, respectievelijk 0,9% en 2,7%. De patiënten die de langere 
behandeling van 32 weken volgden kregen significant meer ernstige ongewenste voorvallen. 
Rekening houdend met het resultaat beschreven in hoofdstuk 6, namelijk dat de behandeling 
van 32 weken geen betere uitkomsten geeft dan de behandeling van 20 weken, is de lange 
behandeling het verhoogde risico op ernstige ongewenste voorvallen niet waard.  
Het onderzoek in hoofdstuk 8 geeft antwoord op de derde onderzoeksvraag. In een eerder 
onderzoek in Bangladesh werd een recente periode van voedseltekort geassocieerd met het 
ontstaan van ziekteverschijnselen van lepra. In ons onderzoek zijn we hier dieper op ingegaan, 
en hebben een case-control studie in Bangladesh uitgevoerd, waarin het voedingspatroon en 
de voedselzekerheid van 52 recent gediagnosticeerde leprapatiënten wordt vergeleken met die 
van een gezonde controlepopulatie uit dezelfde regio, bestaande uit 100 mensen. Door middel 
van interviews hebben we data verzameld over de voedselinname van patiënten en controles in 
de voorafgaande 24 uur en over de voedselzekerheid, de inkomsten, en uitgaven aan voedsel 
van het huishouden. Het bleek dat in huishoudens van leprapatiënten voedseltekorten vaker 
voorkwamen, dat de diversiteit van het voedingspatroon lager was en dat er een hogere 
voedselonzekerheid was. Daarbij gaven patiënten minder geld uit aan voeding, hadden ze een 
lagere body mass index (BMI) en hadden minder voedselvoorraden in huis. Doordat er minder 
geld aan voeding uitgegeven kon worden was het duidelijk dat voedingsmiddelen met hoge 
nutritionele waarden, zoals vlees, vis, fruit, groenten, eieren en melk, minder geconsumeerd 
werden Het is mogelijk dat door lagere inname van micronutriënten het immuunsysteem niet 
optimaal werkt en daardoor klinische lepra kan ontstaan. 
In het laatste deel komen de conclusies en aanbevelingen aan bod. In hoofdstuk 9 worden de 
bevindingen bediscussieerd en de onderzoeksvragen beantwoord. Ondanks dat lepra één van 
de oudst bekende ziektes is, zijn er nog veel aspecten van deze ziekte onbekend. Het is 
ingewikkeld om de bacterie te bestuderen, mede doordat deze niet buiten het lichaam groeit (in 
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vitro) en omdat de bacterie een erg lange incubatietijd heeft (tussen de 2 en 5 jaar gemiddeld). 
Hierdoor begrijpt men nog niet goed hoe de ziekte zich verspreidt, hoe en wanneer het 
immuunsysteem precies op de bacillen reageert en hoe zenuwbeschadiging en reacties 
ontstaan. Ook is er tot op heden geen effectief vaccin ontwikkeld om lepra te voorkomen. Mede 
door deze nog bestaande uitdagingen is lepra nog niet overal geëlimineerd. Gelukkig wordt er in 
studies steeds vooruitgang geboekt en helpen grootschalige studies als de TENLEP-studie om 
onze kennis verder uit te breiden.  
Naar aanleiding van de bevindingen in dit proefschrift heb ik de volgende praktische 
aanbevelingen gedaan om de opsporing en behandeling van verslechterde zenuwfunctie in het 
veld te verbeteren:  
§ De nervus radialis en de nervus suralis zouden geïncludeerd moeten worden in de 
standaard routine van de monofilament test 
§ Maak gebruik van sensitievere methodes om neuropathie in een vroeg stadium op te 
kunnen sporen. De draagbare Thermal Sensitivity Tester en de NeuroQuick zijn 
veelbelovend voor dit doel 
§ Zorg voor ondersteuning van mensen met een laag inkomen in lepra-endemische 
regio’s, zodat zij over nutriënt-dichte voedingsmiddelen kunnen beschikken tijdens 
periodes van voedseltekort en zij zo de diversiteit van hun dieet kunnen vergroten  
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